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Preface 
The work described in this Ph.D. thesis was carried out at the Center for Microbial 
Biotechnology, Technical University of Denmark, from March 2008 to March 2012, under the 
joint supervision of Associate Professor Uffe H. Mortensen and Kiran Raosaheb Patil, Group 
Leader at the European Molecular Biology Laboratory in Heidelberg, Germany (EMBL). From 
September 2010 to the end of the Ph.D. I have been a visiting Ph.D. student at the Patil group, 
Computational Biology Unit, EMBL. The Portuguese governmental institution responsible for 
financing and evaluating the scientific research activities, Fundação para a Ciência e a 
Tecnologia, ensured financial support throughout the 4 years (ref. SFRH/BD/41230/2007). Travel 
expenses and conferences have been additionally supported by Otto Mønsteds Fund (Denmark) 
and SYSINBIO – Systems Biology as a Driver for Industrial Biotechnology, Coordination and 
Support Action (call FP7-KBBE-2007-1). 
The multidisciplinary nature of my Ph.D., which will become apparent to the reader from the 
beginning of this thesis, was a feature that immediately cached my attention when Kiran firstly 
proposed it to me in 2007. My Ph.D. started with a very appealing project for improving a yeast 
vanillin cell factory through metabolic engineering. Despite the successful outcome of this 
project, I recognized that many aspects which are considered as “fundamental research” assume 
a determinant role in applied situations. It became clear to me that if we really aim at 
engineering the metabolism of a cell, there are still a vast amount of “fundamental principles” 
that we need to uncover, so we achieve a level of knowledge that enables fully controlled 
manipulation of metabolic features. Therefore, the last project I accomplished for my Ph.D. 
embraces a much more basic question; rather than engineering a cell, I would like to be able to 
better predict cellular fate in the metabolic context. While running between the pipettes at the 
lab bench and the C++ programs I started to develop in my computer, I realized that being able 
to understand the mathematical aspects underlying model formulation, while having the 
opportunity to perform the experiments which tackle the hypothesis thereby derived, enables a 
unique sensation of freedom and inspiration. Experimental and modeling approaches to study 
biology may demand very distinct cognitive skills, but they complement each other in such 
rewarding manner, that, to my experience throughout the last 4 years, I can say it was totally 
worth. At last, I hope I was able to transcribe my enthusiasm into words while writing this thesis. 
Ana Rita Brochado, April 2012 
Heidelberg. Germany. 
5
6
 iii 
 
Acknowledgments 
For accomplishing the multifaceted venture that was my Ph.D., I was very fortunate to have Prof. 
Uffe H. Mortensen and Kiran R. Patil as my supervisors, to whom I gladly thank for leading me 
through this experience. Without Uffe’s support, who introduced me to molecular biology and 
yeast genetics, it would have been impossible for me to learn the experimental skills essential to 
accomplish the work herein presented. Thank you for all valuable discussions and for welcoming 
me in your laboratory, where there was always people willing to help, not only by providing 
useful scientific advice, but also by making it a very enjoyable working environment at the 
bench. To Kiran, who shared with me his experience in fermentation technology in such a 
tireless way (even if I almost accidently burned his hand while trying to fix a reactor at eleven in 
the night!), who taught me most of what I learned about modeling of metabolism and for being 
my mentor, I am especially grateful. Thank you for uncountable valuable discussions and for 
always supporting me, even when nothing seemed to make sense. Thank you for accepting me 
as your Ph.D. student in Denmark and also for “bringing” me along when you took a step 
forward in your carrier by moving to EMBL in Germany. 
I thank all our previous and current group members, especially Louise Mølgaard, who was at 
CMB since the first day I arrived and shared with me much of her scientific knowledge, but also 
many good moments in the lab and in our office. Aleksej Zelezniak, who started his Ph.D. soon 
after me and also moved to EMBL, for our valuable scientific discussions and for sharing “a beer” 
anytime things got hard. To Sergej Andrejev, our scientific programmer, who continuously saved 
me of drowning in my own programs while sharing the office with me for more than 1.5 years at 
EMBL. I also want to thank him for teaching me one of the most relevant and truthful sentences 
I have recently heard. After I questioned him whether the simple program we had just made was 
optimal or not, he replied, “Optimal?!?! No! It is optimistic!!”. 
Thanks to the determined and always motivated master’s students I was fortunate to co-
supervise: Cláudia Matos, Ana Machás, Małgorzata E. Bejtka, Tomasz Boruta, Emauela Monteiro, 
Joanna Guzicka and Justyna Nocoń. 
Thanks to the secretariat team at CMB and EMBL for all administrative support, as well as I thank 
the research technicians team at CMB for helping with all laboratory assistance I requested. 
Thanks to Manuel Quirós, Ana Paula Oliveria, Zita Soons, Gary Male, Olga Ponomarova, Lars 
Poulsen, Line Due Buron, Bo Salomonsen, Martin Engelhard Kogle, Sujata Sohoni, Jakob 
7
 iv 
 
Blæsbjerg Nielsen, Tomas Stručko, Erica Valentini, Birger L. Møller, Jørgen Hansen, Martin Beck 
and Wolfgang Huber for valuable scientific discussions. 
To my friends, especially Arnau Montagud, Sarah Lieder, Tilman Plass and Ana Machás, a very 
big thanks for everything! Last but not least, I thank my family, in particular my mother for her 
unconditional support. 
8
 v 
 
Synopsis 
Genome-scale metabolic models are increasingly used for simulation of cellular phenotypes as 
reflected in their metabolic physiology, such as growth rate, metabolite secretion and usage of 
metabolic pathways. In particular, they offer a privileged opportunity to investigate genotype to 
phenotype relationships for gene deletion mutants, as the deletion of a gene can generally be 
translated to the absence of the corresponding reaction in the metabolic network. Experimental 
evidence for the predictive power of genome-scale metabolic models, comprising the metabolic 
network and the modeling approach, is commonly limited to gene essentiality analysis. 
Extrapolation of the current modeling tools for covering the deletion of multiple genes, which 
are relevant from both fundamental and applied perspective, is largely unclear. The work herein 
presented focused on the experimental evaluation and development of new tools for prediction 
of cellular phenotypes from a metabolic physiology perspective, i.e. prediction of metabolic 
phenotypes. The baker’s yeast Saccharomyces cerevisiae was chosen to carry out the work 
presented in this thesis, motivated by the availability of extensive knowledge about its 
physiology, its suitability for industrial applications and a vast collection of molecular biology, as 
well as of high-throughput data generation technologies. 
Experimental assessment of the predictive power of the yeast genome-scale metabolic network 
and established modeling approaches was done in the context of metabolic engineering. The 
yeast genome-scale metabolic model was used to design a strategy for increasing heterologous 
vanillin production in S. cerevisiae by applying OptGene, a simulation framework for finding gene 
deletions towards maximization of productivity.  The choice of minimization of metabolic 
adjustment (MoMA) over flux balance analysis (FBA) for maximization of growth as biological 
objective highly influenced the simulation results for strain design. Up to 2-fold improvement of 
vanillin production was observed upon physiological characterization of the mutants obtained 
following MoMA biological objective, confirming that metabolic proximity towards the reference 
strain can successfully describe the behavior of metabolic networks upon single gene deletion. 
In a following study, the metabolic flux through the vanillin biosynthetic pathway was found to 
be limited by the activity of one of the pathway enzymes. Moreover, such limitation was 
exclusively observed in one of the mutants previously obtained through in silico guided 
metabolic engineering, for which cofactor and precursor availability was increased. This result 
demonstrates the fundamental importance of accounting for the entire metabolic network while 
modulating the metabolic flux of a single pathway. In this context, regulatory circuits often 
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modulate the expression of several genes or even entire pathways, rendering regulatory genes 
attractive targets for metabolic engineering. Integration of regulatory information with genome-
scale models is still in its infancy, partially due to incomplete knowledge and characterization of 
regulation mechanisms. Within this work, HAP4, a transcription factor involved in glucose 
repression, was overexpressed in the vanillin producing yeast, based on previous observations 
that it leads to mutants with increased respiratory capacity. As a consequence of higher 
availability of ATP, the production of vanillin increased by 30%. In addition to other studies, this 
example confirms that manipulation of regulatory targets, in this case by gene overexpression, 
can cause the re-adjustment of fluxes distributed around important metabolic branches. 
Furthermore, this study demonstrates not only the need for development of new computational 
tools accounting for regulatory targets for metabolic engineering, but also the need for better 
understanding the relationship between gene transcription changes and the resulting alteration 
of metabolic fluxes.  
Predicting the phenotype of perturbed metabolic networks is essential for using stoichiometric 
models for metabolic engineering, as well as to infer gene functions from the phenotype of 
deleted mutants. Cumulative genetic perturbations embody a large potential for both applied 
and fundamental research, as they might reveal functional association between the involved 
genes. The accuracy of phenotype prediction of mutants carrying multiple genetic perturbations 
is currently poorly assessed, mainly due to lack of large-scale systematic experimental studies. 
To this end, the recently available map of genetic interactions for S. cerevisiae offers the 
possibility for extending the validation of stoichiometric models to include the accuracy of 
metabolic phenotype prediction of double deletion mutants, as well as the accuracy of 
prediction of genetic interactions. The last part of this thesis presents a computational tool for 
simulation of metabolic phenotypes, termed Minimization of Metabolites Balance – MiMBl, 
which focuses on the formulation of objective functions, particularly of those concerning 
simulation of perturbed metabolic networks. Numerous established objective functions were 
found to be sensitive to the stoichiometric representation of the biochemical reactions, 
especially visible for cumulative gene deletions. MiMBl allows formulating objective functions 
describing established and newly suggested biological principles in a robust manner. MiMBl was 
used to predict and analyze the yeast genetic interaction network and it largely outperformed 
previously established simulation algorithms for predicting the phenotype of perturbed 
metabolic networks, namely lMoMA. Moreover, MiMBl and FBA were used in combination for 
interpreting the metabolic rerouting induced by double gene deletions, illustrating how different 
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biological principles can be used to provide useful mechanistic insights about operation modes 
of metabolic networks. 
Overall, the work presented in this thesis demonstrates how genome-scale metabolic models 
can be used for exploring genotype to phenotype relationships, from both experimental and 
theoretical perspectives. 
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Resumo em Português 
Os modelos metabólicos à escala genómica são cada vez mais utilizados para simulação de 
fenótipos na perspectiva de fisiologia microbiana, nomeadamente para a simulação de taxa de 
crescimento, secreção de metabolitos e utilização de vias metabólicas (aqui denominado 
“fenótipo metabólico”). Em particular, estes modelos proporcionam uma oportunidade 
privilegiada para investigar a relação genótipo-fenótipo em mutantes com genes eliminados, 
dado que a supressão de um gene pode ser facilmente traduzida para a ausência da reacção 
correspondente na rede metabólica. A avaliação do poder preditivo dos modelos metabólicos à 
escala genómica é actualmente basea, na sua maioria, em evidências experimentais relativas à 
análise de genes essenciais. A extrapolação das ferramentas de modelação actuais para cobrir a 
previsão de fenótipos resultantes de eliminação de múltiplos genes, interessantes tanto numa 
perspectiva fundamental como aplicada, permance, em grande parte, por explorar. O trabalho 
aqui apresentado centrou-se na avaliação experimental e no desenvolvimento de novas 
ferramentas computacionais para previsão de fenótipos numa perspectiva de fisiologia 
metabólica, ou seja, previsão de fenótipos metabólicos. Dada a disponibilidade de amplo 
conhecimento sobre a sua fisiologia, a sua adequação para aplicações industriais e um vasto 
conjunto de tecnologias disponíveis para biologia molecular e geração de dados à escala 
genómica, motivou a escolha de Saccharomyces cerevisiae para este estudo. 
A capacidade preditiva da rede metabólica à escala genómica da levedura foi 
experimentalmente availada neste projecto no contexto de engenharia metabólica, assumindo a 
minimização de ajuste metabólico (MoMA) de mutantes com um gene eliminado em relação a 
estirpe de referência. Este modelo foi utilizado para projectar uma estratégia de melhoramento 
de produção heteróloga de vanilina em S. cerevisiae, que após implementada resultou no dobro 
da produção. O algoritmo OptGene foi utilizado para seleccionar os genes a eliminar, tendo em 
conta a maximização de produtividade. Estes resultados confirmam a proximidade metabólica 
de mutantes após a eliminação de um gene em relação a estirpe de referência como princípio de 
simulação adequado. 
Num segundo estudo, constatou-se que o fluxo metabólico da via biossintética da vanilina 
estava condicionado pela actividade de uma das enzimas da via. Tal limitação foi exclusivamente 
observada num dos mutantes previamente obtidos com base no modelo metabólico à escala 
genómica, realçando a importância de ter em conta a rede metabólica na sua totalidade, mesmo 
quando o fluxo de uma única via metabólica está em questão. Neste contexto, os genes 
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internevientes em cascatas de regulação são também alvos atractivos para a engenharia 
metabólica, já que estes afectam a expressão de vários genes, ou mesmo de vias metabólicas 
completas. Na realização deste trabalho a produção de vanilina foi intensificada pela 
superexpressão do gene HAP4, um factor de transcrição envolvido nos circuitos regulatórios 
para a repressão por glucose em S. cereviaise. Embora a inclusão de circuitos de regulação em 
modelos metabólicos esteja ainda no início do seu desenvolvimento, este resultado evidencía os 
potenciais benefícios da inclusão de proteínas reguladoras na modelação de metabolismo, 
nomeadamemte como alvos plausíveis para engenharia metabólica. 
A previsão de fenótipos resultantes de múltiplas perturbações genéticas é de grande interesse 
não só para investigação aplicada, mas também para a investigação científica de carácter 
fundamental, já que os efeitos cumulativos da eliminação de múltiplos genes podem revelar 
associações funcionais entre os genes envolvidos. A última parte deste trabalho descreve uma 
nova ferramenta computacional desenvolvida para formulação de funções objectivo a utilizar na 
simulação de fenótipos metabólicos, particularmente dedicada à simulação de fenótipos após 
eliminação de um ou mais genes. O novo algorítmo foi demoniado Minimization of Metabolites 
Balance – MiMBl. O MiMBl foi utilizado para prever e analisar a recentemente publicada rede de 
interacções genéticas de levedura, tendo em grande parte superado os algoritmos existentes. 
Adicionalmente, o MiMBl foi utilizado em combinação com um algoritmo ja estabelecido (FBA) 
para a interpretação do reencaminhamento metabólico induzido pela eleminação de dois genes, 
ilustrando como diferentes princípios biológicos podem ser utilizados para fornecer informações 
mecanísticas sobre modos de operação de redes metabólicas. 
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Dansk Sammenfatning 
Genom-skalerede metabolske modeller bliver hyppigere og hyppigere brugt til at simulere 
cellulære fænotyper, for eksempel til beskrivelse af den metabolske fysiologi, vækst rate, 
metabolit sekretion og brug af metabolske reaktionsveje. Især tilbyder de en attraktiv mulighed 
for at undersøge sammenhængen mellem genotype og fænotype for mutanter, hvor et gen er 
blevet elimineret, idet denne mangel ofte vil resultere i fraværet en specifik reaktion i cellens 
metabolske netværk. Eksperimentel evidens til støtte for genom-skalerede modellers evne til at 
forudsige metabolske ændringer er hovedsageligt begrænset til at forudsige om et gen er 
essentielt eller ej. En udvidelse af dette koncept til at omfatte, hvad der sker, hvis flere gener 
elimineres kan i øjeblikket ikke gøres særlig præcist, selv om sådanne forudsigelser ville være 
særdeles relevante for projekter indenfor både grund- og anvendt forskning. Forskningsarbejdet, 
der præsenteres i denne rapport, fokuserer på eksperimental evaluering og udvikling af nye 
værktøjer, som muliggør at forudsige cellers fænotype ud fra et metabolsk fysiologisk 
perspektiv, det vil sige, til forudsigelse af fænotyper. Bagegær, Saccharomyces cerevisiae, blev 
valgt som modelorganisme for dette stadium, idet den er industriel relevant og idet der er 
akkumuleret en enorm mængde viden om dens fysiologi, og idet der er udviklet mange nyttige 
genetiske, molekylærbiologiske og ”high throughput” værktøjer.  
Eksperimentel validering af genom-skalerbare netværks og modellers evne til at forudsige 
fænotyper blev udført med fokus på ”metabolic engineering” opgaver. Den genom-skalerbare 
metabolske model for gær blev brugt til at designe en strategi for heterolog produktion af 
vanillin i S. cerevisiae. Ved at følge en in silico designet strategi som blev foreslået af 
computerprogrammet OptGene og algoritmen ”minimization of metabolic adjustment” (MoMA) 
som målfunktion, blev der opnået en fordobling af udbyttet. I et efterfølgende studium blev det 
påvist, at det metabolske flux gennem vanillin syntesevejen var begrænset af aktiviteten af et af 
enzymerne i syntesevejen. Denne begrænsning blev udelukkende set i en af de mutanter, der 
blev skabt som funktion af den in silico guidede strategi nævnt ovenfor, hvilket viser 
nødvendigheden af at gøre rede for hele det metabolske netværk, når fluxet igennem en enkelt 
biosyntesvej skal ændres. I denne sammenhæng er regulatoriske gener attraktive mål for 
”metabolic engineering”, fordi de kan ændre udtrykket af mange gener eller hele biosyntesveje 
via en enkelt genetisk ændring. I denne rapport bliver det demonstreret, hvordan vanillin 
produktionen yderligere kan forøges ved at overudtrykke genet HAP4, der koder for en 
transkriptionsfaktor involveret i glukose repression. Selvom inkludering af regulatoriske kredsløb 
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i metabolske modeller stadig er i sin barndom, så viser dette resultat, at disse med fordel kan 
udnyttes i ”metabolic engineering” strategier. At kunne forudsige de fænotyper, der vil opstå 
som funktion af kumulerende mutationer vil kunne bidrage til at forstå sammenhængen mellem 
mange gener og deres funktioner, og har derfor et stort potentiale som kan bruges både i grund- 
og i anvendt forskning. Den sidste del af denne rapport angriber denne problemstilling og 
beskriver udviklingen af et nyt computerbasere beregningsværktøj, der kan simulere metabolske 
fænotyper, kaldt MiMBL, og som fokuserer på at formulere målfunktioner, især dem der 
indvirker på forskudte metabolske netværk. MiMBL blev brugt til at forudse og analysere det 
samlede netværk af genetiske interaktioner i gær som for nylig er blevet offentliggjort, og det 
viste sig, at forudsigelserne ved brug af MiMBL generelt var bedre end dem, der blev opnået 
med andre lignende værktøjer som for eksempel lMoMA. MiMBL og FBA blev også brugt i 
kombination til at fortolke ændringer i det metabolske kredsløb induceret forårsaget af 
deletionen af to gener, hvilket illustrerer hvordan forskellige biologiske principper kan blive 
brugt til at opnå brugbar mekanistisk indsigt i hvordan det metabolske netværk fungerer. 
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Nomenclature 
List of Abbreviations 
3DSD 3-dehydroshikimate dehydratase 
3DSH 3-dehydroshikimate 
ACAR Aryl Carboxilic Acid Reductase 
acet acetate 
ATP Adenosine Triphosphate 
BPCY Biomass Product Coupled Yield 
COBRA Constraint-Based Reconstruction and Analysis 
DW Dry weight 
eth ethanol 
FBA Flux Balance Analysis 
GLPK GNU linear programing kit 
gly glycerol 
GRAS Generally Recognized as Safe 
hsOMT Homo Sapiens O-methyltransferase 
lMoMA linear Minimization of Metabolic Adjustment 
MiMBl Minimization of Metabolites Balance 
MoMA Minimization of Metabolic Adjustment 
NADPH Nicotinamide adenine dinucleotide phosphate 
NMR Nuclear Magnetic Resonance 
OD Optical Density 
PAC Protocathechuic acid 
PAL Protocathechuic aldehyde 
PCR Polymerase chain reaction 
PPTase Phosphopantetheinyl transferase 
ROOM Regulatory On/Off Minimization of metabolic flux changes 
SAM S-adenosylmethionine 
TCA Tricarboxylic acid 
UDP-glc UDP-glucose 
VG vanillin β-D-glucoside 
WT Wild Type 
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List of Symbols 
Δ gene deletion 
↑ gene overexpression 
μ specific growth rate, h-1 
μmax maximum specific growth rate, h-1 
YS Metab Yield of metabolite Metab on substrate S, mgMetab/gS 
rMetab Specific uptake or production rate of metabolite Metab, mmolMetab/(gDW.h) 
X Biomass, gDW/l 
R3 Reward-Risk-Ratio 
S Stoichiometric matrix 
v vector of all fluxes 
vi flux of reaction i, mmol/(gDW.h) 
tm turnover of metabolite m, mmol/(gDW.h) 
θ factor for linear scaling of matrix S 
ε epistasis 
ub upper bound 
lb lower bound 
N set of reactions 
M set of intracellular metabolites 
αm,i stoichiometric coefficient of metabolite m in reaction i 
min minimization, in the context of linear optimization 
max maximization, in the context of linear optimization 
B optimal basis matrix 
ci objective function coefficient of variable vi 
ic  reduced cost of variable vi 
cB vector of the objective coefficients of basic variables 
4  Scaling matrix 
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Chapter 1: Introduction and Thesis Outline 
Understanding how the cell reads and processes the information maintained within the genome 
so it displays a given phenotype, is one of the most challenging questions faced in biology. The 
presence of a gene does not imply that this gene is continuously expressed. Expressing it to 
constant levels, also does not guarantee that it affects the phenotype equally over time or under 
different environmental conditions. There are several layers of regulation which allow the cell to 
translate its genotype into a phenotype. An integrated approach for studying cellular systems is 
expected to enable a better understanding of how this relationship occurs. Systems biology 
focuses on elucidating the structure and dynamics of such cellular systems, rather than studying 
individual cellular components, such as a given gene or protein. A cellular state is characterized 
by a set of expressed genes, a set of synthesised proteins, a set of available metabolites and so 
on, yet this does not reveal structural or dynamic cellular organization.  Uncovering the complex 
and coordinated interactions between cellular components is fundamental for understanding 
functional biological systems. For instance reactions must occur between metabolites to form a 
metabolic network allowing the utilization of external resources and building of new cells. Many 
of these reactions are catalyzed by individual proteins (enzymes), involving interaction between 
proteins and metabolites, but also by protein complexes, implying interaction between proteins. 
Additionally, important regulatory mechanisms also engage interaction between cellular 
components, such as allosteric regulation, transcriptional regulation or signal transduction. 
Dynamic coordination of all cellular processes arising from such interactions ultimately enables 
the cell to translate its genotype to the phenotype. 
Metabolism is arguably the subcellular system which is closest to the phenotype, as observable 
phenotypic traits, such as growth, have a very tight association with metabolic features, for 
instance provision of energy and cellular building blocks. Cellular metabolism has been studied 
for several years within Biochemistry and a comprehensive collection of metabolic reactions 
have been characterized. The rapid development of molecular biology techniques allowed 
further characterisation of biochemical reactions by helping to uncover gene-to-enzyme 
associations. Yet, as much as metabolism can be considered a well characterized subcellular 
system, in many cases phenotype still cannot be predicted from genotype, especially in cases 
involving changes in the expression of multiple genes. High confidence prediction of cellular 
phenotypes, as reflected in their metabolic physiology, by using genome-scale metabolic models 
is commonly confined to prediction of gene essentiality. With the increasing availability of 
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molecular biology tools and high-throughput characterization of cellular phenotypes, 
computational approaches which facilitate a systematic and integrative approach for associating 
phenotypic traits to genotypic features are in demand. 
The aim of my thesis was to investigate genotype to phenotype relationships in a systematic 
manner, through stoichiometric simulation of metabolic phenotypes by using genome-scale 
metabolic models. Predicting the behaviour of the metabolic network in the absence of a 
reaction is considered to be a proxy for predicting the phenotype of the corresponding gene 
deletion mutant, therefore large-scale metabolic models provide excellent platforms for 
investigating genotype-phenotype relationships. Saccharomyces cerevisiae was chosen as a 
biological system, because of its status as a eukaryotic model organism, for which there is 
extensive knowledge and technology available. In the present work, stoichiometric modeling of 
the yeast genome-scale metabolic network was used for studying genetic interactions, as well as 
for providing guidance for a metabolic engineering strategy for increasing heterologous vanillin 
production. Both applications are based on predicting the phenotype based on known genetic 
modifications (Fig. 1.1). 
 
Figure 1.1: Genome-scale metabolic modeling for investigating genotype to phenotype relationships. Different 
genetic modifications (genotypes) are represented by different colours, yellow or red, as well as their corresponding 
phenotype. The wild type is represented in gray, while the combination of the yellow and red genetic modifications is 
represented in green. Stoichiometric modeling was used to provide guidance for metabolic engineering (top arrow) 
and for analysing genetic interactions, where the simulation results were used to suggest possible modes of operation 
of the metabolic network, while facilitating a methodical analysis of the functional association between genes (bottom 
arrow). 
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For metabolic engineering, prediction capability of a multitude of phenotypic traits is usually 
desired upon deletion of a gene(s) (reaction(s)), including growth and production yield of the 
compound of interest. For analysis of genetic interactions, the phenotypic trait most commonly 
measured is growth, due to the simplicity of its quantitative assessment for a large number of 
mutants. Although stoichiometric modeling is used in both cases for predicting the phenotype of 
gene deletion mutants, different uses of the simulation results are illustrated by the different 
applications. For metabolic engineering, stoichiometric modeling was used to provide guidance 
for experimental work. For analysing genetic interactions, the simulation results were used to 
suggest possible modes of operation of the metabolic network, while facilitating a methodical 
analysis of the functional association between genes (Fig. 1.1). 
Chapter 2 provides state-of-the-art concepts and a literature survey about Systems Biology, 
Metabolic Engineering and Genome-Scale Metabolic Modeling. 
Chapter 3 illustrates a case study of application of the yeast genome-scale metabolic model 
towards the improvement of a vanillin cell factory. Vanillin is one of the most widely used 
flavouring agents, and it is mainly obtained via chemical synthesis from petrol based substrates. 
Environmental concerns raised the urge for an alternative, and de novo vanillin biosynthesis 
from glucose in S. cerevisiae was previously demonstrated. Prior to engineering the cell factory 
towards increased vanillin production, product toxicity to the host is decreased by supplying the 
cell factory with an additional enzymatic step catalyzing vanillin glycosylation. A metabolic 
modelling guided strategy to improve the assembled cell factory is then presented and 
implemented. The results indicate the relevance of accounting for the entire metabolic network 
for increasing the flux through the pathway of interest, by the manipulation of genes which are 
metabolically distant from the target compound. 
While taking a global engineering approach for strain improvement, it is assumed that the flux 
through the pathway of interest is controlled by the availability of precursors and cofactors, 
rather than by enzyme activity. However, metabolic control resides in a subtle balance between 
the contributions of both factors and a shift can take place upon altering one of them. Indeed, in 
Chapter 4 it is shown that, after global engineering for vanillin production, conversion of 
pathway intermediates to the final product is limited by the availability of one of the pathway 
enzymes. Importantly, it is demonstrated that such enzyme limitation arises exclusively when 
combined with a global engineering approach, supporting the need of a holistic view of 
metabolism for successful metabolic engineering. The advantages of such integrative perception 
of cellular processes for metabolic engineering are further explored by engineering the 
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regulatory circuit for glucose repression, with the goal of simultaneously modulating several 
metabolic fluxes towards additional vanillin production.  
Chapter 5 presents a new computational tool for metabolic modelling, focused on the 
formulation of objective functions. Several objective functions currently used to describe 
biological principles for stoichiometric modelling are shown to be susceptible to stoichiometric 
representation of biochemical reactions. A number of examples are used to illustrate how this 
affects phenotype simulation results for different purposes, namely for estimating internal flux 
distribution, as well as for predicting the behaviour of perturbed metabolic networks, e.g. by 
deleting one or more genes. A new approach for formulation of biological principles is 
presented, Minimization of Metabolites Balance - MiMBl, and several examples are given for 
formulation of other biological principles using MiMBl methodology. Particular focus is given to 
prediction of metabolic phenotypes for perturbed networks, because this feature is on the basis 
of many relevant conclusions and applications driven from genome-scale metabolic modelling. A 
prominent example is the prediction of genetic interactions, which are revealed from phenotypic 
behaviour of gene deletion mutants and often emerge from functional relationship between the 
deleted genes. 
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Chapter 2: Systems Biology, Genome Scale Metabolic Modeling 
and Metabolic Engineering of S. cerevisiae – Acts and Facts 
 
Summary 
A holistic view of the cell is fundamental for gaining insights into genotype to phenotype 
relationships. Systems Biology is a discipline within Biology, which uses such holistic approach by 
focusing on the development and application of tools for studying the structure and dynamics of 
cellular processes. Metabolism is an extensively studied and characterised subcellular system, 
for which several modeling approaches have been proposed over the last 20 years. Nowadays, 
stoichiometric modeling of metabolism is done at the genome scale and it has diverse 
applications, many of them for helping at better characterizing genotype to phenotype 
relationships. Metabolic Engineering is one of the fields in which the complete understanding of 
such relationship would have a striking impact, since phenotype prediction based on genotype is 
fundamental for rationally engineering metabolic networks. This chapter aims at providing the 
reader with relevant state-of-the-art information concerning Systems Biology, Genome-Scale 
Metabolic Modeling and Metabolic Engineering. Particular attention is given to the yeast 
Saccharomyces cerevisiae, the eukaryotic model organism used thought the thesis. 
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Systems Biology 
During the last 20 years, Biology went through a fundamental change of focus from individual 
genes and proteins to cellular processes and interactions between the cellular components [1, 
2]. Knowing all the genes, proteins and metabolites (components) existing within the cell at a 
given stage is not sufficient to understand how the cell operates. How these components 
interact, what phenotypic traits they trigger and how do they enable the cell to respond to 
environmental changes, is fundamental to understand a functional system. Such holistic 
approach to study biological systems has been termed Systems Biology, as suggested by Ideker 
et al. in 2001 [3] and Kitano in 2002 [4]. The aim of Systems Biology is studying “the structure 
and dynamics of cellular and organismal function”. It implies the integration of different data-
types resulting from high-throughput measurements of cellular processes in order to understand 
the functional principles of biological systems [3, 4].  
Given its holistic nature, Systems Biology is a very close interplay between Biology, 
Computational Biology and Technology [1]. Advances in technology are fundamental for 
automatization of experiments, e.g. the synthetic genetic array - SGA [5, 6], as well as for 
acquiring new types of biological data, ranging from pioneering DNA sequencing [7] to the 
contemporary challenge of metabolome analysis [8]. Computational biology contributes with 
tools for modeling and data analysis, primarily to understand the biological principles 
underplaying the data, as well as for guiding experiments [1, 4]. Biology holds the questions to 
be asked and experimental expertise, ranging from molecular biology of a simple bacterium to 
the understanding of brain function or human diseases. 
An ‘omics’ briefing 
Systems Biology becomes progressively more quantitative, so as to draw meaningful conclusions 
from genome-wide/large datasets. The generation and study of such large datasets is generally 
referred as ‘omics’ data. Genomics, together with Functional Genomics, focus on identification 
of genes and entire genome sequences, as well as assignment of gene functions. Recently, the 
availability of new high-throughput sequencing technologies and consequent decreased price of 
genome sequencing, lead to the development of Comparative Genomics [9] and Metagenomics 
[10]. On the path of understanding genotype to phenotype relationship, a comprehensive 
assessment of gene expression patterns through quantification of RNA molecules is the subject 
of Tanscriptomics [11–13]. Because regulation occurs at several layers of the central dogma (Fig. 
2.1) [14, 15], such as post-transcriptional modifications and protein degradation, correlation 
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between gene expression and protein concentration is not always observed [16]. Proteomics 
focus on the quantification of protein concentrations. Mass spectrometry-based methods have 
been recently established and, so far, they are the most comprehensive methods for proteome 
quantification [17, 18]. Metabolomics and Fluxomics are, among the previously mentioned data-
types, those that are closer to the cellular phenotype. Metabolomics aims at quantifying all 
measurable intracellular and extracellular metabolites (e.g. carbohydrates, lipids, amino acids), 
as well as their changes over time or under different environmental/genetic conditions. On the 
other hand, Fluxomics involves the quantification of rate of the metabolic reactions at the 
network scale, ultimately leading to a comprehensive characterization of the functional state of 
the metabolic network. Although different in terms of implied functional information, these two 
fields are closely related by the fact that they both involve (relative) quantification of 
(intra)cellular metabolites. Also here, mass-spectroscopy and NMR are the preferred detection 
methods, often associated with a chromatographic pre-separation of the extracts [19]. 
 
Figure 2.1: Systems Biology tools for understanding genotype to phenotype relationships. 
More than quantification of metabolites, Fluxomics aims at inferring the rate of reactions 
between metabolites, thereby tracing what metabolic pathways are active under the given 
conditions. 13C isotope labeled substrates (e.g. glucose) are commonly used, since the use of 
different metabolic pathways often results in different isotope labeling patterns [20]. This 
approach is also called metabolic flux analysis (MFA) and it is very useful for elucidating pathway 
bottlenecks and regulatory mechanisms within metabolic networks [21–23]. While 
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Transcriptomics, Proteomics and Metabolomics focus on characterizing cellular components and 
their states, Fluxomics and Phenomics characterize cellular functional states and generally 
referred as Interactome (Fig. 2.1) [24]. The list of comprehensive data collection and analysis 
continues to expand and more specialized fields are appearing, such as Lipidomics, Localizomics, 
Glycomics, Phosphoproteomics and others (reviewed in [24, 25]).  
Integrating and interpreting high-throughput data 
The cellular phenotype results from the interplay of many cellular components, such as several 
genes, proteins and metabolites [2, 26]. Thus, comprehensive studies for extending our 
knowledge about cellular function often involve the integration an interpretation of different 
high-throughput data-types. For example, Usaite et al. reported the reconstruction of the yeast 
SNF1 kinase regulatory network and its central role in energy metabolism by using a combined 
analysis of transcriptome, proteome and metabolome [27]. In another example, Nagaraj and 
colleagues reported the mapping of a human cancer cell line using transcriptome and proteome 
[28]. In order to cope with increasing high-throughput data generation, computational biology 
has major tasks to perform, not only the establishment and maintenance of data repositories, 
but also the provision and update of visualization software for several different types of data, 
and, most importantly, the development of cutting-edge algorithms for data integration, 
interpretation and guidance of experiments [24, 29, 30]. Aiming at improving cooperation 
among different fields in Biology, standardization of the information is an absolute requirement. 
To this end, the Systems Biology Markup Language (SBML), an XML-based format, was 
developed for representation of biological networks [31].  
Saccharomyces cerevisiae 
Saccharomyces cerevisiae is a unicellular eukaryote classified in the kingdom of Fungi. It is a 5-10 
μm diameter ovoid-shaped budding yeast, its life cycle alternates between haplophase and 
diploidphase and both can exist in stable cultures. This yeast has been used for brewing, backing 
and wine fermentation since 6000 BC. However, it was not until the 19th century that it became 
object of study, when Louis Pasteur and others firstly associated fermentation with yeast 
metabolism. The species was named after its ability to ferment sugars - “Saccharomyces”, 
meaning sugar fungus, and to produce beer - “cerevisiae”, from “cerveja” in Portuguese or 
“cerveza” in Spanish [32, 33]. 
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Briefing on yeast physiology and central carbon metabolism 
Much of what is known today about S. cerevisiae is due to its biotechnological applications since 
many years. This yeast naturally produces ethanol and carbon dioxide in aerobic conditions and 
high sugar concentration, also known as overflow metabolism or Crabtree effect [34]. Although 
energetically unfavorable, alcoholic fermentation is the main source of energy production in 
high sugar conditions, while the tricarboxylic acids (TCA) cycle and oxidative phosphorylation are 
rather less active [34–36]. In aerobic batch conditions, a first exponential phase of growth occurs 
when glucose is consumed to form biomass and fermentation products, with a biomass yield on 
glucose of ~3.6 gDW/C-mol [34]. After glucose depletion, the culture typically experiences a short 
lag phase (diauxic shift) and restarts to grow on the available carbon sources resulting from 
fermentation, mainly ethanol, although glycerol and acetate are also commonly found. The 
second exponential growth phase is characterized by a slower growth rate (~0.087 h-1 compared 
to ~0.34 h-1 exponential growth rate on glucose), but higher biomass yield, ~10.5 gDW/C-mol, due 
to the occurrence fully respiratory metabolism [34]. Similarly, fully respiratory growth on glucose 
is achieved in continuous cultivation (~15 gDW/C-mol), where glucose is kept at low 
concentration and the dilution rate (and hence growth rate) is below the critical value for onset 
of fermentation [34, 37]. As in most of the living organisms, central carbon metabolism in yeast 
provides all the necessary building blocks for biosynthesis of macromolecules: 1) hexose-
monophosphates, needed for polysaccharides and pentose-phosphates for nucleic acids; 2) 
triose-phosphates, needed for glycerol of phospholipids; 3) pyruvate, the main branch point 
between respiro-fermentatitive metabolism, required for amino acids biosynthesis as well as for 
4) Acetyl-CoA, needed for fatty acids; 5) oxaloacetate and 6) 2-ketoglutarate, major building 
blocks for several amino acids [34]. 
Glucose metabolism in S. cerevisiae has been extensively studied, as glycolysis is usually the 
pathway carrying the highest flux in the metabolic network [34]. In fact, in the presence of 
glucose, most of the genes responsible for utilization of alternative carbon sources, as well as for 
respiration and gluconeogenesis, are repressed due to a phenomenon known as “carbon 
catabolite repression” or simply “glucose repression” [38–42]. The presence of glucose on the 
medium is sensed either by membrane-anchored sensor proteins or by hexose transporters 
(responsible by hexose uptake), which trigger a signaling cascade ultimately responsible for 
transcriptional repression/activation of several genes [38, 39]. Two signaling pathways work in 
synergy; glucose induction pathway and glucose repression pathway (Fig 2.2). 
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Figure 2.2: Simplified representation of the main regulatory pathways for glucose repression in S. cerevisiae. The 
glucose repression pathway (yellow) is responsible for repressing of genes involved in (or activating) the uptake of 
alternative carbon sources (e.g. GAL4, SUC2), gluconeogenesis, respiration and TCA cycle (e.g. HAP4).The glucose 
induction pathway (blue) is mainly responsible for the de-repression of hexose transporters, HXT1-HXT16 (Adapted 
from [43]). 
The glucose induction pathway is mainly responsible for the de-repression of hexose 
transporters, mediated via the membrane receptors Snf3 and Rgt2 leading to Mth1 and Std1 
degradation and consequent Rgt1 hyper-phosphorylation, and therefore inability to repress the 
hexose transporters (HXT1-HXT16) [44]. The glucose repression pathway is mainly responsible 
for repressing genes coding for enzymes involved in the TCA cycle, electron transport chain, 
gluconeogenesis and consumption of alternative carbon sources. Once inside the cell, glucose is 
phosphorylated by Hxk2, the Snf1 complex is inactivated and Mig1 is no longer phosphorylated 
and thereby it represses several genes by binding their promoter regions [44]. Given its similarity 
to higher eukaryotic systems including humans, as well as its relevance for biotechnology 
applications, glucose repression in yeast has received much attention, especially the regulatory 
proteins Snf1, Hxk2, Mig1/Mig2 and the transcriptional activator Hap4 [27, 43–45]. 
An eukaryotic model organism 
A continuously growing and highly interactive scientific community contributed to a great extent 
to the establishment of Saccharomyces cerevisiae as a eukaryotic model organism. One of the 
most important achievements in yeast genetics was the pioneering possibility to perform genetic 
manipulations through transformation, during the 1970’s [46, 47]. In 1996, S. cerevisiae was the 
first eukaryote with its complete genome sequence available, as a result of an EU-funded 
consortium [48]. By then, from the ~6000 structurally annotated genes, a small fraction had 
characterized biological function (30%). Nowadays, the genes with unknown function in yeast 
range from 10 to 15% [33, 49]. The availability of the genome sequence made possible to 
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perform large-scale studies, thus yeast became a preferred organism for establishing several 
high-throughput assays, as well as for libraries construction; gene expression started soon being 
studied with microarray technology [50], as well as the first protein-protein interactions 
networks also started to be uncovered [51]. In 2002, a yeast deletion library was constructed, 
where nearly all the open reading frames were deleted [52]. In 2003, a comprehensive library of 
green fluorescent tagged proteins (GFP) was assembled in order to study protein cellular 
localization [53]. During the same year, the first of a series of genome-scale reconstructions of 
the S. cerevisiae metabolic network was published [54]. Again, this was the first of its kind 
among eukaryotes. 
As consequence of a continuous development of novel technological resources, the number of 
high-throughput studies using yeast continues to increase. One of the most recent examples is 
the assembly of a comprehensive double gene deletion library and the corresponding genetic 
interactions, by Constanzo et al. [55, 56]. A genetic interaction (also called epistatic interaction) 
occurs when the combination of gene deletions results in a phenotype different than expected 
based on the individual gene deletion phenotypes [57–59]. When the observed phenotype for a 
double deletion mutant is worse than expected, it is said to be a negative or aggravating 
interaction between the two genes. If the opposite happens, it is a positive or alleviating 
interaction. Genetic interactions are often the outcome of associated gene functions, and 
therefore highly contribute to better understand genotype to phenotype relationship. The study 
by Constanzo et al. uncovered the interaction profile of ~75% of the yeast annotated genes. 
Similar biological processes were found to cluster together and functional cross-connections 
between all bioprocesses (pleiotropy) were observed. In a subsequent work, Szappanos et al. 
expanded the genetic interactions dataset to include the interaction profiles of 80% of the 
metabolic genes and performed an integrated data analysis using a genome-scale model of yeast 
metabolism [60]. They investigated the connection between degree of genetic interaction and 
pleiotropy within metabolism, a feature also observed in the dataset by Constanzo et al.. 
Ultimately, they introduced a machine-learning method to reconcile empirical interaction data 
with the model predictions, in order to improve the predictive power of the metabolic model. 
Within my thesis, the genetic interactions dataset focused on metabolism was used to validate a 
new algorithm for predicting cellular phenotype using the yeast genome-scale metabolic model, 
while simultaneously aiming at gaining new insights about modes of operation of the metabolic 
network. 
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Profiting from accumulated knowledge over the years, and due to conserved protein sequences 
and functions across species up to higher eukaryotes, S. cerevisiae provides useful insights in 
several disciplines of Biology and Medicine, ranging from Biochemistry and Evolution to Aging 
and even complex Neurological Disorders studies [26, 61, 62]. Many of the generated resources 
useful for yeast research are accessible from dedicated databases and repositories, some of 
them presented in Table ST2.1. 
Industrial applications 
Since the 1970’s, when yeast geneticists introduced direct genetic engineering by 
transformation, a complete new dimension was added to biotechnology of S. cerevisiae. This 
would allow not only improving current knowledge about yeast products and physiology, but 
also the possibility to extend the genetic repertoire of the cell factory in order to obtain desired 
features, such as expanding substrate and product ranges [33]. Together, the practical 
knowledge about yeast physiology and biochemistry obtained over the years and the genome 
sequencing project, further enhanced its potential for industrial application. In fact, S. cerevisiae 
presents several advantages for applications in industry: it holds the GRAS (Generally Recognized 
as Safe) status from the American Food and Drug Administration; its genetic engineering toolbox 
is highly optimized; extensive knowledge about physiology and biochemistry; relatively easy 
scaling-up of industrial processes; tolerance to low pH (3 to 5), high sugar and ethanol 
concentration, thereby decreasing the risk for bacterial contamination; ability to grow 
anaerobically and aerobically; ability to utilize a wide range of sugars [63].  
Nowadays, a broad variety of compounds are obtained from S. cerevisiae; not only 
pharmaceutical proteins, as human insulin, hepatitis and papillomavirus vaccines, but also fine 
and commodity chemicals and biofuels [19, 64]. While protein production potential by this yeast 
can be limited by its inability of accurately achieve the desired glycosylation patterns, production 
of small molecules is continuously gaining popularity among industry and academia [64, 65]. As a 
matter of fact, the fossil based natural resources are becoming scarce, and at the same time 
they directly or indirectly provide most of the fuels, fine and commodity chemicals worldwide. 
Biotechnology presents an attractive alternative, since microorganisms can be used to convert 
renewable sources, e.g. plant biomass, to valuable chemicals [64, 66]. 
Figure 2.3 shows several examples of added-value compounds which have been, or can 
potentially be, produced in S. cerevisiae. Among the represented compounds, native molecules 
such as and glycerol and fumarate are currently used as commodity chemicals. Biofules are also 
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strongly represented; ethanol, native to yeast and by far the dominating biofuel, but also other 
biomolecules with better physicochemical properties, such as propane-1,2-diol, isobutanol and 
2/3-Methyl-1-butanol. The extensive list of fine chemicals contains polyketides (6-methylsalicylic 
acid), isoprenoids and sesquiterpenes (farnesol, valencene, artemisinic acid), carboxylic acids 
and aldehydes (vanillin), polyunsaturated fatty acids (PUFAs), among others [67–76]. These are 
chemically very diverse molecules, typically found as secondary metabolites of fungi, bacteria or 
plants, and have several applications as pharmaceutical ingredients, flavouring and preserving 
agents to be used in perfume and food industries [19, 64]. With a currently increasing capability 
for screening for novel compounds, many other molecules are to come [19, 77]. Despite their 
chemical diversity, most of the compounds can be obtained from intermediates of the central 
carbon metabolism, such as pyruvate and acetyl-CoA or from amino acid biosynthesis, such as 
aromatic amino acids and isoleucine, leucine and valine super family (Fig. 2.3). Tuning the 
distribution of the metabolic fluxes around these key branches of the metabolic network could, 
in principle, favour the synthesis of all the products obtained from the same native precursor. 
Additional network rewiring would be required for specific energy and cofactor supply for each 
of the products. Retrofitting of the metabolic network towards desired cellular properties has 
been termed Metabolic Engineering [78, 79], as described in detail in the next section. 
Metabolic Engineering 
Many added-value biomolecules are naturally found in a panoply of microbial or plant hosts. 
However they are usually present in trace amounts, which impair the economical viability of a 
potential biotech application [19, 77]. In 1991, J. Bailey and G. Stephanopoulos proposed, in two 
independent publications, what today is a field in biological sciences, Metabolic Engineering [78, 
79]. Metabolic engineering was defined as “the improvement of cellular activities by 
manipulations of enzymatic, transport and regulatory functions of the cell with the use of 
recombinant DNA technology” [79]. This way, they propose the retrofitting of the metabolic 
network towards the desired feature in a rational and targeted manner. Indeed, in order to 
improve the yield and productivity of the desired product, knowledge-oriented strategies are 
required often involving 1) improving precursor metabolites and cofactors supply, 2) up-
regulation of genes involved in product export routes or 3) redesign of metabolic pathway, so 
feedback inhibitions and competing pathways are avoided, among others [19]. 
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One of the most prominent examples of successful metabolic engineering is the production of 
the antimalarial drug precursor, artenimisinic acid, in S. cerevisiae [73]. The strategy required the 
heterologous expression of two enzymes for synthesizing artenimisinic acid from farnesyl 
pyrophosphate, an intermediate of the mevalonate pathway, essential for obtaining ergosterol. 
Additionally, de-regulation of the mevalonate pathway was performed by overexpressing several 
pathway genes, in order to increase the precursor supply for artenimisinic acid [73]. Other 
examples of successful metabolic engineering are higher alcohols production by E. coli [80], 
sesquiterpenes and biofules production by S. cerevisiae [76, 81]. Applications of metabolic 
engineering are not limited to increase product range and yield. Several attempts for 
engineering microbes for expanding substrate range are underway, due to the absolute 
requirement of avoiding resource competition between food and chemicals production [63, 64, 
82]. Substrates such as waste cheese whey and agricultural by-products (corn-cob, bagasses and 
lignocellulosic plant stocks) represent possible options, yet they usually comprise a diversity of 
sugars which are not naturally metabolized by conventional microorganisms [64, 83]. Thus, 
several efforts have been put into expanding S. cerevisiae range of substrate utilization, e.g. 
cellulose [84], L-arabinose [85], lactose [86], galactose [62] and xylose [87, 88]. 
Metabolic engineering cycle 
The process to obtain microbial cell factories engages a sequence of design, construction and 
analysis, often applied in a cyclic manner (Fig. 2.4) [89]. Over the last decade, advances in 
Synthetic and Systems Biology generated new resources and technologies extremely useful for 
metabolic engineering [19, 90]. Nowadays, the concept of metabolic engineering for strain 
improvement is expanded from “rational metabolic engineering” to include “evolutionary 
engineering” and “reverse metabolic engineering”, with implication on different stages of the 
strain improvement process [19, 90]. 
The first stage while establishing a cell factory is the decision about what workhorse to select. 
Several factors must be considered, such as whether the host is, or not, a native producer, its 
response to different substrates, toxicity of the compound and pathway intermediates, 
availability of genetic engineering tools, availability of vast knowledge about physiology and cell 
biology (important for further engineering) and suitability to the fermentation process [77]. 
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Figure 2.4: Metabolic engineering cycle. Improving cell factories involves three consecutive steps, design, 
construction and analysis. Each circle corresponds to one step. Design employs computational tools and comparative 
‘omics’ in order to find target for genetic manipulation. Construction employs genetic and protein engineering, as well 
as synthetic biology tools for introducing the desired modifications. Adaptive evolution can be used as a global 
approach to evolve the cell factory under the appropriate selective pressure, so the desired phenotype is favored. 
Analysis employs strain characterization and systems biology tools for obtaining a complete readout of the engineered 
phenotype. Computational biology plays a fundamental role, often applied for integrated data analysis. 
The design phase might be the first stage of the cycle, when one aims at producing a 
heterologous compound, or a more advanced step, when the host already produces the desired 
metabolite and the goal is to improve its productivity [89]. The design of cell factories for 
heterologous production of valuable compounds benefits from Synthetic Biology tools for 
assembly of new metabolic pathways [91]. In silico tools allowing the simulation of novel 
pathways, such as the Biochemical Network Integrated Computational Explorer (BNICE), are 
especially helpful for providing guidance for experimental work [92]. Alternatively, when the aim 
is to improve an existent pathway, the question is how to retrofit the entire metabolic network 
so it can support high product yields. Several options can be employed here; one possibility is to 
take a rational approach involving a genome-scale metabolic model and available algorithms to 
find gene targets to be manipulated, thereby increasing the production [93, 94]. This approach is 
discussed in detail in the next section. Otherwise, one can take an organism which has the 
desired phenotype, carry out different high-throughput analysis and perform reverse 
engineering to implement the relevant findings on the selected strain.  The organism with the 
desired features might be a native producer, or it may also be found while screening a mutant 
library, or even a mutant obtained through adaptive evolution [95–98]. 
The construction step is the implementation of the designed strategy. Synthetic biology and 
protein engineering are the excellence fields, providing the most sophisticated tools for 
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engineering the cells. Depending on the strategy to be implemented, different tools might be 
applied for constructing the improved cell factory. Some of them focus on targeted effects, such 
as control of gene expression and protein activity, while other approaches are rather global, 
such as adaptive evolution or global transcription machinery engineering [19, 90]. Quantitative 
control of gene expression levels is the most established approach and it can be achieved in a 
number of different ways. One option is to control of the gene copy number, which can be 
accomplished by providing a plasmid or by genomic integration (or deletion) of the target gene. 
Instead, the native promoter of the target gene can also be swapped with another promoter of 
interest. Both approaches for controlling gene expression largely benefit from promoter 
libraries, generated either from native [99] or synthetic promoter regions [100–102]. Finally, 
riboregulators, such as antisense RNA or short interfering RNAs (siRNA) can also be used to 
efficiently regulate gene expression by post-transcriptional control [103–105]. The increasing 
availability of fast cloning techniques, such as the Gateway system [106] or USER cloning [107, 
108], highly facilitate the construction step, since they allow the assembly of fairly big DNA 
constructs, while being relatively cheap and uncomplicated techniques. Rather than controlling 
gene expression, increasing efficiency of an enzyme, either by increased enzyme activity or 
selectivity (e.g. change of the cofactor usage), constitutes another option for improving cell 
factories. Protein and enzyme engineering research areas contribute with different options; 1) 
rational design by site-directed mutagenesis based on existing knowledge and computational 
design, and 2) directed evolution achieved through random mutagenesis based on error-prone 
PCR or DNA shuffling [109, 110].  
Global approaches are useful if fine-tuning of multiple genes is required. Multiple Gene 
Promoter Shuffling – MGPS and global Transcription Machinery Engineering – gTME, are two 
examples [111, 112]. Modulating the spacial organization of enzymes, either by using a protein 
scaffold or by directly fusing of the proteins of interest, is an alternative option also to be used 
for increasing the metabolic flux through a given pathway [113, 114]. Al last, adaptive evolution 
can be used as a global approach to evolve the cell factory, if the appropriate selective pressure 
can be applied and the desired phenotype is favored [62]. 
The analysis step aims at evaluating the cell factory and it always follows the strain construction 
and precedes the next design step. In order to assess the quality of the cell factory, fully 
characterization of the obtained mutant is needed. This usually involves physiological 
characterization of the strains, if possible, in well controlled conditions [89]. The analysis of 
mutant phenotypic traits has improved enormously within the last 10 years, since it highly 
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benefits from Systems Biology tools, such as transcriptome, proteome, metabolome and 
interactome [19, 90]. If the selected construction strategy implied random genetic mutations, 
e.g. random mutagenesis or adaptive evolution, genome (re)sequencing will also take part in the 
analysis [97]. Computational tools very much contribute to the data analysis, since models are 
helpful for data integration and interpretation, especially when multiple types of data are in use 
[93]. The algorithm for identification of reporter metabolites is a pioneering example of 
integration of gene expression data with the genome-scale metabolic network topology in order 
to find the metabolites around which the most significant transcriptional changes occur [115]. 
The analysis step is fundamental for a good following strategy design step in the case of further 
improvement, yet it may be also the last step of the strain improvement, when the desired 
features are obtained [89]. 
Genome-Scale Metabolic Modeling 
In order to fully characterize a given cellular state, one would profit of knowing all the genes 
being transcribed, as well as all the proteins and metabolites existing within the cell given 
certain conditions. Yet, as already mentioned above, how all these components interact is 
fundamental to fully understand biological systems. To this end, metabolism is a privileged 
subcellular system, since interactions between enzymes and substrates/products have been 
extensively collected and characterized over several years [34, 93]. Metabolic pathway 
reconstruction has been around for reasonably long time, and availability of complete genome 
sequences, from the late 1990’s, prompted the assembly of complete metabolic networks, the 
so called genome-scale metabolic network reconstructions [93, 116]. Such reconstructions 
essentially contain a set of stoichiometric equations representing the biochemical reactions of 
the cell, as well as detailed information about reaction reversibility and cofactor usage. 
Furthermore, as many of the reactions have known association with genes, these models 
provide an excellent opportunity for studying genotype to phenotype relationships [93]. 
Briefing on genome-scale metabolic models reconstruction 
Historically, the initial application of genome-scale metabolic models was to provide 
understanding of the characteristics of microbial pathogens, so the first model available was for 
Haemophilus influenza [117]. Since then, several organisms had their network reconstructed, 
including E. coli [118], among other bacteria, S. cerevisiae [54], the first eukaryote, Arabidopsis 
Thaliana [119], the first plant, and even Homo sapiens [120]. To date, more than 60 species have 
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genome-scale metabolic reconstructions available and an especially dedicated knowledgebase – 
Biochemical Genetic and Genomic (BiGG) – is assembled [121]. Since whole genome sequencing 
prices continue to decrease and an automated pipeline for metabolic network reconstructions is 
already available, many more genome scale reconstructions are to come [122]. Kim and co-
workers (2011) provide a comprehensive timeline of genome-scale models reconstructed since 
1999 until 2011 [116].  
Methods for building genome-scale metabolic reconstructions have been established and 
extensively reviewed [116, 123, 124]. There are three important steps; 1) initial network 
reconstruction is carried out based on the functional annotated genome sequence followed by 
2) extensive literature search for collecting biochemical evidence from several different sources 
including databases, text books and scientific articles. As much information as possible is 
collected about enzymes and reactions characteristics, such as EC number, localization, 
associated gene(/s) and reaction reversibility, so as to obtain a well curated reconstruction. 3) 
The reconstruction is converted into a mathematical model (described in the next section) that 
can be analysed through constraint based approaches and validated using experimental data on 
cell physiology. Although network reconstruction has been extensively standardized, new 
relevant information about the organisms is constantly arising, especially concerning organisms 
with extensive research communities, such as S. cerevisiae or E. coli. Thereby, several updated 
and, in some cases, manually curated high-quality models are usually available for such 
organisms. S. cerevisiae is an outstanding example with 10 different models available, including a 
consensus model obtained by a community effort towards standardization of this resource [125, 
126]. 
Applications of genome-scale models 
The applications of the genome-scale metabolic models are continuously increasing and they are 
often conveniently divided into different categories, such as: contextualization of high-
throughput data, directing hypothesis-driven discovery, network properties analysis, study of 
multi species relationships, evolution of metabolic networks and guidance for metabolic 
engineering. Several reviews focusing on genome scale models applications are recently 
available [93, 116, 126], thus only few examples will be referred here. 
Numerous studies are available where the metabolic network is used to interpret high-
throughput data in an integrative fashion [27, 115, 127, 128]. Zelezniak et al. used network 
topology analysis to elucidate transcriptional regulatory signals of Type 2 Diabetes [129]. Other 
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examples suggest the use of genome-scale models for finding drug targets [130, 131]. Recent 
applications have appeared suggesting the use of such models for studying microbial 
interactions [132–134]. At last, genome-scale models are extensively used for designing 
metabolic engineering strategies [81, 135, 136], also the subject of Chapter 2 of the thesis. 
Predicting the distribution of metabolic fluxes 
While some applications (e.g. network properties or contextualization of high-throughput data) 
often use stoichiometric models as scaffold for analysis, focusing on the network topology, 
others make use of the predictive capabilities of the models for estimating cell physiology and 
internal flux distributions (e.g. metabolic engineering). Therefore, these quantitative approaches 
require a proper mathematical description of the metabolic network and its operation modes. 
Already in the 1970’s, Metabolic Control Analysis aimed at elucidating the parameters 
responsible for the control of metabolic fluxes [137, 138]. Flux control is determined by the 
kinetic parameters of the enzymes, as well as by the thermodynamic constraints of each 
reaction. Therefore, kinetic modeling of metabolism requires extensive knowledge about 
enzyme parameters, which should, ideally, be collected at conditions similar to those in vivo. 
Unfortunately, this is not the case for most of the available data, mostly because of lack of 
knowledge for reproducing the intracellular environmental conditions. It was not until 2010 that 
efforts have been put together to characterize the intracellular pH, as well as the concentration 
of several salts, so standard conditions for measuring kinetic parameters could be established 
[139–141]. Yet, dynamic modeling of metabolism would also require information about allosteric 
regulation and post-translational modifications of the enzymes, which still remain highly 
uncharacterized [142]. 
In contrast, Metabolic Flux Analysis (or Metabolic Network Analysis) became popular in the 
1990’s, initially using models describing the central carbon metabolism, and it aims at 
elucidating the metabolic flux distribution based on reaction stoichiometry, metabolite exchange 
rates and thermodynamic constraints [21, 126, 143]. This approach for modeling cellular 
metabolism relies on mass conservation and thermodynamic constrains at a steady state, 
thereby it does not require extensive knowledge about reaction kinetics. The metabolic model is 
represented as a system of linear equations (Fig. 2.5A). The stoichiometric coefficients are 
represented in the stoichiometric matrix, where the number of rows corresponds to the number 
of intracellular metabolites, and each column corresponds to a reaction (Fig. 2.5B). Because the 
metabolic networks usually contain more reactions than metabolites (more linearly independent 
46
Ph.D. Thesis, Ana Rita Brochado 
23 
 
variables than constraints), the system is frequently underdetermined and many solutions are 
possible. There are two major categories for solving such linear system, thus predicting what 
metabolic pathways are active under certain environmental and genetic conditions: pathway-
based approaches and optimization-based approaches [144]. Pathway-based approaches 
explore the entire reactions space by using one of the four methods currently established: 
extreme pathways [145], elementary flux modes [146], extreme currents [147] and minimal 
generators [148] (reviewed in [149, 150]). Given the combinatorial nature of the underlying 
solution space, application to large-scale metabolic networks, as genome-scale models, is still 
limited [151]. Therefore, optimization-based approaches, which use the same mass balance and 
thermodynamic constrains, can be applied in order to find the active flux distribution by using a 
pre-defined objective function. 
 
Figure 2.5: Fundamentals of optimization based approaches for simulation of cellular phenotype. A) The metabolic 
network, which contains all stoichiometric relationships between metabolites (circles), as well as reversibility 
information concerning all the reactions (arrows). U1 represents the reaction for substrate uptake (red). Reaction B 
(green) connects all the metabolites required for growth. Reaction R9 (purple) represents a metabolite which is 
known to be secreted (blue circle). B) The stoichiometric matrix contains all the stoichiometric coefficients. Each row 
corresponds to one metabolite, while each column corresponds to one reaction. The steady state assumption after 
applying mass balance constraints to each intracellular metabolite implies that there is no variation of the metabolites 
concentration over time (column of zeros). C) The stoichiometric matrix, together with the thermodynamic 
constraints, as well as information about metabolites uptake and secretion constraint the solution space. D) An 
objective function is established and maximization/minimization of the objective function yields to the optimal 
internal flux distribution (yellow). 
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Flux Balance Analysis (FBA) was initially proposed by Varma and co-workers in 1993, and it was 
the first optimization-based method established for estimating active flux distributions [152, 
153]. The problem was implemented by using a linear programming formulation (LP [154]), and 
solved for maximizing growth, hypothesised as metabolic objective function (Fig. 2.5D) [152, 
153]. Reactions reversibility information is used for upper and lower bounds to constraint the 
flux of the reactions (variables), and the exchange rates between the cell and the extracellular 
broth, e.g. glucose uptake and ethanol production rates, are also taken into account for further 
constraining the solution space (Fig. 2.5C). 
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Where vGorwth represents the flux through the reaction converting all required metabolites into 
biomass (biomass equation), S represents the stoichiometric matrix, v is the vector containing 
the fluxes, vilb and viub correspond to the lower and upper bounds applied to reaction i, vglc 
represents the glucose (or other substrate) uptake rate, which is experimentally determined (a). 
If no more information is given, e.g. experimentally determined fluxes, the upper and lower 
bounds are defined by the reaction reversibility. For reversible reactions both upper and lower 
bounds are considered to be unbounded (+/- infinity). In the case of irreversible reactions, the 
lower bound is set to zero (Fig. 2.5B). 
This approach proved to be very useful, especially for predicting gene essentiality and, to some 
extent, the flux distribution for microbes growing under optimal conditions [155, 156]. 
Nowadays, FBA is vastly used for metabolic modeling and there are several reviews on the 
method [157, 158]. New methods were established based on FBA, such as dynamic FBA, for 
estimating metabolic distributions over a time-course [159], rFBA, for including regulatory 
constraints [160], iFBA, which includes regulatory constraints over a time-course [128], 
FBAwMC, which includes molecular crowding as additional constraints [161], among many 
others (reviewed [94]). The COBRA toolbox is a specialized Matlab package for constraint-based 
reconstruction and analysis of genome scale models [162, 163]. 
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Designing and selecting objective functions for metabolic modeling 
While using optimization-based approaches, the outcome of the simulations is totally dependent 
on the objective function to be used, therefore it is very important that the selected objective 
function is suitable for the problem [154]. The design of objective functions, properly 
formulating the desired biological principles, has been a topic of discussion over time. 
Computational tools have been proposed to address this question, e.g. ObjFind [164], 
GrowMatch [165] and BOSS [166]. Moreover, Schuetz and colleagues experimentally tested 
several hypothesis applicable to E. coli growing under different experimental conditions, e.g. 
maximization of growth, maximization of ATP yield or minimization of overall intracellular flux 
[167]. Their findings suggest that there is no universal objective function which applies to all the 
conditions and systems, implying that the biological principles governing cellular metabolism 
under different conditions might also be different. 
The principle underlying the objective function first selected for FBA, maximization of growth, 
implies that the organisms are optimized for maximal growth, coherent with evolutionary 
theories [152, 153]. On the other hand, many approaches to answer biological questions lay on 
perturbation of the system and evaluation of the outcome. For instance, a widely spread 
method for assigning gene function is to delete the gene and look for missing features [52, 55]. 
Thus, if metabolic modeling is to be used for understanding such mechanisms, other objective 
functions must be used instead of maximization of fitness, since deleting a gene may impair the 
assumption of “fully adapted behaviour” [168]. Predicting the behaviour of perturbed metabolic 
networks is extremely relevant for basic research, as simulation of gene deletions, but also for 
applied fields, e.g. metabolic engineering, where the aim is to select the genetic perturbation 
leading to specific cellular features [79].  
In 2003, Segre and co-workers proposed Minimization of Metabolic Adjustment (MoMA) as 
biological principle to simulate the behaviour of perturbed metabolic networks [168]. In contrast 
to FBA, MoMA relies on the premise that the mutant flux distribution will be as similar as 
possible to that of the wild-type. It was originally formulated as a quadratic programming 
problem [169] for minimization of quadratic distance between the flux distribution of the wild-
type and the mutant [168]. A linear programming formulation for MoMA has also been 
proposed, lMoMA, and it is has been shown to have comparable results [162]. MoMA was 
reported to outperform FBA in some applications, namely related to the prediction of single 
gene deletion phenotypes and their internal flux distributions [168, 170], metabolic engineering 
[81] and microbial community analysis [132]. It is important to mention that the quality of the 
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wild-type flux distribution to be used as reference is crucial for obtaining meaningful results with 
MoMA. Such reference flux distribution is often obtained by using FBA while, desirably, extra 
information from 13C based flux analysis can be used to impose additional constraints on the 
metabolic network. At this stage, minimization of intracellular flux (another objective function) 
can also be used in order to minimize mathematical artifacts, such as closed loops of fluxes that 
do not bring net change, and further improve the reference flux distribution [170]. At last, for 
predicting the phenotype of perturbed metabolic networks, Regulatory On/Off Minimization of 
metabolic flux changes – ROOM, has also been proposed [171]. With a similar biological 
hypothesis to MoMA, ROOM aims at minimizing the number of significant flux changes with 
respect to the wild type, but it applies a Mixed Integer Linear Programming (MILP [154]) 
formulation, as opposed to minimizing the total distance between the flux vectors. 
Metabolic modeling for guiding metabolic engineering 
As previously mentioned, retrofitting the metabolic network by rewiring metabolic fluxes is 
fundamental for obtaining increased production of the desired compound, and thereby 
sustainable cell factories [19, 90]. However, the high connectivity-degree of metabolic networks, 
often related to the usage of cofactors, such as ATP and NADH, weakens the potential of 
intuitive solutions for the problem [172]. Furthermore, an optimized cell factory requires a fine-
tuned balance of allocation of cellular resources between the production of biomass and of the 
desired compound [21, 89, 173]. To this end, genome-scale metabolic models can be applied in 
order to provide guidance for metabolic engineering, while finding target genes for genetic 
manipulation. The implementation of such problem is not trivial; if a linear programming routine 
is applied for maximizing the production of a given metabolite, the optimal solution does not 
lead to biomass formation in most of the cases, therefore the solutions are often not biologically 
meaningful. In 2003, the first platform developed towards finding target genes, deletion of 
which would lead to improved yield of a desired compound, while the biological objective 
function is still satisfied, was proposed by Burgard et al. [174]. OptKnock uses an elegant 
approach for finding the genes that, when deleted, would couple the production of the desired 
compound to biomass formation. In genome-scale metabolic modeling context, a gene deletion 
is formulated by setting the upper and lower bounds of the corresponding reaction to zero. By 
using a bi-level (or nested) optimization, they suggested the maximization of the production of 
the desired metabolite (design objective), subject to maximization of growth (biological 
objective, Fig. 2.6A). The number of genes to be deleted is a parameter decided prior to 
simulation and it depends on the product and producing host; deletion of several genes is often 
50
Ph.D. Thesis, Ana Rita Brochado 
27 
 
required, due to the robustness of metabolism [172, 175, 176]. Given the number of genes to be 
deleted, OptKnock is guaranteed to find the targets leading to the highest production (global 
optimal solution) [174]. Patil et al. put forward another platform for finding metabolic 
engineering targets based on Darwinian evolutionary principles, OptGene [177]. They propose 
the use of a genetic algorithm, which goes through rounds of mutations, crossing and selection 
in order to find the best candidate, given a fitness function (Fig. 2.6B). The fitness function is also 
of particular novelty within this algorithm, because such framework enables the use of non-
linear functions as objective. A proxy for productivity is suggested by the authors, which is 
obtained by multiplying the growth flux by the flux leading to the product of interest, Biomass-
Product Coupled Yield - BPCY. As a genetic algorithm cannot guarantee to find the optimal 
solution for the problem, the number of generations or the fitness function can be used as 
stopping criteria for OptGene [177]. 
 
Figure 2.6: OptKnock and OptGene optimization frameworks for guiding Metabolic Engineering. A) Bi-level 
optimization structure of OptKnock (in [174]).  B) OptGene schematic overview (adapted from [177]).  
Several other algorithms with different/improved characteristics are available nowadays; 
OptStrain, which finds optimal reactions to be deleted from, as well as to be added to, the 
metabolic network in order to improve the phenotype [178]. OptForce, which finds reaction 
targets for deletion or overexpression in order to achieve a desired phenotype [98]. OptORF, 
which aims at finding optimal metabolic and regulatory perturbations to design metabolic 
engineering strategies [179]. An open-source software platform for in silico metabolic 
engineering, termed OptFlux, focused on providing the user with some of these frameworks, as 
well as different options for alternative objective functions, is already available [180]. 
Alternatively, the latest version of the COBRA Toolbox (v2.0) also includes some of these 
algorithms [163]. 
Even though several in silico tools for guidance of metabolic engineering are available, obtaining 
improved cellular features through rational design is still a challenge. For instance, though 
optimization problems are guaranteed to provide an optimal solution, this does not imply 
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uniqueness [154]. Given the existence of several alternative pathways within metabolism, some 
of these pathways may satisfy the same requirements for the objective function, thereby they 
are also alternative solutions. Identifying the uniqueness of a solution can be accomplished by, 
e.g.  maximizing and minimizing all fluxes under the given set of constraints (flux variability 
analysis), while identifying all optimal solutions may be accomplished by implementing a MILP 
routine or by elementary mode analysis [146, 176, 181]. Flux variability analysis should always 
be taken into account while using genome-scale models, especially for metabolic engineering, in 
order to guarantee that the selected targets will lead to improved cellular features, 
independently of the uniqueness of the solution. RobustKnock is an extension of OptKnock and 
it aims at finding optimal set of gene deletions for improved production, while guaranteeing that 
non-unique solutions (solutions presenting alternative pathways) are avoided [182]. 
Fine-tuning of metabolic networks often involves the reduction, suppression and/or 
amplification of fluxes. While deletion of a reaction is a binary problem, therefore relatively 
simple for in silico formulation, reduction or amplification of fluxes implies knowing the 
amplitude of the variation. More importantly, once a reaction if found as a target for 
amplification (or reduction), e.g. by OptForce, a quantitative relationship between reaction 
amplification (or reduction) and gene overexpression (or downregulation) should be known in 
order to accurately predict the effect of the genetic manipulation [98]. Because of complex 
mechanisms of regulation, the attempts to verify linear correlations between gene expression 
and flux changes have failed so far, suggesting the prevalence of non-linear relationships [183]. 
Further characterization of the cellular regulatory mechanisms is expected to contribute to 
better characterize such non-linear relationships. Moreover, this would allow more accurate 
quantitative prediction of genetic manipulations, useful for metabolic engineering, but also for 
expanding our understanding of genotype to phenotype relationships. 
At last, incorporation of regulatory constraints in metabolic models is expected to greatly 
influence the outcome of predictions. As mentioned before, some frameworks for including 
transcriptional networks within phenotype simulations are already available [160], as well as a 
simulation platform for including regulatory genes as targets for metabolic engineering, OptORF 
[179]. Despite providing better predictive power in some cases [160], these frameworks are 
limited due to lack of extensive knowledge about regulatory mechanisms from a qualitative, but 
mostly from a quantitative perspective. Regulatory networks mostly present non-linear 
behaviour and, also here, finding a solution for combining non-linear approaches with the 
established linear optimization tools would be of great interest for the scientific community. 
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Conclusions 
Metabolism is one of the most well characterized subcellular systems, as biochemical reactions 
occurring within the cell have been studied and assembled in metabolic pathways over the 
years. A large fraction the genes coding for enzymes, referred as metabolic genes, are 
functionally annotated. Yet, prediction of phenotype based on genotype is, in many cases, still 
not possible. A holistic approach of cellular systems is needed to completely understand how 
phenotype arises from the genotype, and genome-scale stoichiometric models represent a 
suitable computational framework for simulating and studying such relationships. Better 
characterization of biological features, such as regulation, are expected to expand the range of 
application and quality of genome-scale models. 
Availability of extensive knowledge and dedicated technology for genetic manipulation and high-
throughput data generation conferred S. cerevisiae its current status of a eukaryotic model 
organism. Additionally, this yeast is largely used for production of food and beverages and, 
thereby, it is well established among industrial applications. Combined, these attributes make S. 
cerevisiae a preferred host for metabolic engineering. This chapter illustrated the current 
applications of yeast as a model organism and as cell factory. The importance of applying 
stoichiometric genome-scale modeling for metabolic engineering was also emphasized. 
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Chapter 3: Metabolic Engineering for Vanillin Production in S. 
cerevisiae. Part 1 – Metabolic Modeling for Strain Improvement 
 
This chapter is based on the publication: 
“Improved vanillin production in baker’s yeast through in silico design”. Ana Rita Brochado, 
Claudia Matos, Birger L Møller, Jørgen Hansen, Uffe H Mortensen, Kiran Raosaheb Patil. 
Microbial Cell Factories 9:84 (2010) 
Abstract 
Vanillin is one of the most widely used flavoring agents, originally obtained from cured seed 
pods of the vanilla orchid Vanilla planifolia. Currently vanillin is mostly produced via chemical 
synthesis. A de novo synthetic pathway for heterologous vanillin production from glucose has 
recently been implemented in baker’s yeast, Saccharomyces cerevisiae. In this study we aimed at 
engineering this vanillin cell factory towards improved productivity and thereby at developing an 
attractive alternative to chemical synthesis. 
Expression of a glycosyltransferase from Arabidopsis thaliana in the vanillin producing S. 
cerevisiae strain served to decrease product toxicity. An in silico metabolic engineering strategy 
of this vanillin glucoside producing strain was designed using a set of stoichiometric modeling 
tools applied to the yeast genome-scale metabolic network. Two targets (PDC1 and GDH1) were 
selected for experimental verification resulting in four engineered strains. Three of the mutants 
showed up to 1.5 fold higher vanillin β-D-glucoside yield in batch mode, while continuous culture 
of the ∆pdc1 mutant showed a 2-fold productivity improvement. This mutant presented a 5-fold 
improvement in free vanillin production compared to the previous work on de novo vanillin 
biosynthesis in baker’s yeast. 
Use of constraints corresponding to different physiological states was found to greatly influence 
the target predictions given minimization of metabolic adjustment (MoMA) as biological 
objective function. In vivo verification of the targets, selected based on their predicted metabolic 
adjustment, successfully led to overproducing strains. Overall, we propose and demonstrate a 
framework for in silico design and target selection for improving microbial cell factories. 
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Background 
Vanillin is a plant secondary metabolite and the main constituent of natural vanilla - one of the 
most important flavoring agents. The annual market for vanillin exceeds 16,000 tons, although 
only 0.25% of this originates from cured seed pods of the vanilla orchid, Vanilla planifolia. The 
remaining demand for vanillin is fulfilled by chemical synthesis from lignin or fossil 
hydrocarbons, in particular guaiacol [1]. Sustainable and environmental friendly routes have 
been proposed for obtaining vanillin through bioconversion of eugenol and ferulic acid by 
bacteria or fungi [2–4]. Alternatively, an attractive option was recently reported by Hansen et al 
(2009), who demonstrated de novo vanillin biosynthesis from glucose in baker’s and fission 
yeasts [5]. The native metabolic precursor for this de novo pathway is 3-dehydroshikimate (3-
DHS), an intermediate of the shikimate pathway for aromatic amino acids biosynthesis. To 
convert 3-dehrydroshikimate into vanillin, four genes encoding the required four enzymatic 
activities were obtained from different organisms, Podospora pausiceta, Nocardia sp., 
Escherichia coli and Homo sapiens (Fig. 1) [5]. Inspired by the fact that metabolic engineering has 
been successfully applied to improve the yield of e.g. sesquiterpenes [6], ethanol [7, 8], 
artemisinic acid [9] and succinic acid [10] production in Saccharomyces cerevisiae, we 
hypothesized that vanillin production could also be improved by implementing a metabolic 
engineering strategy [11]. An immense collection of systems biology tools, in addition to well-
established technologies for genetic manipulation, renders S. cerevisiae a very amenable 
organism for metabolic engineering [12–14]. 
 
Figure 3.1: Schematic representation of the de novo VG biosynthetic pathway in S. cerevisiae (as designed by 
Hansen et al [5]). Metabolites are shown in black, enzymes are shown in black and in italic, cofactors and additional 
precursors are shown in red. Reactions catalyzed by heterologously introduced enzymes are shown in red. Reactions 
converting glucose to aromatic amino acids are represented by dashed black arrows. Metabolite secretion is 
represented by solid black arrows where relative thickness corresponds to relative extracellular accumulation. 3-DSH 
stands for 3-dedhydroshikimate, PAC stands for protocathechuic acid, PAL stands for protocatechuic aldehyde, SAM 
stands for S-adenosylmethionine. 3DSD stands for 3-dedhydroshikimate dehydratase, ACAR stands for aryl carboxylic 
acid reductase, PPTase stands for phosphopantetheinyl transferase, hsOMT stands for O-methyltransferase, and UGT 
stands for UDP-glycosyltransferase. Adapted from Hansen et al. [5]. 
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The aim of this study was to design and construct an improved S. cerevisiae vanillin cell factory 
guided by genome-scale metabolic modeling. In silico metabolic engineering algorithms were 
used to identify target reactions in the metabolic network, knockout of which would lead to 
improved vanillin production. A set of knockouts that maximizes the flux towards a desired 
metabolite must be searched for, while the overall flux distribution is determined by the cellular 
objective function (e.g. maximization of biomass yield). This problem was formulated by Burgard 
et al. (2003) as a bi-level optimization algorithm termed OptKnock [15]. OptKnock can be applied 
in case of a linear design objective, such as maximizing flux towards a desired metabolite [15]. 
Optimization of non-linear objective functions, such as productivity, is also of great interest for a 
variety of metabolic engineering problems. OptGene, an extension of OptKnock, allows 
maximization of non-linear objective functions, while at the same time accounting for non-linear 
constraints on the metabolic network [16]. 
The most widely used approach for calculating flux distribution is flux balance analysis (FBA), 
where a given flux (or a linear combination of chosen fluxes) is used as the objective function 
[17]. For microorganisms, biomass maximization is generally accepted as a cellular objective 
function while simulating flux distributions [18, 19]. FBA has been successfully applied to predict 
gene essentiality [20, 21], end point of adaptive evolution experiments [22] and optimal 
metabolic states under given environmental conditions [19]. However, a mutant strain that is 
not subjected to evolutionary pressure might have a disturbed metabolic network and the 
principle of optimality for growth may not be prevailing. To address this question, the algorithm 
Minimization of Metabolic Adjustment (MoMA) has been suggested by Segrè et al. (2002), 
where it is advocated that the cellular objective for a mutant strain is to minimize its metabolic 
distance from the wild type flux distribution [23]. Mathematically, metabolic adjustment of a 
mutant is defined as the Euclidean distance between the reference and the mutant flux 
distribution vectors. In MoMA approach, it is crucial to have a physiologically meaningful wild 
type flux distribution, as it will strongly influence the predicted phenotype [23]. Within this 
study, the S. cerevisiae genome-scale stoichiometric model iFF708 [21] was used to identify and 
select target reactions for maximizing vanillin production by using OptGene [16]. MoMA [23] 
was used as the biological objective function with wild type flux distributions spanning three 
major modes of yeast metabolic physiology. The model-based metabolic engineering strategy 
was tested experimentally by strain construction and characterization. These research efforts 
resulted in three mutant yeast strains with significantly increased vanillin production. 
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Results and Discussion 
Vanillin β-D-glucoside production in S. cerevisiae 
Vanillin is toxic to many living organisms. In case of S. cerevisiae, growth defect is significant with 
concentrations as low as 0.5 g/l [5]. Tackling the problem of vanillin toxicity is therefore an 
important pre-requisite for building an economically viable vanillin cell factory. An elegant 
solution is glycosylation of vanillin, which is observed in the natural producer Vanilla planifolia 
[25, 26]. This strategy was successfully implemented by Hansen et al. (2009) in 
Schizosaccharomyces pombe [5]. The glycosylation step implies reducing the maximum 
theoretical yield from 486 mgvan/gglc changes to 293 mgVan/gglc. Nevertheless, given the toxicity 
and low solubility of vanillin, reaching high titers is not a favourable option. Extracellular 
concentration of vanillin β-D-glucoside (VG) up to 25 g/l has been shown not to affect growth, 
therefore it is more suitable for commercial production. 
In S. pombe, heterologous expression of UGT72E2, a gene encoding a plant family 1 
glycosyltransferase from Arabidopsis thaliana, resulted in 80% conversion of vanillin to vanillin 
β-D-glucoside [5]. Within this study, UGT72E2 was expressed in the vanillin producing S. 
cerevisiae strain VAN286, obtained from Hansen et al. [5]. The resulting strain, VG0, produced 
significantly more VG than vanillin (> 100 mg/l versus < 7 mg/l), indicating efficient conversion of 
vanillin into VG. 
In silico design 
The yeast genome-scale metabolic model iFF708 [21] was used to provide guidance for a 
metabolic engineering strategy for improving the vanillin β-D-glucoside cell factory. The 
existence of large number of alternative flux routes (pathways) within the metabolic network 
requires the use of experimental constraints in order to obtain physiologically meaningful flux 
distributions. This is even more so in the case of MoMA, where predictions of mutant flux 
distributions will be highly dependent on the solution provided for the wild type (or reference) 
flux distribution [23]. Different metabolic states of S. cerevisiae are characterized by different 
nutrient uptake rates, different metabolite production rates and different biomass yields. 
Therefore, it is to be expected that different constraints (corresponding to different metabolic 
states) may lead to different suggestions for the metabolic engineering targets. 
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Reference metabolic states 
S. cerevisiae uses two major pathways for generating energy necessary for growth: glycolysis and 
oxidative phosphorylation (respiration). In the presence of oxygen and high glucose 
concentration, typically observed in batch conditions, glycolysis is highly active and ethanol 
formation is observed, also called overflow metabolism. The co-existence of fermentation and 
respiration leads to significantly lower biomass yield than purely respiratory metabolism, due to 
carbon channeling towards ethanol [26, 27]. However, if glucose concentration (or glucose 
uptake rate) is bellow a critical threshold, the flux through glycolysis is reduced, most of the 
energy is obtained from respiration and higher biomass yield on glucose is observed [26, 28, 29]. 
Different metabolic scenarios spanning different yeast life-styles were used for obtaining the 
reference flux distribution for MoMA simulations. Reference 1, representing fully respiratory 
metabolism, is characterized by no ethanol formation and low glucose uptake rate. Reference 2 
was simulated for respiro-fermentative metabolism, characterized by high glucose uptake rates, 
alcoholic fermentation and less active respiration. Reference 3 corresponds to VG0 flux 
distribution predicted by using FBA and physiological constraints obtained in this study from 
chemostat cultivations at a dilution rate of 0.1 h-1. This reference was introduced in order to 
have a biological meaningful flux distribution of the reference strain concerning the production 
of vanillin related compounds, as the vanillin biosynthetic pathway is predicted to have no flux is 
while maximizing growth, unless constrained. 
Assessment of in silico predictions 
Simulations were performed using OptGene for maximization of Biomass Product Coupled Yield 
(BPCY), a proxy for productivity [16], by deletion of up to six reactions. Improved vanillin β-D-
glucoside production was not predicted when using maximization of biomass production as 
biological objective, while the use of MoMA [23] suggested interesting targets even after a single 
reaction deletion. Among a variety of possible target reactions, biomass and vanillin β-D-
glucoside yield are generally related with an inverted trend; when predicted biomass yield is 
high, predicted product yield is modest and vice-versa (Fig. 3.2A). 
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Figure 3.2: Comparison of targets predicted by OptGene for improved VG productivity. A – Biomass versus VG yield 
is represented for each knockout mutant phenotype obtained after OptGene simulation using three different 
reference flux distributions for MoMA. Experimental yields observed for VG0 are represented by the red empty 
triangle and bar. B/C/D – The predicted VG yield (mol/molglc) obtained for each knockout mutant after OptGene 
simulation using Reference 1/2/3 is given by the length of the coloured bars. For each reference flux distribution, the 
R3 score was estimated for each of the mutants was calculated and normalized to the mutant presenting the highest 
value: MAmut/MAmax*100. 100% represents the mutant with highest R
3 score for a given flux distribution. Candidate 
80%PDC is not a knockout in silico mutant, rather its PDC reaction is constrained to 80% of the upper bound. 
Target selection for experimental validation must strike a good balance between improved 
vanillin β-D-glucoside production and a reasonable prediction for biomass yield. Herein, 
metabolic adjustment (as defined by Segrè et al., 2002 [23]) was used as an additional factor to 
rank each of the candidate target sets. Our hypothesis is that smaller metabolic adjustments are 
more likely to be achieved in vivo than large adjustments. This was taken into account by 
introducing a new metric for ranking in silico predicted mutants, viz., the Reward-Risk-Ratio (R3), 
defined as the ratio between BPCY (reward) and metabolic adjustment (risk). 
adjustmentmetabolic
BPCYR  3  
Depending on the reference flux distribution used for MoMA, different reactions were suggested 
for deletion (Fig. 3.2 B-D). A number of reactions, for example GDH1, were identified while using 
more than one reference flux distributions. Yet they are differently ranked using R3, 
demonstrating that the best targets in one physiological scenario are not necessarily the best 
targets in another. The results of the prediction analysis suggest that VG production is favoured 
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at those physiological conditions leading to respiro-fermentative metabolism as compared to 
exclusively respiratory metabolism. Diverting ethanol flux towards formation of VG is predicted 
to compel less metabolic adjustment than diverting flux from biomass constituents. Indeed, 
several candidates found using the references 2 and 3 are predicted to have lower ethanol 
formation than the reference. Furthermore, the biomass yield predicted for all the suggested 
mutants using reference 3 is slightly higher than for the reference, again at the expense of 
ethanol formation. 
Target selection 
The targets for in vivo implementation were selected based on their R3 score under different 
simulation conditions in combination with manual evaluation of their suitability for gene 
deletion. Literature and database search included the possible existence of iso-enzymes, 
experimentally observed single gene deletion phenotypes and the assessment of the importance 
of regulatory links to other processes [30]. Based on this analysis, two gene candidates, PDC1 
(Pyruvate decarboxylase) and GDH1 (Glutamate dehydrogenase), were selected for strain 
construction and characterization. 
The Gdh1 catalyzed reaction was predicted for deletion when using respiratory or respiro-
fermentative metabolism, therefore it was selected for further work, despite its prediction for 
large metabolic adjustment. GDH1 encodes an NADPH-dependent glutamate dehydrogenase 
involved in ammonium metabolism through glutamate biosynthesis, which is reported to 
provide 85% of the cellular nitrogen sources [31]. Ammonium metabolism has been extensively 
studied in S. cerevisiae and in particular, deletion of GDH1 was previously used as a metabolic 
engineering strategy for improving ethanol and sesquiterpenes production [6, 8, 32]. Even 
though it was not a priority target considering our R3 score due to high metabolic adjustment, 
prior work reported that deletion of GDH1 leads to increased NADPH pool, which may favour the 
conversion of PAC to PAL by ACAR. 
Pyruvate is a key metabolite in S. cerevisiae metabolism and the branch point between 
respiratory and fermentative metabolism. Pyruvate decarboxylases (PDCs) have a crucial 
significance for fermentation, since they catalyze the conversion from pyruvate to acetaldehyde, 
an intermediate towards ethanol formation [33]. The S. cerevisiae genome harbours three PDC 
structural genes (PDC1, 5 and 6), one regulatory gene (PDC2) and two other genes with potential 
contribution towards PDC activity (PDC3 and 4) [33, 34]. Complete suppression of pyruvate 
decarboxylase activity (pdc1∆, pdc5∆ & pdc6∆) creates a mutant which is unable to grow on 
glucose as sole carbon source [34, 35]. By in silico analysis, PDC was found as a target to increase 
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the formation of VG considering both respiratory and respiro-fermentative reference flux 
distributions for MoMA, but not when VG0 data was used to constrain the network. 
Furthermore, complete absence of pyruvate decarboxylase activity under highly fermentative 
conditions (as reference 3) was predicted to result in zero growth, as lack of PDC activity would 
require a very large metabolic adjustment. This in silico observation is in good agreement with 
the experimental observation that a PDC negative mutants are not able to grow while utilizing 
glucose [34, 35]. Remains to be clarified to what extent partial reduction of PDC activity, e.g. by 
deletion of one of the structural genes would influence VG production. In silico analysis was 
carried out by constraining PDC flux to 80% of the flux observed in the reference strain. This 
simulation predicted positive growth, as well as higher VG production in comparison to other 
targets such as GDH1 (Fig. 3.2C and D). Among the three PDC structural genes, PDC1 was 
selected for deletion in vivo as there is experimental evidence that its removal results in ~30% 
reduction of total pyruvate decarboxylase activity [35]. 
Strain construction and characterization 
Following the selection of the two target genes, two single gene deletion mutants, gdh1∆ and 
pdc1∆, were constructed from strain VG0, resulting in strains VG1 and VG2, respectively. To test 
whether simultaneous deletion of PDC1 and GDH1 would have a positive synergistic effect on VG 
accumulation, mutant VG3, with both deletions, was also obtained. The strains were initially 
characterized in batch cultures in well-controlled bioreactors, using minimal medium. 
Table 3.1: Physiological parameters for the reference and metabolically engineered strains in batch cultivation. 
Strains Engineered Genotype μmax
a YS X
b YS EtOh
c YS gly
d 
VG0  0.14 0.10 0.23 0.05 
VG1 gdh1∆ 0.10 0.07 0.25 0.03 
VG2 pdc1∆ 0.20 0.14 0.23 0.07 
VG3 pdc1 ∆gdh1∆ 0.11 0.10 0.27 0.05 
VG4 pdc1 ∆gdh1∆ ↑GDH2 0.17 0.17 0.25 0.07 
aMaximum specific growth rate, h-1. 
bOverall yield of biomass on substrate, gDW.gglc
-1 
cOverall yield of ethanol on substrate, geth.gglc
-1 
dOverall yield of glycerol on substrate, gGly.gglc
-1 
The biomass overall yield in glucose (YS X) was calculated based on all the biomass obtained after glucose and ethanol 
consumption. Ethanol and glycerol yields were calculated based on production only in the glucose consumption 
phase. 
 
Mutant VG2 (pdc1∆) showed an overall increased fitness compared to the reference strain (VG0) 
as documented by its 43% higher maximum specific growth rate and 40% higher biomass yield 
on glucose (YSX, Table 3.1). On the other hand, mutant VG1 (gdh1∆) showed reduced strain 
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fitness, illustrated by reduced μmax and YSX. The adverse fitness effects of strain VG1 were 
partially relieved by deletion of PDC1 (strain VG3), as verified by slightly improved μmax and YSX 
(Table 3.1).  
In agreement with previous reports, our results confirm the deleterious effect of GDH1 deletion, 
most likely due to a reduced nitrogen assimilation rate [36]. In the absence of GDH1, the GS-
GOGAT system (co-action of two enzymes, a glutamate synthase, GLT1, and a glutamine 
synthase, GLN1) and the glutamate dehydrogenase, coded by GDH2, are responsible for 
ammonia assimilation [37–39]. Both alternatives use NADH instead of NADPH, thus explaining 
the high metabolic adjustment predicted for the GDH1 in silico mutants (Fig. 3.2B and C). In 
comparison with Gdh1, lower activity has been reported for both of the alternative systems. 
Consequently, overexpression of the enzymes involved in the alternative pathways is a required 
step in order to recover the cellular fitness [40]. We proceeded experimentally with GDH2 
overexpression as the use of the GS-GOGAT system has the disadvantage of using an important 
cellular resource – ATP. The resulting strain VG4 (pdc1 ∆gdh1∆ ↑GDH2) showed a significantly 
improved cellular fitness compared to VG3 with similar μmax and YSX to those observed for VG2 
and better than those obtained with VG0. At these experimental conditions, none of the 
introduced mutations seem to affect ethanol production, except GDH1 deletion, which induces a 
slight increase in the substrate yield of ethanol (Table 3.1). 
 
Figure 3.3: Vanillin β-D-glucoside yield observed for the reference strain (VG0) and metabolically engineered 
mutants (VG1-4) in batch cultivations. Substrate overall yield for vanillin β-D-glucoside (YS VG, mgVG/gglc), 
protocatechuic acid (YS PAC, mgPAC/gglc) and protocatechuic aldehyde (YS PAL, mgPAL/gglc) obtained for the reference and 
engineered strains in batch culture. Pie charts are presented to illustrate relative distribution of PAC, PAL and VG for 
each strain. 
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Strain VG1 showed the lowest total yield of vanillin related compounds, most likely as 
consequence of the general decreased fitness observed of this strain (Fig. 3.3). The other three 
engineered strains displayed better performance than VG0 concerning VG production (Fig. 3.3). 
Single deletion of PDC1 (strain VG2) increased VG yield by 52%, as well as the total yield of all 
vanillin related compounds by 30%. Despite the adverse effect of GDH1 deletion, double 
deletion of PDC1 and GDH1 (strain VG3) yielded 15% increase in VG production. Strain VG4 has 
over 55% increased VG yield. Accumulation of several intermediates from the vanillin pathway 
was observed for all mutants, particularly protocatechuic acid (PAC) and protocatechuic 
aldehyde (PAL), which accounted for more than 50% of the total products formed (Fig. 3.3). 
Respiratory vs fermentative metabolism for VG production 
The extent to which VG production is affected by the presence or absence of alcoholic 
fermentation is still unknown. In chemostat cultivation, glucose concentration is kept at low 
levels and, below the critical dilution rate, glucose uptake rate is low enough to ensure exclusive 
respiratory metabolism, thus no ethanol is formed [26, 28, 29]. 
VG0, the reference strain, and the best performing mutants in batch cultivations (VG2 and VG4) 
were selected for further characterization in glucose-limited chemostat cultures at a dilution 
rate of 0.1 h-1. VG2 showed increased fitness as demonstrated by a higher biomass yield (YSX) 
accompanied by a slightly decreased glycerol yield, as compared to VG0 (Table 3.2). Under these 
conditions, VG2 shows 40% higher VG yield on glucose than VG0. In contrast, VG4 displayed a 
considerable decrease in YSX, while ethanol and glycerol production were significantly increased 
(Table 3.2). The VG production by this strain remained very similar to that of the reference 
strain. 
The lower glucose uptake observed for VG2 decreases the overflow metabolism, and 
subsequently smaller rates of ethanol, glycerol and acetate formation by this strain (Table 3.2). 
The opposite trend is verified for mutant VG4, indicating higher overflow metabolism. 
Accordingly, a significantly increased production of ethanol (1.5-fold) and glycerol (4-fold) was 
observed (Table 3.2). 
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Table 3.2: Physiological parameters for the reference and metabolically engineered strains in chemostat cultivation 
at dilution rate 0.1 h-1.  
Strain VG0 VG2 VG4 
Engineered Genotype  pdc1∆ pdc1 ∆gdh1∆ ↑GDH2 
YS X (gDW.gglc
-1) 0.151 ± 0.008 0.159 ± 0.003 0.115 ± 0.005 
YS eth (geth.gglc
-1) 0.283 ± 0.005 0.290 ± 0.008 0.32 ± 0.01 
YS gly (mggly.gglc
-1) 3.4 ± 0.3 2.1 ± 0.4 11 ± 9 
YS acet (mgacet.gglc
-1) 7.3 ± 0.3 7.6 ± 0.3 4 ± 2 
YS PAC (mgPAC.gglc
-1) 27 ± 2 23.5 ± 0.3 15.5 ± 0.3 
YS PAL (mgPAL.gglc
-1) 7 ± 2 9 ± 2 7.2 ± 0.2 
YS VG (mgVG.gglc
-1) 4 ± 1 5.6 ± 1 4.16 ± 0.07 
rs(mmolglc.gDW
-1.h-1) 3.9 ± 0.2 3.5 ± 0.3 4.8 ± 0.2 
reth(mmoleth.gDW
-1.h-1) 4.3 ± 0.3 3.9 ± 0.3 6.1 ± 0.4 
rgly(mmolgly.gDW
-1.h-1) 0.026 ± 0.003 0.014 ± 0.004 0.10 ± 0.08 
racet(mmolacet.gDW
-1.h-1) 0.086 ± 0.006 0.079 ± 0.006 0.05 ± 0.003 
rPAC(mmnolPAC.gDW
-1.h-1) 0.12 ± 0.01 0.10 ± 0.01 0.087 ± 0.03 
rPAL(mmolPAL.gDW
-1.h-1) 0.036 ± 0.008 0.040 ± 0.007 0.045 ± 0.003 
rVG(mmolVG.gDW
-1.h-1) 0.009 ± 0.003 0.011 ± 0.002 0.012 ± 0.001 
Substrate yields for biomass (X), ethanol (eth), glycerol (Gly), acetate (Ace), protocathechuic acid (PAC), 
protocathechuic aldehyde (PAL) and vanillin β-D-glucoside (VG) on glucose (glc) are represented by YS X (or metabolite). 
Specific glucose uptake rate is represented by rS. Specific production rate for ethanol, glycerol, acetate, PAC, PAL and 
VG are represented by rmetabolite. Triplicates of all chemostats were performed. 
VG2 exhibits a higher conversion of PAC into the products of the later steps in the vanillin 
pathway (Fig. 3.4A). Strain VG4, despite the severe impact of the overflow metabolism on its 
biomass yield on glucose, displays the highest conversion of PAC into downstream metabolites, 
particularly PAL (Fig. 3.4A). As hypothesized during target selection, this mutant is likely to have 
higher availability of NADPH, due to the engineered reduced demand for this cofactor for 
ammonium metabolism. 
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Figure 3.4: Vanillin β-D-glucoside yield observed for the reference strain (VG0) and metabolically engineered 
mutants (VG1-4) in continuous cultivations. A - Biomass specific production rate (mgmetab.gdw
-1.h-1) for protocatechuic 
acid (PAC), protocatechuic aldehyde (PAL) and VG  in glucose limited chemostat cultivation at dilution rate of 0.1h-1. B 
- Substrate specific yield (YS Metab, , mgmetab/gglc) for PAC, PAL and VG for strains VG0 and VG2 in glucose limited 
chemostat cultivation at different dilution rates – 0.1 h-1(Top) and 0.015 h-1(*, Bottom). 
The predominantly respiro-fermentative metabolism observed for all engineered strains implies 
that their critical dilution rate, indicative of respiratory capacity, is very low. By gradually 
decreasing the dilution rate in a glucose-limited chemostat, we verified that the critical dilution 
rate for both VG2 and VG0 was below 0.015 h-1. Such a low respiratory capacity could be the 
result of combined effects of product/by-products toxicity and the background of the strain. By 
employing this experimental setup, ethanol production rate was as low as 0.130 mmoleth/(ggw.h) 
for VG0 and 0.065 mmoleth/(ggw.h) for VG2, while the rate of glucose uptake was 0.37 and 0.30 
mmolglcggw-1.h-1, respectively. The VG concentration in the fermentation broth of VG2 was 500 
mg/l, (32 mgVG/gglc), a two-fold increase compared to that of VG0, which produced 250 mg/l (15 
mgVG/gglc) (Fig. 3.4B). These results confirm that VG2 has better respiratory capacity than the 
reference strain VG0 and lowering the overflow metabolism results in higher VG yield. For both 
strains, the observed conversion of PAL into VG is more efficient at low dilution rates, suggesting 
that low overflow metabolism is linked to increased precursor and/or cofactors supply, enabling 
higher VG productivity. 
Analysis of the experimental results 
In an attempt to better understand the metabolic flux changes at the whole network level, and 
therefore the basis for the observed improved vanillin β-D-glucoside production, the flux 
phenotypes of VG0, VG2 and VG4 were simulated by using FBA [17]. The experimental results 
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obtained from the chemostat cultures, i.e. glucose uptake rate and biomass, ethanol, acetate, 
glycerol and CO2 production rates, were added as constraints to the metabolic model. The 
bounds for reaction GDH1 were set to zero. As deleting PDC1 does not imply that pyruvate 
decarboxylase activity will be zero, the choice of constraints for the PDC1 deletion is not 
straightforward. To circumvent this issue, and to account for different glucose uptake rates of 
the mutants, the upper bound for PDC flux was identified in each condition. Subsequently, the 
phenotypes were simulated with upper bound for PDC constrained to 80% of the previously 
found upper bound. 
Flux variability analysis 
The flux distributions obtained with FBA are guaranteed to be optimal, but not necessarily 
unique due to the existence of a large number of alternative routes. This renders the 
transformation of the experimentally determined levels of the products obtained into 
intracellular fluxes, a difficult task. Nevertheless, stoichiometric simulations provide an estimate 
of the possible range of flux values for every reaction in the network. Fluxes which are unique 
will have the same maximum and minimum possible values. The flux ranges of all reactions of 
VG2 and VG4 were calculated and compared with those of VG0, resulting in different categories 
as illustrated in Fig. 5. The first category consists of those reactions for which flux is infeasible at 
steady-state, i.e. blocked reactions. Among the remaining reactions (~570), only 50 have unique 
flux values for all the strains. Almost all of these reactions belong to category a, i.e. with no 
change between the reference strain and the tested mutants. As chemostat experiments at the 
same dilution rate were used for all strains, the flux of reactions directly coupled to biomass 
biosynthesis also fall in this category. Examples include reactions from lipid, nucleotide and 
amino acid metabolism. 
75
Chapter 3: Vanillin Production in S. cerevisiae – part 1 
52 
 
 
Figure 3.5: Flux variability analysis. Reactions were classified based on the comparison of their flux variability range 
between the reference VG0 and the mutants VG2 and VG4. A - The scheme on the left-hand side illustrates the flux 
variability ranges defining the six different categories (Blocked and a to e). Flux variability range for the reference 
strain (VG0) is represented in gray, and the mutant in black. The distribution of VG2 and VG4 reactions among 
different categories are presented in the bar chart, yellow and red, respectively. B - The reactions from mutant VG2 
belonging to categories b and c are further classified accordingly to their metabolic function. 
Categories b and c contain the majority of the reactions (~70%) for VG2 and VG4, yet the 
distribution among the two categories is not alike for the two mutants. For the strain VG4, most 
of the reactions fall in category b, a larger variability range than observed for the reference 
strain, as expected due to its higher glucose uptake rate. In the case of VG2, there is an even 
distribution of reactions between the categories b and c (reactions with smaller variability range 
than the reference). VG2 exhibits a decreased glucose uptake rate as compared to the reference, 
therefore reactions from glycolysis belong to category c. However, as its biomass yield is similar 
to the reference, equivalent quantity of energy must be available. In strain VG2, several 
reactions from the tricarboxylic acid (TCA) cycle and gluconeogenesis fall in category b, reflecting 
its improved respiratory capacity. A more active respiration in this strain is further confirmed by 
the in silico predicted increased oxygen uptake rate. Even though this reaction is found in 
category c (with decreased flux range), its lower bound is higher in VG2 than in VG0. 
The remaining reactions present flux variability ranges with partial or no overlap between the 
reference strain and the mutants. These reactions were grouped in category d, where the 
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mutant flux upper bound is higher than the reference flux upper bound, and category e where 
the mutant flux lower bound is lower than the reference flux lower bound. Together, categories 
d and e comprise the reactions with the clearest differences between the mutants and the 
reference. These include reactions related to product formation (e.g. biosynthesis of S-
adenosylmethionine – the methyl-group donor in the vanillin pathway) and glucose uptake 
(which was experimentally determined), as well as reactions from the ammonia metabolism. 
Metabolite-centric analysis 
Despite the increased VG production, strain VG2 exhibits a decreased flux through the aromatic 
amino acid biosynthesis pathway from which the vanillin precursor is derived. Likewise, this 
strain shows a reduced total flux through the VG pathway. The same trend was found for the 
VG4 strain, implying that the metabolic network is being adjusted for increased PAL and VG 
production at the expense of a reduction of the total carbon flow into aromatic amino acids until 
the VG biosynthesis branch. In fact, the reaction after which the production is increased is the 
conversion from PAC to PAL. This reaction uses NADPH and ATP, two of the most highly 
connected metabolites and cofactors that are competed for by growth requirement. 
To systematically explore the usage of cofactors and other metabolites in the engineered strains, 
the turnover of these metabolites can be calculated by summing all the fluxes which are 
producing (or consuming) them [41]. As the unique values of all the fluxes are unknown due to 
alternative optima inherent to FBA of metabolic networks, the minimum metabolite turnover 
was calculated by solving a linear programming (LP) problem for the minimization of metabolite 
turnover (see Methods for details). This LP formulation guarantees to find the minimum 
turnover of a given metabolite that ensures the observed phenotype. The direction of 
optimization, i.e. minimization, not only avoids the unbound cyclic fluxes around the metabolite 
under question, but also confers with the biological hypothesis of minimal resource allocation by 
the cell in terms of enzyme expression. Minimum metabolite turnover denotes how much flux 
needs to pass through a given metabolite, although the distribution of this flux among possible 
reactions may not be unique in all cases. Nevertheless, the turnover calculated in this way 
provides a lower bound on the flux through a metabolite that can be used in complementation 
with flux variability analysis. 
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Figure 3.6: Minimum turnover of selected metabolites from the central carbon metabolism and from the VG 
biosynthetic pathway (including cofactors).  Metabolites from the central carbon metabolism: glucose-6-phosphate, 
erythrose-4-phosphate, pyruvate and ethanol; Metabolites from the VG biosynthetic pathway (ATP, NADPH, SAM and 
UDP-glucose). Metabolites for which minimum turnover was calculated are represented by filled circles, metabolites 
for which no minimum turnover was calculated are represented by open rings. Reactions are represented as arrows. 
Qualitative variation of the minimum turnovers relatively to the reference (VG0) is shown by the arrows next to each 
metabolite; yellow corresponds to VG2 while red corresponds to VG4. 
Besides NADPH and ATP, the minimum turnover of some other relevant metabolites was also 
calculated (Fig. 3.6). The minimum turnover for PAC is lower in the strains VG2 and VG4 than for 
VG0; while for PAL and VG the opposite trend is verified, in agreement with the flux variability 
analysis. An increase in the glucose uptake rate will result in an increase in glycolysis and 
pentose phosphate pathway, which is reflected in the increased minimum turnover of pyruvate 
and erythrose-4-phosphate in the VG4 strain. On the other hand, the VG2 strain exhibits a 
decreased glucose uptake rate and consequently less flux through glycolysis and pentose 
phosphate pathway. The same trends apply to ATP, implying that most ATP available in strain 
VG0 is being produced from glycolysis. NADPH, S-adenosylmethionine and UDP-glucose 
minimum turnovers are increased for both simulated phenotypes, reflecting the increased flux 
through ACAR, hsOMT and UGT leading to PAL and VG. The analysis above provides insight into 
the intracellular flux changes and pinpoints metabolites that play a role in the engineered 
strains. 
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Conclusions and Future Perspectives 
The framework presented in this study comprises of i) in silico target prediction that accounts for 
the available physiological information; ii) systematic ranking of the targets based on the 
predicted metabolic adjustments; iii) in vivo verification through genetic engineering and 
fermentation; and iv) reaction/metabolite centric analysis of the experimental results. Our 
results demonstrate the applicability of in silico modeling tools for overproduction of a product 
from a multistep heterologous pathway in a eukaryotic system. Three vanillin β-D-glucoside 
overproducing strains were successfully designed and constructed during this study. Low dilution 
rate continuous cultivation of an overproducer resulted in notably high titer of vanillin β-D-
glucoside – 500 mg/l, 5-fold higher than the 45 mg/l reported by Hansen and co-workers [5]. 
The yeast genome-scale model was used throughout this study, from the strain design to the 
analysis of the physiological data resulting from the fermentation studies of the constructed 
mutants. The in silico strategy used herein revealed the sensitivity of target predictions towards 
the choice biological objective function, as well as towards the flux distribution used for 
reference of simulation while using MoMA. To this end, it was crucial to use basic physiological 
knowledge for simulating different relevant yeast phenotypes. In silico analysis of fluxes 
variability and metabolites turnover of the overproducing strains suggested that the 
modification imposed on the metabolic network led to increased cofactor availability for vanillin 
β-D-glucoside production. 
The observed discrepancy between model predictions and experimental observations 
concerning the production yield of vanillin β-D-glucoside (experimental ~3 versus predicted 10 
mmolVG/molglc in batch conditions) is most likely linked to limited kinetic and regulatory 
information. The need for accounting for regulatory information is even more apparent when 
considering an isoenzyme as metabolic engineering target. Quantitative prediction of flux 
distributions following downregulation (similar to deletion of an isoenzyme) or overexpression 
of genes is still in its infancy. Advances towards integration of regulation in metabolic models 
require additional knowledge on the relationship between changes in gene expression and 
metabolic fluxes, as well as flux simulation tools that can integrate such information. Moreover 
regulation at both transcriptional and metabolic level is of particular relevance for vanillin 
production as the shikimate pathway for aromatic amino acids biosynthesis is tightly regulated 
in yeast [42]. As an example, Luttik et al. were able to increase the total flux through this 
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pathway by 4.5-fold in S. cerevisiae through alleviation of the DAHP synthase feed-back 
inhibition mechanisms [43]. 
Due to considerable accumulation of intermediates of the vanillin pathway observed in this 
study, identification and overexpression of an eventual rate limiting enzyme within the 
biosynthetic pathway may serve to enhance conversion of pathway intermediates into the final 
product. Further enhancing the respiratory capacity of the vanillin producing strains is also 
expected to increase vanillin β-D-glucoside production, as illustrated within this study. 
Methods 
Model simulations 
Five new reactions were introduced in the Saccharomyces cerevisiae stoichiometric model [21] 
to convert 3-dehydroshikimate, a natural intermediate in aromatic amino acids biosynthesis, 
into vanillin β-D-glucoside (VG). Furthermore all the intermediates in the pathway were allowed 
to be secreted, based on the experimental evidence. FBA simulations were performed using 
linear programming library GLPK (ftp://ftp.gnu.org/gnu/glpk/), while MoMA simulations were 
performed using quadratic programming library OOQP [44]. 
Strategy design to improve VG production in S. cerevisiae was performed by using OptGene with 
Biomass-Product Coupled Yield (BPCY) as design objective function [16]. 
Minimization of metabolite turnover 
Metabolite turnover or flux-sum is the sum of all incoming or outgoing fluxes around a particular 
metabolite under pseudo-steady state conditions [42,46]. Let Φi denote metabolite turnover of 
metabolite i and its mathematical definition is given by ¦ )
k
kiki vS2
1 , where Sik represents 
the stoichiometric coefficient of metabolite i in reaction k and vk is the flux of reaction k. By 
calculating the sum of all absolute flux values through (in and out) a given metabolite eliminates 
further concern about reactions reversibility. Furthermore, given the steady state assumption, 
the metabolite turnover will be half of the calculated sum. 
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Due to existence of alternative optimal FBA solutions within genome-scale models, minimum of 
metabolite turnover was calculated, given predetermined exchange fluxes (including growth), 
using a linear programming formulation as follows: 
reactions)secretion  and uptake including s,constraintcapacity (Flux   and  and for  
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Plasmids and strains 
The strain Saccharomyces cerevisiae VAN286 obtained by Hansen et al. was used as the 
background strain in this work. In order to produce vanillin, this strain must be transformed with 
a plasmid containing the gene EntD from Escherichia coli, coding for a PPTase. This enzyme is 
indispensable for post-translational activation by phosphopantetheinylation of ACAR in S. 
cerevisiae [5]. All the strains constructed during this study (Table 3.3) were transformed with the 
plasmid containing EntD prior to cultivation in order to produce VG. 
Cloning UGT72E2 in S. cerevisiae VAN286 
The integrative plasmid pARB021 containing the gene UGT72E2 from Arabidopsis thaliana 
coding for a UDP-glucosyltransferase was obtained by replacing the URA3 marker by the HIS3 
marker in plasmid pJH665 with the restriction enzyme XmaI. Restriction enzymes and buffers 
from New England Biolabs were used and the conditions for restriction followed manufacture 
instructions. The HIS3 gene was PCR amplified using the primers His3_Fw and His3_Rev (Table 
ST3.1), the plasmid pWJ1213 [47] was used as template DNA and amplification was achieved 
using PhusionTM Hot Start High-Fidelity DNA Polymerase (Finnzymes Oy, Espoo, Finland).  GFXTM 
PCR DNA and Gel Band Purification Kit (GE Healthcare) were used for DNA purifications and 
ligation was performed with T4 DNA ligase (New England Biolabs). The plasmid was treated with 
Antarctic Phosphate (New England Biolabs) in order to avoid recirculation. The ligation mixture 
was deactivated and transformed into chemo-competent DH5α E. coli cells. Ampicillin resistance 
was used as E. coli selection marker and plasmid extraction was performed using a GenElute HP 
Plamsid Miniprep Kit (Sigma-Aldrich). The plasmid ARB021 was verified by restriction analysis 
and sequencing of the PCR amplified HIS3 marker with the primers MarkSeq_Fw and 
MarkSeq_Rev from Table ST3.1 (StarSEQ, Mainz, Germany). The correct plasmid was then 
restricted with SphI and transformed into the yeast TPI1 promoter locus of VAN286, thus 
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creating the strain VG0, producing VG from glucose. High efficiency yeast transformation 
method was used to construct the yeast strains [48]. 
Table 3.3: Yeast strains and plasmids used in this study. 
Yeast Strain  Relevant genotype  Reference  
VAN286 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX] 
Hansen et al. 
2009 [5] 
VG0 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX]::UGT72E2 [HIS3] 
This study  
VG1 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX]::UGT72E2 [HIS3] gdh1 
This study  
VG2 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX]::UGT72E2 [HIS3] pdc1 
This study 
VG3 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX]::UGT72E2 [HIS3] pdc1 gdh11 
This study 
VG4 
MATa his3D1 leu2D0 met15D0 ura3D0 adh6::LEU2 bgl1::KanMX4 PTPI1::3DSD 
[AurC]::HsOMT [NatMX]::ACAR [HphMX]::UGT72E2 [HIS3] pdc1 gdh1 GDH2::PPGK1-
GDH2 
This study  
Plasmid Gene content Plasmid type 
Selection 
marker 
Reference 
pJH589a EndD (E. coli) CEN-ARS (S. cerevisiae) URA3 
Hansen et al.  
[5]  
pJH665a UGT72E2 (Arabidopsis thaliana) CEN-ARS (S. cerevisiae) URA3 
Hansen et al.  
[5]  
pARB021 UGT72E2 (Arabidopsis thaliana) Integration (S. cerevisiae) HIS3 This work 
pWJ1042b 
Recyclable URA3 (Kluyveromyces 
lactis) 
CEN-ARS (S. cerevisiae)  Reid et al. [46] 
pPGK1-GDH2c PPGK1-GDH2 (S. cerevisiae) Integration (S. cerevisiae) KanMX3 Nissen et al. [8]  
Model guided strain construction 
PDC1 and GDH1 gene deletions, as well as GDH2 overexpression were achieved by gene 
targeting through homologous recombination of bipartite PCR fragments, using URA3 gene from 
Kluyveromyces lactis as a marker [49]. The marker was flanked by direct repeats that allowed 
restoring of uracil auxotrophy by plating the cells in agar medium containing 5-Fluoroorotic acid 
(5-FOA) after each genetic manipulation [50]. 
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The primers used for amplifying the up and downstream regions flanking the PDC1 and GDH1 
gene (approximately 500 bp each) are listed in Table ST3.1, as well as the primers used to 
amplify K. lactis URA3 flanked by direct repeats from the plasmid pWJ1042 [46]. Strain VG1 was 
obtained by deleting the gene GDH1 in the strain VG0. Strain VG2 was obtained by deleting the 
gene PDC1 also in the strain VG0. Strain VG3 was obtained by deleting gene GDH1 in the strain 
VG2. The deletions were verified by analytical PCR using the primers PDC1_Ver_FW and 
PDC1_Ver_REV for PDC1 deletion, and GDH1_Ver_FW and GDH1_Ver_REV for GDH1 deletion 
(Table ST3.1). Strain VG4 was obtained from VG3 by swapping the native GDH2 promoter by the 
strong constitutive promoter of the gene PGK1, as previously reported by Nissen et al. [8]. A 500 
bp fragment upstream the GDH2 open reading frame (ORF) used for homologous recombination 
was obtained from VG3 genomic DNA with the primers GDH2(UP)_Fw and GDH2(UP)_Rev (Table 
ST3.1). The downstream fragment used for homologous recombination was amplified from the 
plasmid pPGK1-GDH2 [8] with the primers PGK1_GDH2(Dw)_Fw and PGK1_GDH2(Dw)_Rev listed 
in Table ST3.1. 1479 bp of the PGK1 promoter region were used to substitute the GDH2 original 
promoter, while the initial 500 bp of the GDH2 OFR were used to ensure accurate targeting. The 
promoter swapping was verified by analytical PCR with the primers PGK1verif and Gdh2verif 
(Table ST3.1), amplifying 420 bp of the PGK1 promoter to 1300 bp of GDH2. 
Media Composition 
A defined minimal medium as described by Verduyn et al. (1992) with 20 g/l glucose as sole 
carbon source was used for cell cultivation [51]. The medium composition used for batch and 
continuous cultivation in well controlled bioreactors was as follows: 5.0 g/l (NH4)2SO4, 3.0 g/l 
KH2PO4, 0.5 g/l Mg2SO4, 2.0 ml/l trace metal solution, 1.0 ml/l vitamins solution, 0.05 ml/l 
antifoam 204 (Sigma-Aldrich A-8311) and 80 mg/l L-methionine. Trace metal solution contained 
3 g/L FeSO4.7H2O, 4.5 g/L ZnSO4.7H2O, 4.5 g/L CaCl2.6H2O, 0.84 g/L MnCl2.2H2O, 0.3 g/L 
CoCl2.6H2O, 0.3 g/L CuSO4.5H2O, 0.4 g/L NaMoO4.2H2O, 1 g/L H3BO3, 0.1 g/L KI and 15 g/L 
Na2EDTA.2H2O. Vitamins solution included 50 mg/l d-biotin, 200 mg/l para-amino benzoic acid, 
1.0 g/l nicotinic acid, 1.0 g/l Ca-pantothenate, 1.0 g/l pyridoxine HCL, 1.0 g/l thiamine HCl and 25 
mg/l m-inositol. 
The pH was adjusted to 5 by addition of 2N NaOH prior to autoclavation, the glucose was 
autoclaved separately and methionine and vitamins solutions were sterile filtered (0.2 μm pore-
size Ministart®-Plus Sartorius AG, Geottingen, Germany) and added after autoclavation. 
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Batch cultivations 
Batch cultivations were executed in well-controlled, aerobic, 2.2 B Braun Biotech Biostat B 
fermentation systems with a working volume of 2 L (Sartorius AG, Geottingen, Germany). Proper 
mixing conditions were ensured by two disk-turbine impellers rotating at 800 RPM and 4 baffles. 
The pH was automatically controlled at 5 by addition of 2N NaOH. The temperature was kept 
constant at 30 oC. The air flow rate was 1 vvm (volume air per volume of broth per minute).  
Prior to inoculation, 100 ml precultures were cultivated in 500 ml baffled shake-flasks at 30 oC 
until OD600 nm 5 in an orbital shaker (150 RPM). Minimal medium as described above was used to 
grow the precultures with 20 g/l glucose. The bioreactors were inoculated to an initial OD600 nm 
ranging from 0.5 to 0.7. 
Continuous cultivations 
Aerobic, carbon limited continuous cultivations were carried out in 2.2 B Braun Biotech Biostat B 
fermentation systems (as described above for batch cultivations) with a constant working 
volume of 1.5 L. The temperature was kept at 30 oC, the pH was maintained at 5 by addition of 
2N NaOH, the stirring speed was 600 RPM and the air flow was 1 vvm. Minimal medium with 20 
g/l glucose was used to feed the bioreactors at a constant dilution rate of 0.1 h-1. The volume 
was kept constant at 1.5 l by controlling the level of broth inside the vessel. Steady state 
conditions were assumed after at least 5 residence times and CO2 and biomass concentrations 
were constant. 
Off-gas analysis 
For both cultivation modes (batch and continuous), off-gas passed through a condenser to 
minimize evaporation loss during the fermentation and filter sterilized before carbon dioxide 
and oxygen were quantified in a Brüel & Kjær 1308 acoustic gas analyzer (Brüel & Kjær, Nærum, 
Denmark). 
Biomass determination 
Samples were maintained at 4 oC post sampling and the biomass concentration was monitored 
by optical density at 600 nm (OD600 nm) and dry cell weight. OD600 nm was measured throughout all 
the fermentation in a Shimadzu UV mini 1240 spectrophotometer (Shimadzu Europe GmbH, 
Duidberg, Germany). The samples were diluted with distilled water in order to obtain 
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measurements in the linear range of 0 to 0.6 OD600 nm. Dry cell weight was determined by 
filtering a known volume of fermentation broth with pre-dried 0.45 μm pore-size nitrocellulose 
filters (Sartorius AG, Geottingen, Germany), which were subsequently washed with a 3x sample 
volume 0.9 % NaCl saline solution. The filters were then dried for 20 minutes at 150 W in a 
microwave oven and kept in a desiccator while cooling for at least 2 h. The filters where finally 
weighted using an analytical balance. 
Glucose and external metabolites analysis 
The fermentation samples were immediately filtered using a 0.45 μm pore-size syringe-filter 
(Sartorius AG, Geottingen, Germany) and stored at -20 oC until further analysis. Glucose, ethanol, 
glycerol, pyruvate, succinate and acetate were determined by high performance liquid 
chromatography (HPLC) analysis using an Aminex HPX-87H ion-exclusion column (Bio-Rad 
Laboratories, Hercules, CA). The column temperature was kept at 60 oC and the elution was 
performed using 5 mM H2SO4 with flow rate of 0.6 ml/min. Metabolites detection was 
performed by a RI-101differential refractometer detector (Shodex) and an UVD340U absorbance 
detector (Dionex) set at 210 nm. 
Extracellular vanillin, vanillin β-D-glucoside (VG), protocatechuic acid (PAC), protocatechuic 
aldehyde (PAL) and vanillic acid were quantified by high performance liquid chromatography 
(HPLC) using Agilent 1100 series equipment with a Luna C18 column (Phenomenex). A gradient 
of methanol (+ 1% tetra-fluoroacetic acid) and water (+ 1% tetra-fluoroacetic acid) at a flow rate 
of 0.3 ml/min was used as mobile phase. The column was kept at 300 bar and 30 oC. Metabolite 
detection was performed using a UV diode-array detector set at 280 and 310 nm. 
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Chapter 4: Metabolic Engineering for Vanillin Production in S. 
cerevisiae. Part 2 – Pathway and Regulatory Engineering 
 
Part of this chapter was used for the manuscript: 
Overexpression of O-methyltransferase leads to improved vanillin production in baker’s yeast 
only when complemented with model-guided network engineering. Ana Rita Brochado and 
Kiran R. Patil. Submitted. 
Abstract 
Vanillin is one of the most used flavoring agents worldwide. A yeast cell factory for vanillin 
production in its more soluble form, vanillin E-D-glucoside, was previously assembled and we 
recently reported an in silico based metabolic engineering strategy for improved vanillin 
production. Accumulation of several pathway intermediates was observed and promoting their 
conversion to the final product is the following step towards further strain improvement. The 
metabolic flux through the vanillin biosynthetic pathway is controlled by i) the availability of 
precursor and cofactors and ii) the enzyme activity of the pathway enzymes. In order to ensure a 
maximum outcome of the network engineering strategy previously implemented for boosting 
cofactors supply, limitation of the enzyme activity at the pathway level must not occur. The 
dominant effects between the local and global aspects are, however, hard to estimate a priori. 
The present study aims at deciphering if the metabolic flux towards vanillin is controlled by 
pathway enzyme availability or by global aspects, such as cofactor supply. Herein, we detect and 
optimize the expression of the rate limiting enzyme of the vanillin biosynthetic pathway. 
Additionally, attempting to further increase the ATP availability for vanillin biosynthesis, we 
suggest alleviating the yeast glucose repression phenomenon. Following the mentioned 
strategies, hsOMT and HAP4 overexpression resulted in 60% increase in vanillin E-D-glucoside, 
with a final concentration of 400 mg/l in the fermentation broth. 
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Background 
Vanillin, or 4-hydroxi-3-metoxibenzaldehyde, is the main compound responsible for vanilla 
aroma, one of the flavoring agents most widely used. Given its chemopreventive properties, 
vanillin can be used as antimicrobial and antioxidant agent. Several recent studies also suggest 
vanillin to be used for cancer treatment, as a metastasis suppressor [1–3]. Natural vanillin 
originates from the seed pod of the vanilla orchid, Vanilla planifolia. Approximately 40,000 
manually pollinated flowers are required to produce 1 kg of vanillin; thereby naturally produced 
vanillin is not enough to fulfill the worldwide demand.  Only about 0.25% of the annual vanillin 
market is obtained from natural sources, while the remaining demand is fulfilled by chemical 
synthesis from lignin or fossil hydrocarbons (in particular guaiacol) [1, 4]. Bioconversion of ferulic 
acid and eugenol by bacteria and fungi has been proposed as an environmental friendly process 
[5–9]. Alternatively, a de novo vanillin biosynthetic pathway from glucose was developed in 
yeast Saccharomyces cerevisiae [4]. The native metabolic precursor for de novo vanillin 
biosynthesis in yeast is 3-dehydroshikimate (3DHS), an intermediate of the shikimate pathway 
for aromatic amino acids biosynthesis (Fig 3.1). Three enzymes, a 3-dedhydroshikimate 
dehydratase (3DSD), an aryl-carboxylic acid reductase (ACAR) and an O-methyltransferase 
(hsOMT), catalyze the conversion from 3DHS to vanillin. In order to obtain a functional pathway, 
ACAR post-translational activation is performed by a heterologous phosphopantetheinyl 
transferase (PPTase), from E. coli, C. glutamicum or N. farcinica [4]. 
 
Figure 4.1: De novo vanillin β-D-glucoside biosynthesis in S. cerevisiae. A simplified metabolic map of the yeast 
central carbon (gray) and amino acid metabolism (blue) containing relevant reactions for the vanillin biosynthetic 
pathway (yellow) is shown. Metabolites are represented by filled circles in the case of central and amino acid 
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metabolism, and by their chemical structures in the case of vanillin biosynthetic pathway. Circles with multiple 
connecting lines represent highly connected metabolites. Reactions are represented by the connecting lines. Dashed 
yellow lines represent the synthesis of isovanillin, an undesired by-product. Italicized names refer to genes, while the 
other names refer to metabolites. The gene deletions (red crosses) and overexpressions (green arrows) correspond to 
a global engineering strategy carried out in previous work [10]. PAC, PAL and VG stand for protocatechuic acid, 
protocatechuic aldehyde and vanillin β-D-glucoside respectively. 3DSD, ACAR, hsOMT and UGT stand for 3-
dehyroshikimate dehydratase, aryl-carboxylic acid reductase, O-methyltransferase and UDP-glycosyltransferase, 
respectively. 
In a previous work [10], we achieved five-fold increase in vanillin production, in its less toxic and 
more soluble form, vanillin β-D-glucoside, based on a genome-scale modeling approach for 
designing metabolic engineering strategies [11–13]. Minimization of metabolic adjustment [14] 
was used as cellular biological objective function and OptGene [15] was used as modeling 
platform to identify genes within the yeast metabolic network [16], deletion of which would 
increase vanillin production. The strategy suggested by the modeling exercise was to, i) delete 
one of the pyruvate decarbolxilases (PDC1), ii) delete the most active glutamate dehydrogenase 
(GDH1) and iii) ensure sufficient nitrogen uptake by overexpressing the less used GDH2 (Fig. 4.1). 
These modifications resulted in increased respiratory capacity of the cell, as well as shifted the 
cofactor usage of nitrogen uptake from NADPH to NADH. Both cofactors, ATP and NADPH, are 
required for the vanillin biosynthetic pathway to convert protocatechuic acid (PAC) in 
protocatechuic aldehyde (PAL) [4]. 
Nevertheless, apart from vanillin E-D-glucoside, several by-products were also accumulated in 
the fermentation broth, including intermediates of the vanillin biosynthetic pathway. At the 
most, vanillin E-D-glucoside accounts for approximately 25 % (mol/mol) of the total vanillin 
related compounds produced. Thus, decreasing the by-product formation will ultimately lead to 
increase the vanillin yield up to 4-fold, as well as decreased accumulation of potentially toxic 
compounds on the fermentation broth. The aim of the present study is to explore whether the 
metabolic flux through the vanillin biosynthetic pathway is regulated by enzyme availability at 
the pathway level, or by cofactors supply. To this end, we suggest i) detecting and optimizing the 
expression of rate limiting enzymes of the vanillin biosynthetic pathway and ii) alleviating the 
yeast glucose repression phenomenon in order to increase the ATP availability for vanillin 
production (through increased respiration). Towards the first goal, we tested two extra PPTases 
(from Aspergillus nidulans and Nocardia sp.), tackling the possibility that they would better 
activate ACAR in S. cerevisiae. Afterwards, we evaluated the effects of overexpressing ACAR and 
hsOMT on vanillin E-D-glucoside production. Finally, we assessed the effect of alleviating the 
glucose repression of respiration through Hap4 overexpression. 
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Results and Discussion 
Different PPTases for ACAR post-translational activation lead to altered vanillin E-D-
glucoside production 
Enzymes requiring activation by phosphopantetheinylation are not abundant in S. cerevisiae, 
therefore this microorganism displays a rather reduced repertoire of PPTases. It is also known 
that this class of enzymes can be highly organism specific, since PPTases accomplishing similar 
function across closely related organisms might not be able to activate both target enzymes [4, 
17]. Hansen et al. [4] observed that only three, out of eleven tested bacterial PPTases, were able 
to activate ACAR in S. cerevisiae. Given that ACAR activity is highly influenced by the PPTase, we 
heterologously expressed two additional PPTases and studied their impact on vanillin E-D-
glucoside production; i) npgA from Aspergillus nidulans, which was previously reported to be 
functional in S. cerevisiae by successfully activating a polyketide synthase [18] and a non-
ribosomal peptide synthase [19] and ii) npt from Nocardia sp., which was reported to be the 
PPTase activating ACAR in the native host [20]. Both genes were codon optimized and expressed 
in the reference strain VG0 (Table 4.2) from low-copy-number-replicating plasmids (CEN-ARS) 
under the yeast TPI1 promoter (Methods). Furthermore, two of the PPTases previously used by 
Hansen et al. (entD from E. coli and PPTcg-1 from C. glutamicum) were also heterologously 
expressed for comparison. 
 
Figure 4.2: Impact of heterologous expression of different PPTases in ACAR activation in S. cerevisiae. Concentration 
of vanillin-related metabolites (vanillin β-D-glucoside (VG), vanillic acid, protocatechuic acid (PAC) and protocatechuic 
aldehyde (PAL)) in the fermentation broth (90 h in microtiter plates cultivation) for strain VG0 expressing four 
different PPTases. Results for the strain without PPTase are shown as a control. 
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ACAR catalyzes the conversion from PAC (protocatechuic acid) to PAL (protocatechuic aldehyde), 
as well as from vanillic acid to vanillin (Fig. 4.1). As expected, nor PAL neither vanillin are 
produced if there is no heterologous PPTase expression (negative control, Fig. 4.2). All PPTases 
seem to efficiently convert PAC to PAL, as PAL is accumulated in the extracellular broth. 
Nevertheless, the yeast strain carrying the gene entD (E. coli) showed the highest vanillin E-D-
glucoside production (~100 mg/l) and, therefore, this was the selected PPTase for further work. 
The genes npt and npgA had very similar effects on vanillin E-D-glucoside production, and not so 
far from the best candidate, entD. If, at certain stage of further strain improvement, ACAR is 
found to be limiting step, these two genes might be taken into consideration once again. 
hsOMT catalyses the rate-limiting step for de novo vanillin E-D-glucoside biosynthesis 
in S. cerevisiae 
In our previous study we showed that the conversion of pathway intermediates to vanillin E-D-
glucoside was incomplete even after a successful round of strain improvement by engineering 
the cell for increased cofactors and energy supply (strain VG4, Table 4.2) [10]. Typically, around 
50% of the vanillin-related compounds accounts for PAC, suggesting that either ACAR or hsOMT 
(which catalyze the conversion from PAC into downstream pathway intermediates, Fig. 4.1) 
might be limiting the flux though the pathway. Consequently, to decipher whether one or both 
enzymes are limiting the metabolic flux towards vanillin, we overexpressed each gene by 
chromosomal integration of a second copy in the globally engineered strain VG4 (Methods, 
Table 4.2, and Scheme 3.1). 
While overexpressing ACAR appears to have no significant effect of vanillin E-D-glucoside 
production (strain VG4-A1), the effect of overexpressing hsOMT is clear at the metabolite level 
(strain VG4-O1), with 30% increase of vanillin E-D-glucoside production (Fig. 4.3). The raise in 
vanillin E-D-glucoside production was accompanied by a decrease of accumulation of both 
intermediates, PAC and PAL, attesting the increased hsOMT activity in strain VG4-O1. 
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Figure 4.3: Effect of ACAR and hsOMT overexpression on vanillin E-D-glucoside production in S. cerevisiae. 
Concentration of vanillin-related metabolites on the fermentation broth (70 h cultivation in microtiter plates) for 
strains VG4, VG4-A1 (ACAR overexpressed), VG4-O1, VG4-O2 and VG4-O1-O2 (hsOMT overexpressed). 
Exploring if stronger overexpression could further increase vanillin E-D-glucoside production, a 
third copy of hsOMT was integrated in strain VG4-O1, leading to strain VG4-O1-O2 (Table 4.2). 
Herein, the genomic integration site was selected based on the data from Bai et al. (2009) which 
systematically characterized genomic integration sites for heterologous gene expression in S. 
cerevisiae [21]. As the transcription levels vary between different chromosomal regions, 
selecting the appropriate integration site allows adjusting the expression level for the inserted 
gene [21–24]. We selected the integration site YPRC'15 (#20) among the 24 sites characterized 
by Bai et al. (2009), because it showed the highest gene expression levels. Additionally, we chose 
TEF1 promoter sequence (also a strong constitutive promoter) instead of TPI1, to avoid further 
increasing the competition for the same transcription factors; TPI1 is already used for activation 
of all the genes from the vanillin biosynthetic pathway. We also constructed strain VG4-O2 
(Table 4.2) by inserting a second copy of hsOMT in strain VG4 at YPRC'15 locus, so we could 
compare both overexpression strategies (VG4-O1 vs VG4-O2). Strain VG4-O2 produced around 
13% more vanillin E-D-glucoside than strain VG4-O1 (Fig. 4.3), indicating that integration at 
YPRC'15 locus together with TEF1 promoter is a better strategy for higher gene expression in 
strain VG4, compared to Met15 locus together with TPI1 promoter, used for VG4-O1. This result 
also indicates that hsOMT expression level in strain VG4-O1 might still be limiting vanillin 
production. Simultaneous genomic integration of the two additional copies of hsOMT (strain 
VG4-O1-O2) resulted in the same titer as the one verified for strain VG4-O2. This led us to 
conclude that overexpression of hsOMT from YPRC'15 locus under TEF1 promoter is sufficient 
for relieving the flux limitation through the vanillin pathway imposed by hsOMT. 
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Notably, all the strains having hsOMT overexpressed show a significant decrease in PAL 
accumulation, which is explained by the fact that hsOMT is catalyzing the conversion from PAL 
to vanillin. On the other hand, a rather counter-intuitive trend is verified for PAC, which 
increases when hsOMT is overexpressed from YPRC'15 locus. From previous experiments we 
observed that PAC accumulation takes place mostly when the cells are exponentially growing on 
glucose (as opposed to ethanol), as well as we often observed a positive correlation between 
biomass and PAC concentration (data not shown). Indeed, both strains overexpressing hsOMT 
from YPRC'15 locus have increased biomass formation, compared to VG4 (Fig. 4.4A). 
 
Figure 4.4: Effect of deletion of YPRC'15 locus on the growth of strain VG4. A) Final biomass concentration 
(measured by OD600 nm) of strains VG4 and VG4-O2 obtained after 70 h cultivation in microtiter plates. B) The growth 
of strains VG4 and VG4-Δ2 was followed over time using Enzyscreen (Methods). This experiment was carried out 
without expressing the PPTase, therefore no PAL, vanillin or vanillin E-D-glucoside are produced in these conditions. 
Such strong effect on biomass yield is, most likely, the outcome of a combination of different 
factors. Nevertheless, we hypothesize that major contributions can come from having additional 
protein activity and consequent changes in the pool of by-products, as well as from the choice of 
overexpression locus itself. Although Bai et al. [21] mention that expressing a reporter gene form 
YPRC'15 locus did not significantly altered growth, we hypothesise that this might not be the 
case for the vanillin producing strains. Moreover, their study was carried out in a different strain 
background, which can be another source of variation [21]. We further explored the integration 
site related effects by constructing a control strain using the same strategy as used for VG4-O2, 
but the gene, promoter and terminator were omitted (VG4-Δ2, Table 4.2). Strains VG4 and VG4-
Δ2 were grown prior to expression of the PPTase, so most of the vanillin related compounds 
were not produced. This way, we try to minimize the effects of cellular resources spent on the 
vanillin pathway, as well as effects coming from the accumulation of several different vanillin 
related compounds (only PAC and vanillin acid are produced). The control strain was found to 
have altered growth kinetics comparing to VG4, particularly evident while consuming glucose 
(Fig. 4.4B). Preliminary strain characterization suggests faster growth on glucose, as well as 
higher biomass yield on this substrate. More comprehensive conclusions would require better 
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strain characterization, namely to grow the control strain in vanillin producing conditions, so the 
effects of harboring the active pathway would also be taken into account. Nevertheless, these 
results do not contradict the fact that hsOMT is a rate-limiting enzyme for vanillin production, 
since in all hsOMT overexpressed strains, higher vanillin E-D-glucoside-to-PAL ratio is observed, 
independently of the overexpression strategy. 
Another important aspect is that all the hsOMT overexpressed strains showed a significant 
increase in an unidentified compound, as detected in the chromatographic analysis. Production 
of this unknown compound was found to be strongly affected by hsOMT overexpression, so we 
speculate that the unidentified substance might be vanillic acid in its glucosylated form. 
Alternatively, hsOMT might lead to the formation of the by-product isovanillic acid, which would 
subsequently be reduced to isovanillin, in a reaction catalyzed by ACAR (Fig. 4.1). Accordingly, 
the unidentified compound can also be isovanillin, isovanillic acid or their glycosylated forms. 
The results obtained so far indicate that the bottleneck of the pathway is no longer the hsOMT 
enzyme activity. In order to assess whether the control for the flux though the vanillin pathway 
moved from hsOMT to ACAR, we overexpressed ACAR in strain VG4-O2, again by genomic 
integration from Met15 locus (Table 4.2). We found that ACAR overexpression did not further 
increase vanillin E-D-glucoside. 
Overexpression of hsOMT leads to improved vanillin production in baker’s yeast only 
when complemented with model-guided network engineering 
Overexpressing genes belonging to the pathway of interest for obtaining the desired product is a 
commonly used metabolic engineering strategy [25–27]. On the other hand, global metabolic 
network approaches, which target the metabolic network nodes distant from the pathway of 
interest, have also been shown to be effective. Ultimately the most efficient solution is, as we 
herein show, the complementary usage of both approaches [28, 29]. The two approaches are 
closely interrelated; global approaches often aim at boosting the pathway of interest through 
the supply of cofactors and precursors, while rather local approaches focus on relieving the flux 
through the pathway from enzyme limitations. Thus, whether a global strategy is pre-required 
for the success of a local strategy, or vice-versa, is difficult to estimate a priori. 
Following the same strategy as before, we overexpressed hsOMT from YPRC'15 locus in strain 
VG0 (Table 4.2, Methods) and measured vanillin E-D-glucoside production. 
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Figure 4.5: Overexpression of hsOMT leads to improved vanillin production only when complemented with model-
guided network engineering. Concentration of vanillin-related metabolites on the fermentation broth of strains VG0 
and VG4 before (gray) and after (blue) overexpression of hsOMT. 
Figure 4.5 shows that overexpression of hsOMT in VG0 does not increase vanillin E-D-glucoside 
production, reinforcing that the cofactor and energy supply for vanillin biosynthesis is of primary 
importance, compared to the level of expression of the enzymes from vanillin biosynthesis 
pathway. Furthermore, the best cell factory is obtained when both strategies are combined, 
strain VG4-O2, resulting in a final titer of ~380 mg/l of vanillin E-D-glucoside. Also here, 
increased PAC accumulation for strain VG0-O2 is explained by increased biomass yield on 
glucose due to the integration locus. 
Engineering glucose repression in S. cerevisiae leads to improved vanillin E-D-glucoside 
production 
Tackling the problem of further increasing the availability of cofactor and energy supply for 
vanillin E-D-glucoside production, we propose to alleviate glucose repression in batch 
cultivation. When glucose concentration is above a given threshold, many genes involved in 
respiration, gluconeogenesis and utilization of non-glucose carbon sources are expressed at low 
levels or not at all, while alcoholic fermentation is highly active [30–32]. Comparing to alcoholic 
fermentation, respiration is much more efficient from the energetic perspective [32, 33]. This 
makes it an attractive solution for increasing vanillin production, which requires ATP. To this 
end, the activation of many enzymes is required and manipulating a regulatory circuit represents 
an elegant option. Glucose repression in yeast takes place mainly via two regulatory pathways: 
the induction pathway, ultimately responsible for derepressing hexose transporters, and the 
repression pathway, responsible for repressing most of the genes involved in respiration, among 
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other cellular processes [30, 34]. Among the repressed genes, there is the Hap2/3/4/5p 
regulatory complex, which activates transcription of genes coding for enzymes of the TCA cycle, 
as well as for the respiratory chain. It has been previously confirmed that overexpression of 
HAP4, coding for one of the subunits of the complex, activates several TCA cycle genes, as well 
as, respiratory genes in high glucose concentration (batch conditions) [33, 35]. Hereby, we 
hypothesize that HAP4 overexpression will increase the respiration-to-fermentation ratio and 
thereby increase the ATP availability to produce vanillin E-D-glucoside. 
 
Figure 4.6: Overexpression of HAP4 increases the production of vanillin E-D-glucoside. A) Fermentation profile of 
biomass (OD600 nm), glucose, ethanol and vanillin E-D-glucoside during aerobic batch cultivation in microtiter plates of 
strain VG4-O1. B) Fermentation profile of biomass (OD600 nm), glucose, ethanol and vanillin E-D-glucoside during 
aerobic batch cultivation in microtiter plates of strain VG4-O1-H2. C) Concentration of vanillin-related metabolites 
corresponding to the time-point with the highest concentration of vanillin E-D-glucoside, for strains VG4-O1 and VG4-
O1-H2. 
Overexpression of HAP4 was accomplished by genomic integration of a second copy of the HAP4 
in YPRC'15 locus, under TEF1 promoter, in strain VG4-O1 (VG4-O1-H2, Table 4.2). In agreement 
with previous studies [33, 36], overexpressing HAP4 led to an increased biomass yield and 
decreased ethanol formation (Fig. 4.6A&B). The final concentration of vanillin E-D-glucoside on 
the fermentation broth of the strain VG4-O1-H2 was ~400 mg/l, approximately 30% higher than 
that of VG4-O1 (Fig. 4.6C). PAL concentration in the fermentation broth is also increased, 
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suggesting that alleviation of the glucose repression indeed contributed to better conversion 
from PAL to PAC, where ATP and NADPH are used as cofactors. 
Overview of metabolic engineering strategies towards improving vanillin E-D-glucoside 
production 
The improved biomass production observed for strain VG4-O1-H2 is not independent of the 
integration locus, as discussed before. A similar strategy for obtaining a control strain should be 
followed here in the future, in order to confirm the exact contribution of HAP4 to the observed 
phenotype. Nevertheless, the production of vanillin related compounds obtained with strain 
VG4-O1-H2 can be also compared to that of VG4-O2, where integration site related effects on 
biomass are equal and hsOMT is overexpressed as well, although from a different locus (Fig. 
4.7). 
 
Figure 4.7: Overview of metabolic engineering strategies towards improving vanillin E-D-glucoside production. A 
proxy for metabolite yield on biomass, based on OD600 nm, is used to compare strain VG4, VG4-O1, VG4-O2 and VG4-
O1-H2. 
A general overview of all the metabolically engineered mutants shows that overexpression of 
hsOMT from the Met15 locus leads to the highest vanillin E-D-glucoside production from 
biomass (Fig. 4.7). However, biomass production is 2-fold higher when hsOMT or HAP4 are 
overexpressed from YPRC'15 locus, thereby this strategy is, overall, more effective for 
converting glucose into vanillin E-D-glucoside. Independently of the integration site, hsOMT 
overexpression is highly beneficial for converting PAL into downstream compounds of the 
vanillin pathway. Additional HAP4 overexpression further increases vanillin E-D-glucoside 
production, strain VG4-O1-H2 presents the highest vanillin E-D-glucoside titer obtained among 
all the mutants, ~400 mg/l. This strategy also results in a pronounced change in the profile of 
vanillin related compounds, with a 3-fold increase of PAL concentration. As previously discussed, 
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this suggests that, after hsOMT overexpression, cofactors like ATP probably became, once again, 
the bottleneck for converting PAC into PAL in strain VG4-O2. Also supporting this hypothesis is 
the fact that ACAR overexpression did not change the vanillin related compounds production 
profile (strain VG4-A1-O2). Further studies could include investigating the recurrent limitation of 
the hsOMT enzymatic step, focusing on both, boosting enzyme activity and cofactor supply (S-
adenosylmethionine). 
Conclusions and Future Perspectives 
The present study aimed at improving a vanillin E-D-glucoside S. cerevisiae cell factory by 
boosting the conversion of vanillin pathway intermediates to the final product. Identification of 
hsOMT, which catalysis the conversion of PAL into vanillin, as the rate-limiting step of the vanillin 
biosynthetic pathway and its consequent overexpression led to 30% improvement of vanillin E-
D-glucoside production. Additionally, we performed regulatory engineering, by overexpressing 
HAP4, with the goal of increasing the respiration-to-fermentation ratio, so that less ethanol 
would be produced and more ATP would be available for the vanillin biosynthetic pathway. This 
genetic modification yielded further increase in vanillin E-D-glucoside production. The final 
concentration in the fermentation broth was ~400 mg/l in batch cultivation, corresponding to 
~20 mgVG/gglc, considerably higher than ~15 mgVG/gglc, previously reported for similar conditions 
[10]. Most importantly, higher accumulation of PAL in the fermentation broth was again 
observed, which suggests higher ATP availability for the vanillin biosynthetic pathway. Further 
strain characterization, such as chemostat cultivation or measurement of the respiratory 
quotient (RQ) in batch cultivation, could confirm higher respiratory capacity of this strain. 
Transcriptome analysis would be useful for carefully examining transcription levels of relevant 
genes, possibly affected by the overexpression of the transcription factor HAP4. 13C isotope 
labeled fluxome analysis would also be of great interest for further characterizing the observed 
phenotype. Such data would also offer a chance of performing an integrated analysis with the 
yeast genome-scale model and find targets for the next metabolic engineering round. On a 
perspective of increasing enzyme specificity, protein engineering could be very valuable to 
reduce/eliminate by-product formation, namely vanillic acid and isovanillin related compounds 
[13, 37]. 
In conclusion, this study showed that accounting for the local pathway effects for metabolic 
engineering is of much higher value when it is combined with global approaches, which involve 
whole metabolic network, as well as regulatory effects. Although algorithms for including such 
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targets are already starting to appear, e.g. OptORF [38], this research field still in its infancy. 
Further efforts on characterizing regulatory networks are expected to provide valuable insights 
for integrating regulatory circuits with metabolic models [38, 39]. 
Methods 
Strains and Plasmids 
Common molecular biology protocols  
Restriction enzymes and buffers were obtained from New England Biolabs and the conditions for 
restriction followed manufacture instructions. GFXTM PCR DNA and Gel Band Purification Kit (GE 
Healthcare) was used for DNA purification. Ligation was performed with T4 DNA ligase (New 
England Biolabs) prior to plasmid transformation into chemo-competent DH5α E. coli cells. 
Ampicillin resistance was used as E. coli selection marker and plasmid extraction was performed 
using a GenElute HP Plamsid Miniprep Kit (Sigma-Aldrich). PCR amplification was performed 
using PhusionTM Hot Start High-Fidelity DNA Polymerase (Finnzymes Oy, Espoo, Finland) to 
obtain all the DNA fragments, except for amplification of fragments for USER cloning. In such 
cases, PfuX7, a mutant Pfu DNA polymerase designed for advanced uracil-excision, was used 
instead [40]. All the primers used for this study were acquired from Sigma Aldrich and are listed 
in Table ST4.1. 
USER cloning was performed as previously described [41] with minor modifications. The USER 
vectors (containing a USER cassette) were digested with PacI, followed by digestion with the 
appropriate nicking endonuclease, Nt.BbvCI. Purified digested vector (0.1 pmol) was mixed with 
1 pmol purified PCR products (total concentration of the 3 PCR fragments, equimolar) and 
incubated with 1 U USER enzyme (New England Biolabs) for 20 min at 37°C, followed by 20 min 
at 25°C. 10-μl of the reaction mix was directly used to transform chemically competent E. 
coli cells. 
S. cerevisiae heterologous DNA expression was achieved by using low-copy-number-replicating 
plasmids, CEN-ARS, for the PPTases genes and chromosomal integration for the remaining 
genes. The yeast transformation protocol was performed as described by Gietz et al. [42]. 
Chromosomal integration was achieved by gene targeting through homologous recombination 
of linear DNA fragments, which was either a digested vector, or bipartite PCR fragments. MET15 
or URA3 from Kluyveromyces lactis [43] were used as selection markers. The URA3 marker used 
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for chromosomal integration was flanked by direct repeats that allowed restoring of uracil 
auxotrophy by plating the cells in agar medium containing 5-Fluoroorotic acid (5-FOA) after each 
genetic manipulation [44]. 
PPTase-coding genes subcloning and expression in S. cerevisiae VG0 strain 
Plasmids pJH589, pJH592, pARB118 and pARB117 (Table 4.1) were used for heterologous 
expression of the PPTase-coding genes entD, PPTcg-1, npgA and npt (respectively) in strain VG0 
(Table 4.2). The backbone plasmid is identical for all the genes, including the yeast auxotrophic 
marker (URA3) and the promoter responsible for transcriptional activation of the genes (PTPI1), in 
order to reduce variability.  
Table 4.1: Plasmids used in this study. 
Plasmid Gene content Plasmid type 
Selection 
marker 
Reference 
pJH665 UGT72E2 (Arabidopsis thaliana) CEN-ARS (S. cerevisiae) URA3 Hansen et al.  [4]  
pRS426 n.a. Episomal (S. Cerevisiae) URA3 Christianson et al. [45] 
pWJ1042 
Recyclable URA3 (Kluyveromyces 
lactis) 
CEN-ARS (S. Cerevisiae) URA3 Reid et al. [46] 
pJH589 endD (E. coli) CEN-ARS (S. cerevisiae) URA3 Hansen et al.  [4]  
pJH592 PPTcg-1 (C. Glutamicum) CEN-ARS (S. Cerevisiae) URA3 Hansen et al.  [4] 
pESC-npgA-
pcbAB 
npgA (Aspergillus nidulans) CEN-ARS (S. Cerevisiae) URA3 Siewers et al. [19] 
pJ204-npt 
npt (Nocardia sp.), synthetic codon 
optimized 
n.a. n.a. DNA-2-Go™ 
pJH674 
ACAR (Nocardia sp.), synthetic 
codon optimized 
Integration (S. cerevisiae) HphMX Hansen et al.  [4] 
pJH543 
hsOMT (Homo sapiens), synthetic 
codon optimized 
Integration (S. Cerevisiae) NatMX Hansen et al.  [4] 
pARB118 npgA (Aspergillus nidulans) CEN-ARS (S. Cerevisiae) URA3 This study 
pARB117 
npt (Nocardia sp.), synthetic codon 
optimized 
CEN-ARS (S. Cerevisiae) URA3 This study 
pARB014 endD (E. Coli) Integration (S. Cerevisiae) URA3 This study 
pARB010 n.a. Integration (S. Cerevisiae) URA3 This study 
pARB030 n.a. Integration (S. Cerevisiae) MET15 This study 
pARB032 
ACAR (Nocardia sp.), synthetic 
codon optimized 
Integration (S. Cerevisiae) MET15 This study 
pARB033 
hsOMT (Homo sapiens), synthetic 
codon optimized 
Integration (S. Cerevisiae) MET15 This study 
pARBU2000 PacI/Nt.BbvCI USER cassette [41] Episomal (S. Cerevisiae) n.a. This study 
pARBU2101 
600 bp fragments flanking the 
integration site YPRCΔ15 (S. 
cerevisiae) [21]  
Episomal (S. Cerevisiae) 
Recyclable 
URA3a  
This study 
pARBU2131 
hsOMT (Homo sapiens), synthetic 
codon optimized 
Episomal (S. cerevisiae) 
Recyclable 
URA3 a 
This study 
pARBU2191 HAP4 (S. cerevisiae) Episomal (S. Cerevisiae) 
Recyclable 
URA3 a 
This study 
a URA3 from Kluyveromyces lactis flanked by direct repeats for restoration of uracil auxotrophy [43]. 
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Table 4.1 contains all the plasmids used and obtain in this study. Plasmid pARB118, containing 
the gene npgA from Aspergillus nidulans, was obtained from pJH665 by replacing the gene 
UGT72E2 by npgA, using the restriction endonucleases XbaI and KpnI. The vector was treated 
with Antarctic Phosphatase (New England Biolabs) after restriction with XbaI in order to create a 
blunt end, and only then restricted with KpnI. The gene npgA was obtained by PCR amplification 
with primers O1_f and O2_r, using pESC-npgA-pcbAB as template. Plasmid ARB117, containing 
the gene npt from Nocardia sp. (codon optimized) was obtained from plasmid pJH665 by 
replacement of the gene UGT72E2. XbaI and KpnI were used to restrict pJ204-npt (DNA-2-Go™) 
in order to obtain the DNA fragment containing the gene, which was cloned in the restricted and 
purified vector pJH665 using the same enzymes. 
ACAR, hsOMT and HAP4 subcloning and overexpression in vanillin E-D-glucoside producing S. 
cerevisiae strains 
Plasmid pARB014 was obtained from pJH589 by restriction with FseI and recircularization of the 
purified vector without CEN-ARS. Plasmid pARB010 was obtained from pARB014 by restriction 
with NotI and recircularization of the purified vector without the PTPI1–entD–TTPI1 fragment. 
pARB030 was obtained by replacing the URA3 marker for S. cerevisiae in pARB010 by the marker 
MET15, using AscI. MET15 (incl. native promoter, 450 bp, and terminator, 215 pb) was obtained 
by PCR amplification from CEN.PK 113-7D genomic DNA using primers O5_f and O6_r. pARB032 
and pARB033 were obtained by inserting a fragment containing PTPI1–ACAR–TTPI1 and PTPI1–
hsOMT–TTPI1, respectively, on purified pARB030 after restriction with Not1. The fragments 
containing PTPI1–ACAR–TTPI1 and PTPI1–hsOMT–TTPI1 were obtained by NotI restriction of pJH674 
and pJH543 [4], respectively. 
pARBU2000 contains a PacI/Nt.BbvCI USER cassette [41] and it was the basic USER vector 
constructed and used in this study. It was obtained by restricting pRS426 with XbaI followed by 
recircularization in order to remove the URA3 original S. cerevisiae marker. The intermediate 
vector was restricted with NotI in order to insert the fragment containing the PacI/Nt.BbvCI 
USER cassette. The PacI/Nt.BbvCI USER cassette (restricted with NotI) was kindly provided by 
Bjarne G. Hansen. pARBU2101 was obtained by USER cloning the URA3 recyclable marker (K. 
Lactis) between the flanking regions of S. cerevisiae integration site #20 from Bai et al. 
(YPRCΔ15) [21]. The URA3 recyclable marker was obtained by PRC amplification using primers 
UO1_f and UO2_r, and pWJ1042 [46] as template. The YPRCΔ15 flanking regions were obtained 
by PRC amplification using primers UO3_f, UO4_r, UO5_f and UO6_r, and CEN.PK 113-7D 
genomic DNA as template. Note that primer UO5_f was designed such that the USER cassette is 
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recovered while the fragments are correctly assembled on the plasmid. pARBU2131 and 
pARBU2191 were obtained by USER cloning the promoter region of TEF1 (400 bp) and the 
terminator region of CYC1 (200 bp) flanking the genes hsOMT and HAP4, respectively, on 
pARBU2101. PTEF1, TCYC1 and HAP4 DNA fragments were obtained by PRC amplification using 
primers UO7_f and UO8_r, UO9_f and UO10_r and UO11_f and UO12_r, respectively while using 
CEN.PK 113-7D genomic DNA as template. hsOMT fragment was PCR amplified from pARB033 
using primers UO13_f and UO14_r. pARBU2131 and pARBU2191 can be used for expressing 
hsOMT and Hap4 from plasmid (multi-copy), as well as PCR template for obtaining the fragments 
for chromosomal integration (bipartite method) of the genes. In this work, we followed the 
second approach; the primers used to obtain the PCR fragments for chromosomal integration of 
hsOMT and HAP4 were UO3_f, O10_r and O9_f, UO6_r. 
Strains VG0 and VG4 by Brochado et al. [10] were used as background for the yeast strains 
obtained during this study. Table 4.2 lists all the strains, as well as their relevant genotype. 
Table 4.2: Yeast strains obtained in this study. 
Straina  Relevant genotype  Vanillin pathway overexpressed genes 
VG0 met15Δ0::MET15  
VG4 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0::MET15  
VG0-O2 met15Δ0::MET15 yprcΔ15::hsOMT hsOMT 
VG4-O1 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0::PTPI1-hsOMT[MET15] hsOMT 
VG4-O2 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0::MET15 yprcΔ15::PTEF1-hsOMT hsOMT 
VG4A pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0:: PTPI1-ACAR[MET15] ACAR 
VG4-A1-O2 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0:: PTPI1-ACAR[MET15] yprcΔ15:: PTEF1-hsOMT ACAR & hsOMT 
VG4-O1-O2 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0:: PTPI1-hsOMT[MET15] yprcΔ15:: PTEF1-hsOMT hsOMT 
VG4-O1-H2 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0:: PTPI1-hsOMT[MET15] yprcΔ15:: PTEF1-HAP4 hsOMT & HAP4 
VG4-Δ2 pdc1 gdh1 GDH2::PPGK1-GDH2 met15Δ0::MET15 yprcΔ15  
VG0-Δ2 met15Δ0::MET15 yprcΔ15  
   
a All strains are derivatives from strain VG0 from Brochado et al. [10]. Only the relevant phenotype, not common to all 
the strains, is show in the table. Methionine prototrophy was restored in all the strains by gnomic integration of gene 
MET15 in its original locus. 
Scheme 3.1 contains an overview of all the strains obtained in this study. hsOMT overexpressed 
strains are represented in blue, ACAR overexpression is represented in green. Combined 
overexpression of hsOMT and ACAR is represented in red, while the combined overexpression of 
hsOMT and HAP4 is represented in yellow. Strains not containing additional overexpression of 
any of the genes form the vanillin biosynthetic pathway are represented in gray. 
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VG0 is the reference strain used for this study (gray, Scheme 3.1). VG4 was previously 
engineered for improved vanillin production and it lacks the genes PDC1 and GDH1, while GDH2 
is overexpressed. hsOMT overexpressed strain VG4-O1 was obtained from VG4 by chromosomal 
integration of the liberalized vector ARB033 (Nar1). Strains VG0-O2, VG4-O2 and VG4-O1-O2 
(dark-blue) where obtained from strains VG0, VG4 and VG4-O1, respectively, by chromosomal 
integration of a bipartite substrate containing the recyclable URA3 marker, as well as hsOMT 
under PTEF1. Therefore, these strains are also hsOMT overexpressed, but the genomic integration 
site (YPRCΔ15) and promoter differs from those of VG4-O1. The uracil auxotrophy of these 
strains was re-established after isolation in 5-FoA [43]. Note that this is a fundamental step, 
since vanillin E-D-glucoside production requires the expression of a PPTase, which occurs from a 
low-copy-number plasmid with URA3 as selective marker. ACAR overexpressed strain VG4A 
(green, Scheme 1) was obtained from strain VG4 by chromosomal integration of liberalized 
vector ARB032 (Nar1). ACAR and hsOMT overexpressed strain VG4-A1-O2 (red, Scheme 1) was 
obtained from VG4A by chromosomal integration of a bipartite substrate (recyclable URA3 
marker and hsOMT under PTEF1) similarly to VG4-O2. hsOMT and HAP4 overexpressed strain VG4-
O1-H2 (yellow, Scheme 1) was obtained from VG4-O1 by chromosomal integration of a bipartite 
substrate containing the recyclable URA3 marker and HAP4 under PTEF1. 
 
Scheme 3.1: Overview of the yeast strains obtained during this study. VG0 and VG4 (gray) are the reference and previously 
metabolically engineered strains, respectively. The relevant genotype of the strains is represented bellow the name (gray, in the 
cases of genetic modifications carried out in previous work). Letters A, H and O represent the overexpressed genes ACAR, HAP4 and 
hsOMT, respectively.  Numbers 1 and 2 following A, H and O correspond to integration sites MET15 and YPRCΔ15, respectively. VG4-
O1 (light-blue) and VG4-O1-O2 (dark-blue) have hsOMT overexpressed from the MET15 locus. VG0-O2, VG4-O2, VG4-O1-O2 (dark-
blue) and VG4-A1-O2 (red) have hsOMT overexpressed from the YPRCΔ15 locus. VG4-A1 (green) and VG4-A1-O2 (red) have ACAR 
overexpressed from the MET15 locus. VG4-O1-H2 (yellow) is has Hap4 overexpressed from the YPRCΔ15 locus. 
 
VG0 
Reference 
VG0-O2 
↑hsOMT 
VG4 
pdc1 gdh1 ↑GDH2 
VG4-O1 
pdc1 gdh1 ↑GDH2 
↑hsOMT 
VG4-O1-O2 
pdc1 gdh1 ↑GDH2 
↑hsOMT 
VG4-O1-H2 
pdc1 gdh1 ↑GDH2 
↑hsOMT ↑HAP4 VG4-O2 
pdc1 gdh1 ↑GDH2 
↑hsOMT 
VG4-A1 
pdc1 gdh1 ↑GDH2 
↑ACAR 
VG4-A1-O2 
pdc1 gdh1 ↑GDH2 
↑ACAR ↑hsOMT 
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Media composition 
Lysogeny broth (LB) medium was used to grow Escherichia coli cells for cloning purposes. The 
medium composition is as follows: 10 g/L of tryptone, 5 g/L of yeast extract and 10 g/L of NaCl. 
The medium pH was adjusted to 7.5 with NaOH/HCl 2N, before autoclavation and sterile filtered 
ampicillin was added to a final concentration of 100 mg/L, when needed, after autoclavation. For 
solid medium, 20 g/L agar was added prior to autoclavation. 
YPD medium was used to grow S. cerevisiae cells for cloning purposes. The medium composition 
is as follows: 10 g/L of yeast extract, 20 g/L of peptone and 20 g/L of glucose (glucose was 
autoclaved separately). For solid medium, 20 g/L agar was added prior to autoclavation. 
Synthetic complete (SC) dropout media, SC URA- and SC Met-, were used as selective media to 
grow S. cerevisiae for cloning purposes. The SC medium composition is as follows: 6.7 g/l of 
yeast nitrogen base without amino acids, 40 mg/l of adenine sulphate, 20 mg/l of L-arginine, 100 
mg/l of L-aspartic acid, 100 mg/l of L-glutamic acid, 20 mg/l of L-histidine, 60 mg/l of L-leucine, 
30 mg/l of L-lysine, 20 mg/l of L-methionine, 50 mg/l of L-phenylalanine, 375 mg/l of L-serine, 
200 mg/l of L-threonine, 40 mg/l of L-tryptophan, 30 mg/l of L-tyrosine, 150 mg/l of L-valine, 20 
mg/l of L-uracil and 20 g/l glucose. SC URA- and SC Met- media lack uracil and methionine, 
respectively. Glucose was autoclaved separately. The pH was adjusted to 5.8 prior to 
autoclavation. For solid medium, 20 g/L agar was added prior to autoclavation. 
A defined minimal medium as described by Verduyn et al. (1992) [11] with 20 g/l glucose as sole 
carbon source was used for S. cerevisiae cultivation in batch cultivation in 24-well microtiter 
plates [47]. The medium composition is as follows: 7.5 g/l (NH4)2SO4, 14.4 g/l KH2PO4, 0.5 g/l 
Mg2SO4, 2.0 ml/l trace metal solution, 1.0 ml/l vitamins solution, 0.05 ml/l antifoam 204 (Sigma-
Aldrich A-8311) and 100 mg/l L-methionine when needed. Trace metal solution contained 3 g/L 
FeSO4.7H2O, 4.5 g/L ZnSO4.7H2O, 4.5 g/L CaCl2.6H2O, 0.84 g/L MnCl2.2H2O, 0.3 g/L CoCl2.6H2O, 
0.3 g/L CuSO4.5H2O, 0.4 g/L NaMoO4.2H2O, 1 g/L H3BO3, 0.1 g/L KI and 15 g/L Na2EDTA.2H2O. 
Vitamins solution included 50 mg/l d-biotin, 200 mg/l para-amino benzoic acid, 1.0 g/l nicotinic 
acid, 1.0 g/l Ca-pantothenate, 1.0 g/l pyridoxine HCL, 1.0 g/l thiamine HCl and 25 mg/l m-
inositol. The pH was adjusted to 6 by addition of 2N NaOH prior to autoclavation, the glucose 
was autoclaved separately and methionine and vitamins solutions were sterile filtered (0.2 μm 
pore-size Ministart®-Plus Sartorius AG, Geottingen, Germany) and added after autoclavation. 
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Microtiter plates batch cultivation 
S. cerevisiae cell cultivation was carried out in white, flat-bottom, 24-well microtiter plates 
(Cornig Inc., NY) covered by a sterile sandwich-lid with a black rubber inner layer (Enzyscreen, 
The Netherlands) to prevent contamination. The cultures were grown in minimal medium, initial 
OD600 nm of 0.1 in a total volume of 900 μl per well, using Growth Porfiler 1152 (Enzyscreen, The 
Netherlands), shaking frequency of 200 rpm, with controlled temperature at 30 oC. 
Biomass determination 
Samples were maintained at 4 oC post sampling and the biomass concentration was monitored 
by optical density at 600 nm (OD600 nm). OD600 nm was measured throughout all the fermentation 
in a Shimadzu UV mini 1240 spectrophotometer (Shimadzu Europe GmbH, Duidberg, Germany). 
The samples were diluted with distilled water in order to obtain measurements in the linear 
range of 0 to 0.6 OD600 nm 
Glucose and external metabolites analysis 
The fermentation samples were filtered using a 0.45 μm pore-size syringe-filter (Sartorius AG, 
Geottingen, Germany) and stored at -20 oC until further analysis. Glucose, ethanol, glycerol, 
pyruvate, succinate and acetate were determined by high performance liquid chromatography 
(HPLC) analysis using an Aminex HPX-87H ion-exclusion column (Bio-Rad Laboratories, Hercules, 
CA). The column temperature was kept at 60 oC and the elution was performed using 5 mM 
H2SO4 with flow rate of 0.6 ml/min. Metabolites detection was performed by a RI-101differential 
refractometer detector (Shodex) and an UVD340U absorbance detector (Dionex) set at 210 nm. 
Extracellular vanillin, vanillin β-D-glucoside (VG), protocatechuic acid (PAC), protocatechuic 
aldehyde (PAL) and vanillic acid were quantified by high performance liquid chromatography 
(HPLC) using Agilent 1100 series equipment with a Luna C18 column (Phenomenex). A gradient 
of methanol (+ 1% tetra-fluoroacetic acid) and water (+ 1% tetra-fluoroacetic acid) at a flow rate 
of 0.3 ml/min was used as mobile phase. The column was kept at 300 bar and 30 oC. Metabolite 
detection was performed using a UV diode-array detector set at 280 and 310 nm. 
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Chapter 5: Minimization of Metabolite Balance Explains 
Genetic Interactions within the Yeast Metabolic Network 
 
This chapter is based on the manuscript: 
“Minimization of Metabolite Balance explains complex genetic interactions within the yeast 
metabolic network”. Ana Rita Brochado, Sergej Andrejev, Costas D. Maranas and Kiran R. Patil. 
Sumbitted. 
 
Abstract 
Genome-scale metabolic networks provide a comprehensive structural framework for 
integrative data analysis as well as for metabolic modeling. The solution space for the metabolic 
flux state of the cell is typically very large and optimization-based approaches are often 
necessary for identifying the active metabolic state under specific environmental conditions. The 
objective function to be used is problem dependent and one of the most relevant parameters 
for successful modeling. Although linear combination of selected fluxes is widely used for 
formulating metabolic objective functions, we found that the mathematical implementation of 
these optimization problems is context dependent owing to the non-uniqueness of the 
stoichiometric coefficients scaling. We hereby propose a new method, Minimization of 
Metabolite Balance (MiMBl), which allows consistent formulation of the desired biological 
principles, thereby providing robust predictions for gene essentiality and genetic interactions. 
We demonstrate how MiMBl can be used together with existing algorithms to provide 
mechanistic insights into the yeast genetic interactions network. 
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Introduction 
The fundamental role of metabolism within a living cell has become a focal point of study in 
many disciplines, such as cell biology, physiology, medicine and synthetic biology. The assembly 
of all reactions and metabolites into a genome-scale metabolic network provides a 
comprehensive structural framework for integrative data analysis [1, 2], as well as for 
quantitative modeling of cellular metabolism [3–6]. As the solution space for the metabolic flux 
state of the cell is typically very large, constraint based optimization approaches are often 
applied for simulating metabolic fluxes. In essence, these approaches search for an optimal flux 
distribution that maximizes or minimizes an appropriate biological objective function while 
satisfying the mass balance and metabolite exchange constraints. Among these, Flux Balance 
Analysis [7] is a widely used simulation tool that utilizes a linear programming formulation for 
maximization of growth (synthesis of biomass constituents) as biological objective function. FBA 
has been applied with various degrees of success, albeit mostly for “wild-type” or unperturbed 
metabolic networks [8, 9]. In addition to FBA, different frequently used objective functions were 
reviewed and tested against experimental data by Schuetz et al. [10], including minimization of 
overall intracellular flux, maximization of biomass or ATP yield, among others. In case of 
genetically or environmentally perturbed networks, Minimization of Metabolic Adjustment 
algorithm - MoMA [11] - has been reported to better represent the biological observations [11–
14]. The hypothesis underlying MoMA is that the fluxes in a perturbed cell (e.g. a mutant) will be 
redistributed so as to be as similar as possible to the wild-type. 
The biological principles exemplified by simulation tools for both wild-type and perturbed 
networks are undeniably fascinating, which is confirmed by their numerous applications – 
including prediction of genetic interactions [2, 15, 16], metabolic engineering [13, 14, 17] and 
microbial community modeling [18]. Several of the commonly used objective functions rely on 
the use of linear combination of fluxes, e.g., MoMA or maximization of ATP production (Table 
5.1). We found that the mathematical formulation of this class of problems (i.e. where linear 
combination of fluxes is part of the objective function) is sensitive to the representation of the 
reaction stoichiometry with results strongly dependent on the adopted scaling of the 
stoichiometric coefficients. We find that this non-uniqueness in prediction may confound the 
interpretation of the intended biological objective function. The stoichiometric representation of 
any reaction is subjective, often scaled to have coefficient of 1 for one of the reactants/products. 
Importantly, as the modeling problem involves hundreds of reactions, there is no unique 
possible stoichiometric representation of the metabolic network. 
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We motivate the need for rethinking the problem formulation for metabolic modeling by 
illustrating how the current methods lead to incoherent biological predictions when alternatively 
representing the reaction stoichiometry. Tackling a proper problem formulation, we propose a 
new methodology for metabolic modeling – Minimization of Metabolite Balance (MiMBl), which 
accounts for reaction stoichiometry in the objective function by mapping the flux space into the 
metabolite space. As intended, MiMBl shows robust predictions independently of the 
stoichiometry representation. We demonstrate the biological relevance of the new formulation 
with increased power for predicting genetic interactions in the metabolic network of S. 
cerevisiae. In a recent study reporting a large genetic interactions dataset covering the S. 
cerevisiae metabolic network [2], FBA was found to have limited capability for predicting the 
experimentally observed interactions, partially due to the lack of regulatory information. Within 
this study we successfully challenged MiMBl to accomplish the task of extending the range of 
genetic interactions that can be predicted. By combining the results from MiMBl and FBA we 
obtain novel insights into the operating mechanisms underlying genetic interactions within 
metabolic networks. 
Results and Discussion 
Minimization of sum of fluxes 
Minimization of the sum of intracellular flux is a routinely used objective function for estimating 
intracellular fluxes [10, 19, 20]. By using the iFF708 S. cerevisiae genome-scale metabolic model 
[21], we illustrate how the use of this objective function leads to inconsistent predictions when 
using different, but equivalent, reaction stoichiometry. iFF708 was a model of choice for this 
illustration as it is one of the highly curated yeast models that is most suitable for predicting 
intracellular flux distributions. On the other hand, for studying large scale genetic interactions in 
yeast we will use the more recent and comprehensive model iAZ900 (also manually curated) 
which allows us to analyse a larger part of the dataset. Linear scaling of all stoichiometric 
coefficients of a given reaction (e.g. multiplication by a scalar θ, Methods) preserves the 
stoichiometry and ought not to affect the simulation outcome for a correct problem 
formulation. However, in this case, scaling of a single reaction (RPI1) results in diverting the 
carbon flow from glycolysis to pentose phosphate pathway, which is one of the most important 
metabolic branch points (Figs. 4.1 and S1). This deviation was verified not to be consequence of 
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alternative optima of the same mathematical solution (Fig. S4.1), thus representing divergent 
biological solutions. 
 
Figure 5.1: Minimization of overall intracellular flux leads to divergent predictions for flux distribution when using 
alternative stoichiometry representations. Shown are predicted fluxes through key pathways within the S. cerevisiae 
central carbon metabolism, using alternative stoichiometric representation of reaction RPI1 (θRPI1, Methods). θRPI1 is 
represented on the x-axis, while fold-change of fluxes relatively to θ=1 is represented on the y-axis. A representative 
reaction from each of the pathways was selected to illustrate the flux re-arrangement; FBA1 for glycolysis, ZWF1 for 
pentose phosphate pathway, CIT1 for tricarboxilic acid cycle and NID1 for oxidative phosphorylation. Note that θ=1 is 
an arbitrary reference, as the stoichiometric representation of any reaction is subjective, often scaled to have 
coefficient of 1 for one of the reactants/products. 
In order to understand the nature of the problem leading to the susceptibility of the solution 
towards alternative representation of the stoichiometric matrix, we used a toy-model (Fig. 5.2a). 
As a case study, minimization of metabolic adjustment was chosen as a biological principle and 
formulated as minimization of Manhattan Distance (most commonly used formulation of 
MoMA, termed lMoMA [22]). In the wild-type toy-model, flux goes from A to D via R5. The goal 
is to predict flux distribution in the mutant lacking R5. The biological principle of minimization of 
metabolic adjustment dictates rewiring of the flux through R6. However, lMoMA found 
contradictory optimal solutions, i.e. solutions that re-route the flux via R2-R3-R4 or R6, 
depending on the stoichiometric representation of R6 (Fig. 5.2b). Insight into the cause of this 
behavior can be gained by analyzing the optimal objective function values, i.e. distances, as 
function of θR6 (Fig. 5.2d). Decreasing θR6 (i.e. increasing 1/θR6) implies higher numerical value of 
the flux through R6, hence higher contribution of R6 to the distance. Consequently, after a 
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certain value of θR6, the activation of the longer R2-R3-R4 pathway more than compensates the 
use of R6. The two solutions are not alternative optima, as the objective function value (i.e. 
distance) neither remains constant nor linearly scales with θR6. Such non-linear dependency of 
the objective function value on the scalar θR6 violates the requirement of a correct problem 
formulation. The analytical proof is presented in the Methods section and shows that the 
optimality condition for the linear programming problem after scaling is not guaranteed to be 
satisfied. Notably, widely used FBA-like problems (max/minimization of a single flux as objective 
function) are perfectly robust concerning scaling of the stoichiometric coefficients. As a single 
flux is used objective function, the relative values of all the remaining fluxes (which depend on 
the stoichiometry representation) does not influence the optimal solution to be found (for 
theoretical proof, see Supplementary notes). 
 
Figure 5.2: A toy-model illustrating how, and why, alternative stoichiometry representations influence simulation of 
minimization of metabolic adjustment by using lMoMA or MiMBl. a) Toy-model: R1 to R7 and A to D represent 
reactions and metabolites, respectively. In the wild-type, or reference, flux goes from A to D via R5. R6 and R2-R3-R4 
are two alternative pathways for flux re-distribution after deletion of R5. b) Flux through reactions R2 (full symbols) 
and R6 (open symbols) obtained after simulation with lMoMA (blue) and MiMBl (yellow) using alternative 
representations of reaction R6 (given by different θR6, Methods). c) Formulation of objective functions for lMoMA and 
MiMBl (Methods). d) Optimal objective function value (distance) obtained for minimization of metabolic adjustment 
using lMoMA (blue) and MiMBl (yellow) as function of θR6. 
The mathematical caveat illustrated above means that the contribution of the desired biological 
objective function towards the obtained solution is inseparable from that of the artifacts of 
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stoichiometry representation. Importantly, in large metabolic networks the effects of 
stoichiometric representation of reactions are cumulative. As shown in the following, this 
problem can be solved by proper normalization of the objective function variables with respect 
to stoichiometric representation of the reactions. To achieve such normalization, we devised 
two approaches, normalized lMoMA (normlMoMA) and Minimization of Metabolite Balance 
(MiMBl). In normlMoMA, each variable in the objective function is normalized by its value in the 
wild-type flux distribution. Albeit being simple, this normalization method has three major 
drawbacks: i) many reactions often have null fluxes in the wild-type, thus posing a problem for 
normalization (Methods, Supplementary notes and Fig. S4.2); ii) it requires a reference flux 
distribution to obtain the normalization factors, making it inappropriate to formulate objective 
functions such as minimization of overall intracellular flux; and iii) the influence of each flux on 
the metabolic adjustment would be exclusively due to its fold change, not taking into account 
that reactions carrying higher fluxes could have a stronger impact on the predicted flux 
distribution, as implied in the original concept of minimization of metabolic adjustment. 
Minimization of Metabolites Balance - MiMBl 
To obtain a biological meaningful and mathematically robust normalization, we propose 
Minimization of Metabolite Balance (MiMBl) as a new method for metabolic modeling. The 
objective function in MiMBl is formulated as a linear combination of metabolite turnovers (tM). 
The turnover of a metabolite is the sum of all fluxes producing (or consuming) it, multiplied by 
the corresponding stoichiometric coefficients (Methods). The objective function for 
minimization of metabolic adjustment is reformulated to include metabolite turnovers instead of 
fluxes (Fig. 5.2c). Because the stoichiometric coefficients are taken into account while calculating 
tM, MiMBl is robust to the linear scaling of the stoichiometric matrix, analytical proof of which is 
presented in the Methods section. In case of the toy-model (Fig. 5.2a, d), this robustness is 
illustrated by the invariant nature of the objective function as well as the flux distribution. Note 
that the flux through R6 linearly scales with θR6, while the turnover of all metabolites is 
conserved. The normalization implied in MiMBl formulation is suitable for addressing a variety of 
biological questions involving different objective functions, such as minimization of overall flux 
(by using a null vector for wild-type flux distribution) or maximization of ATP yield (by 
maximizing the ATP turnover for a given substrate uptake rate), among others (Table 5.1). 
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Table 5.1: Formulation of different biological objective functions using MiMBl. 
Biological objective 
function 
Previous objective 
function Description 
MiMBl objective 
function Description 
Minimization of 
metabolic 
adjustment 
¦


Ni
i
WT
i vvmin
 
 
[11] 
 
Minimization of 
Manhattan distance 
between the 
vectors containing 
the reference and 
mutant flux 
distributions 
¦


Mm
m
WT
m ttmin  
Minimization of 
Manhattan distance 
between the vectors 
containing the 
reference and 
mutant intracellular 
metabolites 
turnover 
Minimization of 
overall intracellular 
flux 
¦
Ni
ivmin
 
[19]
 
Minimization of the 
sum of all 
intracellular fluxes 0
min
 
¦

WT
Mm
m
WT
m
t
tt
 
Minimization of the 
sum of intracellular 
metabolites 
turnover 
Maximization of 
ATP yield glucose
max
v
v
Nv
ATP
ATP
¦

 
[23]
 
Maximization of the 
sum of all reactions 
producing ATP 
0
max
glucose
 

WT
ATP
WT
ATP
t
v
tt
 
Maximization of ATP 
turnover 
Minimization of 
ATP yield glucose
min
v
v
Nv
ATP
ATP
¦

 
[24]
 
Minimization of the 
sum of all reactions 
producing ATP 
0
min
glucose
 

WT
ATP
WT
ATP
t
v
tt
 
Minimization of ATP 
turnover 
Minimization of 
redox potential glucose
min
v
v
Nv
NADH
NADH
¦

 
[23]
 
Minimization of the 
sum of all reactions 
producing NADH 
0
min
glucose
 

WT
NADH
WT
NADH
t
v
tt
 
Minimization of 
NADH turnover 
Maximization of 
biomass* 
Growthvmax  
(Varma & Palsson, 
1993, Price et al, 
2004)
 
Maximization of 
biomass flux biomasstmax  
Maximization of 
biomass turnover 
*Note: Typically, biomass production within metabolic models is formulated as one equation accounting for all the 
biomass constitutes. As there is usually only one equation producing biomass, the flux of such reaction equals the 
biomass turnover. Therefore, for simulating such biological objective, the original formulation – FBA – and MiMBl are 
completely equivalent. 
While mapping the flux space into the metabolite space for the objective function formulation, 
as we do for MiMBl, it is possible that, for a few cases, alternative flux distributions are found 
around a given metabolite. We therefore introduce a second optimization step that reinforces 
the proximity to the reference flux distribution. This is achieved by using a normlMoMA routine 
where the optimal objective function value found in the first MiMBl optimization step is used as 
an additional constraint (Methods). Nevertheless, highly connected metabolites ensure a degree 
of network connectivity, which is sufficient for decreasing the number of situations where 
alternative flux distributions around the same metabolite are picked by MiMBl. Indeed, we did 
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not find any case in the simulations performed for this study where growth prediction was 
altered in the second optimization step. An example case where the second optimization step 
will be more relevant is simulations involving export of metabolites, where the choice of a 
particular transporter (as in the reference flux distribution) among several alternative options is 
desired. 
In order to estimate to what extent the lack of normalization of stoichiometric coefficients 
within the objective function influences the biological interpretation of simulation results, we 
used lMoMA for simulating gene knockouts in the S. cerevisiae genome-scale metabolic model 
iFF708 [21]. In case of simulations for triple gene knockouts, more than 200,000 triplets were 
found such that their predicted phenotype switched from lethal to non-lethal (or vice-versa) for 
two synonymous matrix representations (Table ST5.1). From a biotechnological perspective, 
predictions from genome-scale modeling have direct influence on the choice of gene targets 
selected for metabolic engineering. By using lMoMA, we identified metabolic engineering 
strategies (by simulating all possible combinations of knockout of (up to) three genes, Methods) 
for production of two different compounds in yeast: succinate – a native product, and vanillin-
glucoside – a heterologous product. Not only a significant fraction of mutants had divergent 
predictions for product yield when using two alternative stoichiometric matrices, but also 
several highly ranked strategies in one case were low priority targets in the other (Fig. 5.3a, b, c). 
Moreover, we also observed that the number of predicted synthetic lethal pairs differed by 
more than two-fold when using alternative stoichiometric matrix representations (Table ST5.2). 
These inconsistencies have immediate implications on the consequent biological interpretation, 
as well as on the experimental design, and can be successfully overcome by using MiMBl (Fig. 
5.3d, Table ST5.3). 
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Figure 5.3: Stoichiometry representation impacts the design of metabolic engineering strategies depending on the 
nature of the objective function formulation. Shown is the comparison of predicted succinate and vanillin-glucoside 
yields for triple gene knockout mutants obtained with two alternative stoichiometric matrices (S0 and S1, Methods).  
Number of mutants diverging in their lMoMA-predicted a) succinate and b) vanillin-glucoside yields for the two 
alternative representations of stoichiometry. The x-axis represents the percentage of deviation of product formation 
by the mutants relative to S0. c) Comparison of ranks of lMoMA-predicted metabolic engineering strategies for 
improving succinate and vanillin-glucoside production, obtained by using S0 and S1. d) Comparison of ranks of MiMBl-
predicted metabolic engineering strategies for improving succinate and vanillin-glucoside production, obtained by 
using S0 and S1. 
Predicting genetic interactions using MiMBl 
To what extent MiMBl contributes for increasing biological understandings gained from the 
application of optimization-based metabolic modeling? We used one of the most recent and 
comprehensive S. cerevisiae models, iAZ900 [26], to run simulations for single and double gene 
knockouts and challenged MiMBl to predict the epistasis scores of all significantly interacting 
non-essential gene pairs reported by Szappanos et al. [2]. Genetic interaction networks are 
valuable resources towards deciphering the complex genotype-phenotype relationship. A 
genetic interaction between two genes occurs when the phenotype displayed by a double 
deletion mutant is different than the one expected based on the phenotype of the single 
mutants. Accordingly, two genes can display positive, negative or non-epistatic interaction. In 
order to capture most of the biological variability contained in the experimental dataset, we 
propose the use of two different objective functions, maximization of growth (FBA) and 
minimization of metabolic adjustment (MiMBl). FBA is ought to cover situations where 
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maximization of growth is the cellular objective, while MiMBl will account for regulatory effects 
inherent to the wild type flux distribution. FBA is a conservative method for finding genetic 
interactions compared to MiMBl, since the parameter used to define and measure genetic 
interactions is also the objective of optimization, i. e., growth. Within the metabolic network, 
often there are several optimal solutions theoretically satisfying maximum biomass formation. In 
case of a single/double gene deletion mutant where an alternative optimal pathway exists, FBA 
will always find such an alternative solution, even though it may not be biologically plausible due 
to regulatory constraints, and, thereby may miss potential genetic interactions. On the other 
hand, MiMBl will help in capturing more refined regulatory effects where the loss of growth is a 
side effect of minimizing the flux rerouting relative to the wild type. 
The subset of experimental genetic interactions involving non-essential genes from the yeast 
metabolic model contains 17419 interactions (939 positive, 1806 negative and 14674 non-
epistatic interactions) connecting 520 genes (Methods). Around 84 % of these interactions are 
non epistatic. Importantly, both MiMBl and FBA are able to capture > 97 % of non-epistatic pairs, 
meaning that the metabolic model and both simulation algorithms are accurately predicting the 
majority of the interactions within the dataset. Nevertheless, the remainder 16 % of the 
interactions, which we subsequently explore, holds the most interesting information concerning 
functional gene relationships. 
In order to assess the performance of the different algorithms, we carried out a sensitivity versus 
precision analysis. Precision was calculated as the fraction of experimentally validated 
interactions among all predicted interactions, while the sensitivity represents the fraction of the 
experimentally validated interactions captured by the analysis (Methods). A computational 
epistasis cutoff (εcutoff, Methods) was used to call a particular interaction to be epistatic (either 
positive (ε > εcutoff) or negative (ε < - εcutoff)) or non-epistatic (|ε|< εcutoff). The performance of 
both algorithms (MiMBl, FBA and lMoMA) is summarized as ROC (partial receiver operating 
characteristic) curves for both, positive and negative epistasis (Fig. 5.4 a, b). The sensitivity and 
precision of the FBA predictions obtained in this study are within the same range as previously 
reported by Szappanos et al. [2]. MiMBl shows less precision than FBA in case of both positive 
(~20 %, ~30 % respectively) and negative interactions (~50 %, ~60 % respectively), but its 
sensitivity is considerably higher in both cases (~9 %, ~4 % for positive, Fig. 5.4a; ~5 %, ~3 % for 
negative, Fig. 5.4b), which reflects the conservative nature of FBA in predicting genetic 
interactions. Notably, for the entire range of genetic interaction cutoffs, MiMBl sensitivity is 
twice as high as lMoMA and similar trend is observed for precision (Fig. 5.4 a, b). As previously 
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reported by Szappanos and co-workers, lMoMA does not improve FBA predictions. Such 
behavior further emphasizes that a proper mathematical formulation of the biological principle 
(objective function) has a major impact on the ability to interpret in vivo observations. 
 
Figure 5.4: Comparison of the performance of MiMBl, lMoMA and FBA for predicting genetic interactions in S. 
cerevisiae. a, b) The accuracy of prediction of the algorithms was assessed by comparing the sensitivity and precision 
of their predictions (partial receiver operating characteristic ROC curves) for positive (a) and negative (b) interactions. 
Sensitivity reflects the fraction of experimentally validated interactions captured by the algorithm while precision is 
experimentally validated interactions among all predicted interactions. 
We chose a strict interaction cutoff (|εcutoff|= 0.013) for further analysis of the predicted 
interactions (Fig. S4.6). For this cutoff, the correctly predicted genetic interactions map contains 
142 interactions (73 positive and 69 negative) connecting 86 genes (Fig. 5.5a). MiMBl not only 
captures all interactions, except one, predicted by FBA, but also contributes with 48 additional 
interactions (~34 % of all accurate predictions). MiMBl predictions thus span almost all of those 
from FBA (Fig. 5.5b), which we attribute to the fact that many metabolites within the metabolic 
model are directly contributing to biomass formation. Consequently, if the turnover of most 
metabolites is kept constant upon gene deletions, the biomass turnover (growth) will also 
remain constant. On the other hand, FBA is not able to capture many genetic interactions found 
by MiMBl (Fig. 5.5b). These will involve mutants where the loss of fitness upon gene deletion is 
caused by the change from an in vivo well-tuned pathway to an alternative pathway containing 
different metabolites or enzymes. For many of such cases, there are alternative pathways that 
sustain the same growth as the reference and FBA is ought to find such solutions, regardless of 
the magnitude of the turnover adjustment that is required for the cell. Because of this feature, 
MiMBl is capable of capturing a part of the regulatory constraints on the operation of cellular 
metabolism, which lMoMA failed to convey (Fig. 5.5b).  
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Figure 5.5: Understanding genetic interactions by using MiMBl. a) S. cerevisiae genetic interaction network 
accurately predicted using MiMBl and FBA. Genetic interactions (edges) predicted by both algorithms together and 
independently are represented in the map (FBA – dashed line, MiMBl – dotted line, both – full line). Positive and 
negative interactions are distinguished by colour (yellow and blue, respectively) and the opacity of the edges 
illustrates the network distance between the two genes (nodes) involved in the interaction. Opacity increases as the 
distance between the genes decreases. Gray nodes represent genes which display both, positive and negative 
interactions. A gray circle is used to enclose isoenzymes when one of them was found to interact with other genes in 
the metabolic network. b) Venn diagram showing the overlap of accurately predicted interactions by FBA, MiMBl and 
lMoMA. c, d) Distribution of the network distances between genetic interacting genes captured by FBA (c) and MiMBl 
(d). As MiMBl accounts for the majority of FBA predicted interactions, exclusive MiMBl interactions are represented in 
order to illustrate the ability of MiMBl to capture genetic interaction of further distant genes with the network. 
The regulatory constraints imposed by MiMBl assume even stronger relevance in the case of 
positive interactions, where MiMBl exclusively accounts for almost 50% of the all the 
successfully predicted interactions (Fig. 5.5a). In fact, FBA’s ability of predicting positive 
interaction is limited, as the maximum predicted biomass formation of a double deletion mutant 
would never be higher than the highest predicted for the two single mutants. If a single deletion 
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mutant has the maximum predicted fitness of 1 (meaning that the fitness of the mutant is the 
same as that of the wild-type), positive interactions involving the deleted gene will be impossible 
to predict. As FBA is bound to find the optimal solution that provides the highest growth, single 
mutants with maximum fitness are much more often predicted than the ones found by MiMBl, 
where minimal adjustment of the metabolic network is preferred over maintaining maximum 
growth. Indeed, MiMBl predicts decreased single mutant fitness for twice more gene knockouts 
than FBA (~38.4 vs 18.1 %). Consequently, MiMBl also displayed an improved capacity to predict 
both positive and negative epistasis involving the same gene. More than 80 % of the genes 
display this feature in vivo. Interestingly, 30 % of the genes involved in MiMBl predicted epistasis 
interact both positively and negatively, while FBA predicts that only 14 % of the genes do so (Fig. 
5.5a). 
MiMBl predicts genetic interactions between metabolically distant genes 
MiMBl was also able to capture interactions between more distant genes within the metabolic 
network (a measure for pleiotropy). To measure this feature, we calculated the network 
distance between each pair of genes predicted to interact (Methods). MiMBl captured 
interactions between genes that are significantly more distant as opposed to FBA (~40% more 
distant for negative epistasis, p-value = 0.022; ~10% more distant for both positive and negative 
epistasis, p-value = 0.089; Fig. 5.5c, d). Inspection of the flux rerouting and metabolite turnover 
changes revealed MiMBl’s ability to finely adjust (or maintain homeostasis) the use of highly 
connected metabolites (e.g. cofactors). 
Genetic interactions and isoenzymes 
When it comes to double gene deletion events, isoenzymes are a rather interesting class to 
study, since the deletion of two enzymes often have a drastic effect on the cellular phenotype. 
Indeed, in the experimental dataset, ~36.3 % of the isoenzyme gene pairs displays negative 
interaction. In silico, almost 20 % of the negative interactions contained in the interaction map 
hereby predicted (Fig. 5.5a) are between isoenzymes. On the other hand, only by excluding 
isoenzymes, potential interactions occurring between one gene within a group of isoenzymes 
and other genes within the metabolic network can be captured. Furthermore, if such 
interactions are ought to be explained by metabolic means, this will only be the case if the 
deletion of one isoenzyme is not compensated by other isoenzyme. In vivo, most of the single 
deletion of genes coding for isoenzymes contained in the dataset (> 85%) are reported to have 
maximum fitness, thereby indicating that if these genes will display genetic interactions they will 
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be due to other mechanisms than flux rerouting, e.g. regulatory function. The remaining 15 % of 
the genes coding for isoenzymes, which potentially lack in vivo compensation of enzyme activity, 
participate in around 10 % of the total positive and negative interactions. In order to explore 
whether such interactions could be associated to a metabolic fluxes re-distribution, we 
performed additional simulations with total suppression of the reactions carried out by these 
isoenzymes. Half of these reactions were found to be in silico essentials for growth, therefore no 
interactions involving these genes could be predicted. A more detailed approach would be 
needed to study such interactions, for example by simulating decreased enzyme activity. 
Nevertheless, four additional negative and one positive interactions were accurately predicted 
(Fig. 5.5a). 
Using MiMBl and FBA for understanding genetic interactions 
Use of MiMBl not only allowed us to expand the range of genetic interactions predicted by FBA, 
but also the combined use of these two complementary algorithms enabled finding of relevant 
interactions where only one or both of the simulation principles apply. For example, the 
interaction between PGK2 and GDH2, exclusively captured by MiMBl, is due to balancing of 
NADH and glutamate, two of the most connected metabolites in the network. As there are 
alternative pathways for fulfilling NADH and glutamate requirement (despite implying higher 
metabolic adjustments), FBA could not capture this interaction. A similar effect is observed for 
the negative interaction between isoenzymes SER3 and SER33. In the absence of both genes, 
FBA predicts the needed supply of serine to be totally fulfilled by rerouting the metabolic fluxes 
via the glyoxylate shunt and threonine biosynthesis. On the other hand, MiMBl predicts that the 
supply of serine will be shared between the two alternative pathways, but the rescue cannot be 
complete, because the corresponding metabolic adjustment costs overweighs the growth. This 
prediction is in very good agreement with the experimental verification that the double mutant 
growth is impaired and can be restored by adding glycine to the medium, which is the 
intermediate for serine synthesis via glyoxylate or threonine [27]. 
We demonstrated that the use of optimization-based algorithms that are stoichiometry 
representation independent is fundamental for biological applications. These include metabolic 
engineering, gene essentiality and genetic interaction predictions. We anticipate that the 
biological relevance of consistent problem formulation will be even more apparent when 
simulating cells with complex biological objective functions such as human tissues. A proper 
problem formulation is therefore of primary importance. To this end, we developed a new, 
consistent method for metabolic modeling – MiMBl – which we thus used to perform a 
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systematic study of the yeast genetic interaction network. Our results show that the combined 
use of different objective functions is of primary importance in order to achieve a more 
complete understanding of the operating principles behind complex biological phenomena such 
as genetic interactions. We were able to almost double the accurately predicted genetic 
interactions by using MiMBl, emphasizing the impact of flux regulation within the metabolic 
network. 
Methods 
Yeast genome-scale metabolic models 
The Saccharomyces cerevisiae genome-scale stoichiometric model iFF708 [21] was used to study 
the impact of scaling the stoichiometric matrix on the simulation results when using sum of 
fluxes in the objective function. The metabolic network was pre-processed so as to remove 
reactions that carry no flux under the simulated conditions (i.e. blocked reactions). Isogenes – 
genes coding for isoenzymes – were retained. Genes/reactions deemed to be essential by FBA 
were not considered for knockout simulations within this study, since the prediction of their 
knockout does not alter when using other algorithms or alternative stoichiometric matrices. Flux 
Balance Analysis [7] was used to simulate wild-type flux distribution when required, together 
with the constraints based on experimental data. 
For analyzing the predictions of the intracellular flux distribution, the iFF708 model was 
constrained with physiological data for a wild-type strain grown in batch cultivation under 
aerobic conditions [28] and simulations were performed using minimization of overall 
intracellular flux. In the case studies for determining the impact of alternative stoichiometry 
representation on the model predictions for growth, genetic interactions and succinate 
production, the network was constrained in agreement with the experimental conditions as 
described by Szappanos et al. [2]. In the vanillin case study, the vanillin-glucoside heterologous 
pathway according to Brochado et al. [14] was introduced in the metabolic network and 
physiological data from the same study was used to obtain the necessary constraints. The target 
selection for metabolic engineering was done by simulating the deletion of all possible 
combinations (up to 3 genes) of (FBA-) non-essential genes. Following the simulations, the 
metabolic engineering strategies were ranked based on yield on carbon source (glucose) of the 
product of interest (vanillin or succinate). 
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The S. cerevisiae model iAZ900 [26] was used to accomplish the genetic interactions study. 
Genes coding for blocked reactions as well as false essentials predicted from single gene 
deletion simulations were removed from the analysis, thereby reducing the errors due to 
misprediction of single-mutant fitness. The metabolic network was constrained in agreement 
with the experimental conditions as described by Szappanos et al. [2]. 
All algorithms developed and used in this study were formulated as Linear Programming (LP) 
optimization problems and implemented in C++ using GLPK (http://www.gnu.org/s/glpk/). All 
simulations were performed on IBM BladeCenters running CentOS Linux (64bit). Detailed 
description of the LP formulations used for solving FBA, minimization of overall intracellular flux 
and minimization of metabolic adjustment (lMoMA) are provided in Supplementary methods. 
Normalized lMoMA 
Normalized lMoMA was formulated as follows: 
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Where N is the set of all reactions, M is the set of all intracellular metabolites, S is the 
stoichiometric matrix and vi is a flux for reaction i. WT stands for wild-type (or reference), vilb and 
viup are the lower and upper bounds for the flux of reaction i. 
Minimization of metabolites balance – MiMBl 
Metabolite turnover is defined as the sum of all fluxes producing (or consuming) it, multiplied by 
the stoichiometric coefficients: 
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Nm is the subset of N producing or consuming metabolite m and αm,i is the stoichiometric 
coefficient of metabolite m in reaction i. Note that αm,i is always a positive number in the 
definition above, irrespective of m being a substrate or a product. 
MiMBl was formulated as two sequential linear programming problems, as follows: 
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1st optimization: 
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Alternative stoichiometry representations 
Alternative stoichiometry representations were obtained by multiplying a given reaction (or a 
set of reactions) by a scalar θ (or a set of scalars). For any reaction r:ߙ஺௥ܻ ൅ ߙ஻௥ܺ ՜ ߙ஼௥ܼ , an 
equivalent representation is given by:  
0,,, !o TTDTDTD ZXY rZrXrY  
where Y, X and Z represent the metabolites participating in the reaction r and ȘYr, ȘXr, ȘZr 
represent the corresponding stoichiometric coefficients. Note that when the stoichiometry of 
reaction r is scaled by θ, the corresponding flux value will be scaled by 1/θ for the same optimal 
solution. For illustrating the impact of linear scaling of the reactions stoichiometry on the 
internal flux distribution, the reaction RPI1 of iFF708 model was divided by the scalar θ. For 
illustrating the impact of using alternative stoichiometry representations on the design of 
metabolic engineering strategies, two synonymous stoichiometric matrices were used: i) the 
original matrix from the yeast model (S0) and ii) an equivalent matrix (S1) where the 
stoichiometric coefficients of the reactions SERxtO, PDC6, FUR1, GAP1_21, PNP1_1, and CYSxtO 
were divided by 100, 100, 0.1, 0.01, 100 and 0.1, respectively. A third equivalent matrix (S2) was 
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generated by dividing the coefficients of a single reaction (PGK1) by 0.1. The results of the 
comparison between S0 and S2 are presented in Fig. S4.5. 
Impact of scaling stoichiometry on the optimal solution – Analytical evidence 
The impact of scaling the constraints of a given linear programming problem depends on 
whether such changes guarantee the optimality conditions after the scaling. Consider the 
problem: 
0
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t
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
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Ni
ii
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Where ic  is the cost coefficient of variable iv in the objective function. Here, a linear 
combination of non-normalized fluxes is used in the objective function, similarly to e.g. 
minimization of intracellular flux and lMoMA. Assuming that B is an optimal basis matrix for the 
problem, the following optimization condition is satisfied: 
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where j  is the index of variable v  in matrix S , jc is the reduced cost of the variable jv , jc is 
the objective function coefficient of jv , Bc is the vector containing the objective coefficients of 
basic variables and jS is the jth column of matrix S [29]. Linear scaling the problem by the matrix 
4 will result in the following reduced cost for each variable: 
  jjjBBjj SBccc T1' 4 4  
Where 4 is a nxn positive diagonal matrix (scaling matrix) and jjT is the scaling factor for the jth 
column of matrix S . In the cases of entries 1zjjT  the corresponding columns of S are 
accordingly scaled. Analogously, B4 is the scaling matrix corresponding to the basic variables. 
Unless all entries of 4 are identical, 
  NjSBcc jjjBBj d4  0': 1TT  
Therefore the optimality condition is not guaranteed. 
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Corollary 1: When all (diagonal) entries of 4  are identical (uniform scaling matrix), and 
therefore equal to jjT , the optimality condition is simplified to 
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The optimality condition can thus be guaranteed only when the matrix S is uniformly scaled. 
Note that due to the nature of the biological problem, the genuine representation of S might 
not be known, thereby 4  cannot be guaranteed to be a uniform scaling matrix. More 
importantly, for metabolic modeling purposes (where flux units and ranges are problem 
dependent), it is nevertheless undesirable that the solution is sensitive to non-uniform scaling 
and thus context dependent. 
 
Now consider the following problem: 
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Where mJ  is cost coefficient of variable mt in the objective function. The new problem 
biologically corresponds to the previous one, after mapping the flux space into metabolite space. 
We term it as a MiMBl-like problem formulation. 
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Recall that im,D is the stoichiometric coefficient of metabolite m in reaction i . The objective 
function can be re-written as function of iv : 
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Therefore, the objective function coefficients of each iv  is a function of the stoichiometric 
coefficients im,D : ¦

 
Mm
immic ,DJ . 
Similarly to the previous problem, the following optimality condition is satisfied, so v is an 
optimal solution. 
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Scaling the optimality condition will result in: 
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Unlike the previous situation (sum of non-normalized fluxes in the objective function), using a 
MiMBl-like problem formulation guarantees that the optimality condition is always satisfied, 
independently of the stoichiometry representation. 
Genetic interactions – epistasis score 
The fitness (f) of each single and double mutant was calculated by normalization of the mutant 
growth to the wild-type growth. A variety of phenotypic traits can be used to quantify epistasis, 
growth being the most commonly used, due to its accurate experimental quantification in an 
efficient high-throughput manner.  The epistatic interaction (ε) of each double gene combination 
(A and B) was calculated based on the following metrics: 
ߝ ൌ ஺݂஻ െ ஺݂ ή ஻݂ 
To address the accuracy of the different algorithms (FBA, lMoMA and MiMBl) in predicting 
genetic interactions, we did a precision versus sensitivity analysis given the range of 
computational epistasis score cutoffs |εcutoff|<0.05. Precision is the fraction of experimentally 
validated interactions among all predicted interactions, while the sensitivity represents the 
fraction of the experimentally validated interactions captured by the analysis. 
ܲݎ݁ܿ݅ݏ݅݋݊ ൌ  ܶݎݑ݁݌݋ݏ݅ݐ݅ݒ݁ݏܣ݈݈݌ݎ݁݀݅ܿݐ݁݀݌݋ݏ݅ݐ݅ݒ݁ݏ 
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ܵ݁݊ݏ݅ݐ݅ݒ݅ݐݕ ൌ  ܶݎݑ݁݌݋ݏ݅ݐ݅ݒ݁ݏܣ݈݈݁ݔ݌݁ݎ݅݉݁݊ݐ݈ܽ݌݋ݏ݅ݐ݅ݒ݁ݏ 
All significant genetic interactions among the non-essential genes from Szappanos et al. [2] 
dataset involving genes contained in iAZ900 model were included in the present analysis. The 
experimental data was filtered by using a confidence threshold of |ε|<0.08 and P<0.05 [2, 30]. 
R 2.12.1 was used to perform statistics calculations and to generate the plots. The Venn diagram 
from Fig. 5.4b was generated by using the R package “VennDiagram” by Chen & Boutros (2011). 
Cytoscape 2.8.2 was used to generate the genetic interactions map from Fig. 5.4a. 
Metabolic/network distance 
The metabolic connectivity graph obtained from the metabolic model iAZ900 was used to 
calculate the metabolic/network distance between two genes. We define network distance 
between the two as the number of reactions belonging to the shortest path between the two 
genes on the connectivity graph. A pair of directly connected metabolic genes was considered as 
being separated by distance of 2. This way, genes coding for the same reaction (e.g. isoenzymes 
and complexes) have a distance of 1. As highly connected metabolites, as cofactors (ATP, NADH, 
NADPH, FADH2, pyrophosphate and orthophosphate) are not likely to connect genes with 
related metabolic functions, this subset of metabolites was excluded from the connectivity 
graph [32]. Despite being highly connected, mitochondrial protons were kept part of the 
connectivity graph to ensure the integrity of the respiratory chain. Graph Template Library (GTL) 
was used to implement the algorithm for network distance calculations. 
Acknowledgements 
ARB acknowledge Ph.D. research grant from Fundação para a Ciência e Tecnologia (ref. SFRH / 
BD 579 / 41230 / 2007). Authors are grateful to Aleksej Zelezniak, Arnau Montagud, Martin Beck 
and Wolfgang Huber for insightful comments and discussions. 
References 
1. Zelezniak A, Pers TH, Soares S, Patti ME, Patil KR: Metabolic network topology reveals transcriptional 
regulatory signatures of type 2 diabetes. PLoS Computational Biology 2010, 6:e1000729. 
2. Szappanos B, Kovács K, Szamecz B, et al.: An integrated approach to characterize genetic interaction 
networks in yeast metabolism. Nature Genetics 2011, 43:656-62. 
131
Chapter 5: MiMBl 
108 
 
3. Kümmel A, Panke S, Heinemann M: Putative regulatory sites unraveled by network-embedded 
thermodynamic analysis of metabolome data. Molecular Systems Biology 2006, 2:2006.0034. 
4. Oberhardt MA, Palsson BØ, Papin JA: Applications of genome-scale metabolic reconstructions. 
Molecular Systems Biology 2009, 5:320. 
5. Jerby L, Shlomi T, Ruppin E: Computational reconstruction of tissue-specific metabolic models: 
application to human liver metabolism. Molecular Systems Biology 2010, 6. 
6. Osterlund T, Nookaew I, Nielsen J: Fifteen years of large scale metabolic modeling of yeast: 
Developments and impacts. Biotechnology Advances 2011. 
7. Varma A, Palsson BØ: Metabolic capabilities of Escherichia coli: I. Synthesis of biosynthetic precursors 
and cofactors. Journal of Theoretical Biology 1993, 165:477-502. 
8. Ibarra RU, Edwards JS, Palsson BO: Escherichia coli K-12 undergoes adaptive evolution to achieve in 
silico predicted optimal growth. Nature 2002, 420:20-23. 
9. Famili I, Förster J, Nielsen J, Palsson BØ: Saccharomyces cerevisiae phenotypes can be predicted by 
using constraint-based analysis of a genome-scale reconstructed metabolic network. Proceedings of the 
National Academy of Sciences of the United States of America 2003, 100:13134-9. 
10. Schuetz R, Kuepfer L, Sauer U: Systematic evaluation of objective functions for predicting 
intracellular fluxes in Escherichia coli. Molecular Systems Biology 2007, 3:119. 
11. Segrè D, Vitkup D, Church GM: Analysis of optimality in natural and perturbed metabolic networks. 
Proceedings of the National Academy of Sciences of the United States of America  2002, 99:15112-15117. 
12. Kuepfer L, Sauer U, Blank LM: Metabolic functions of duplicate genes in Saccharomyces cerevisiae. 
Genome Research 2005, 15:1421-30. 
13. Asadollahi M, Maury J, Patil KR, et al.: Enhancing sesquiterpene production in Saccharomyces 
cerevisiae through in silico driven metabolic engineering. Metabolic Engineering 2009, 11:328-34. 
14. Brochado AR, Matos C, Møller BL, et al.: Improved vanillin production in baker’s yeast through in 
silico design. Microbial Cell Factories 2010, 9:84. 
15. Suthers PF, Zomorrodi A, Maranas CD: Genome-scale gene/reaction essentiality and synthetic 
lethality analysis. Molecular Systems Biology 2009, 5:301. 
16. Snitkin ES, Segrè D: Epistatic Interaction Maps Relative to Multiple Metabolic Phenotypes. PLoS 
Genetics 2011, 7. 
17. Alper H, Jin Y-S, Moxley JF, Stephanopoulos G: Identifying gene targets for the metabolic engineering 
of lycopene biosynthesis in Escherichia coli. Metabolic Engineering 2005, 7:155-64. 
18. Wintermute EH, Silver P: Emergent cooperation in microbial metabolism. Molecular Systems Biology 
2010, 6:407. 
19. Blank LM, Kuepfer L, Sauer U: Large-scale 13C-flux analysis reveals mechanistic principles of 
metabolic network robustness to null mutations in yeast. Genome Biology 2005, 6:R49. 
20. Lewis NE, Hixson KK, Conrad TM, et al.: Omic data from evolved E. coli are consistent with computed 
optimal growth from genome-scale models. Molecular Systems Biology 2010, 6. 
21. Förster J, Famili I, Fu P, Palsson BØ, Nielsen J: Genome-scale reconstruction of the Saccharomyces 
cerevisiae metabolic network. Genome Research 2003, 13:244-53. 
22. Becker S a, Feist AM, Mo ML, et al.: Quantitative prediction of cellular metabolism with constraint-
based models: the COBRA Toolbox. Nature Protocols 2007, 2:727-38. 
23. Knorr AL, Jain R, Srivastava R: Bayesian-based selection of metabolic objective functions. 
Bioinformatics 2007, 23:351-7. 
24. Gulik WM van, Heijnen JJ: A metabolic network stoichiometry analysis of microbial growth and 
product formation. Biotechnology and Bioengineering 1995, 48:681-98. 
132
Ph.D. Thesis, Ana Rita Brochado 
109 
 
25. Price ND, Reed JL, Palsson BØ: Genome-scale models of microbial cells: evaluating the consequences 
of constraints. Nature Reviews Microbiology 2004, 2:886-97. 
26. Zomorrodi AR, Maranas CD: Improving the iMM904 S. cerevisiae metabolic model using essentiality 
and synthetic lethality data. BMC Systems Biology 2010, 4:178. 
27. Otero JM: Industrial Systems Biology and Metabolic Engineering of Saccharomyces cerevisiae. 
Technology 2009. 
28. Hoek P Van, Dijken JP Van, Pronk JT: Effect of Specific Growth Rate on Fermentative Capacity of 
Baker’s Yeast. Applied and Environmental Microbiology 1998, 64:4226-4233. 
29. Bertsimas D, Tsitsiklis JN: Introduction to Linear Optimization. First Edit. Belmont, Massachusetts: 
Athena Scientific; 1997. 
30. Costanzo M, Baryshnikova A, Bellay J, et al.: The genetic landscape of a cell. Science 2010, 327:425-31. 
31. Chen H, Boutros PC: VennDiagram: a package for the generation of highly-customizable Venn and 
Euler diagrams in R. BMC Bioinformatics 2011, 12:35. 
32. Kharchenko P, Church GM, Vitkup D: Expression dynamics of a cellular metabolic network. Molecular 
Systems Biology 2005, 1.  
133
134
Ph.D. Thesis, Ana Rita Brochado 
111 
 
Chapter 6: Conclusions and Future Perspectives 
Metabolic engineering for vanillin production and analysis of genetic interactions in S. cerevisiae 
were used to contextualise the application of genome-scale metabolic models for prediction and 
systematic analysis of phenotypes resulting from perturbed genotypes. The results obtained 
within this thesis provide experimental evidence for the current capabilities and limitations for 
predicting metabolic phenotypes based on the genotype by using metabolic models. While 
prediction of the metabolic behaviour of single gene deletion mutants can be successfully 
achieved, as we showed by experimentally demonstrating the application of the yeast genome-
scale stoichiometric model to metabolic engineering, predicting metabolic phenotypes of 
multiple gene deletions or overexpression mutants is still a challenge. A newly developed 
computational tool herein presented is expected to contribute for enhancing the predictive 
power of metabolic phenotypes by means of metabolic modeling, particularly relevant for 
multiple gene deletion mutants. 
The yeast genome-scale model was successfully used to guide the design of a metabolic 
engineering strategy for increasing heterologous production of vanillin in S. cerevisiae (Chapter 
3). The biological objective function used to perform metabolic simulations proved to be a 
relevant parameter, as FBA (Flux Balance Analysis) predicted that no vanillin improvement 
would take place even after deleting six metabolic reactions. By using MoMA (Minimization of 
Metabolic Adjustment), and thereby assuming the mutant’s metabolic proximity towards the 
reference strain instead of its optimal growth, several strategies comprising the deletion of one 
reaction were suggested. A thorough analysis of the predicted gene targets was performed 
accounting for different modes of yeast physiology and final target selection for experimental 
work was done based on prioritizing strategies which were predicted to compel the smallest 
metabolic adjustment. Implementation of the metabolic engineering strategies following the in 
silico guided design successfully resulted in three mutants with up to 2-fold increased vanillin 
production. The results from physiological characterization and flux variability analysis of the 
predicted flux distribution of the mutants suggested that increased vanillin production was 
associated with improved cofactors supply for the vanillin biosynthetic pathway. 
Despite the success of taking a global approach for improving vanillin production by using the 
yeast genome-scale metabolic model, lower vanillin yield than expected was obtained, as 
accumulation of several intermediate compounds of the vanillin biosynthetic pathway was 
observed. In order to achieve maximum potential of the global approach for metabolic 
135
Conclusions and Future Perspectives 
112 
 
engineering, the activity of the pathway enzymes must not impose a limitation. Indeed, In 
Chapter 4 it was shown that the O-methyltransferase for vanillin biosynthesis was limiting the 
conversion of pathway intermediates to the final product, vanillin glucoside. Moreover, the 
limitation was found to prevail exclusively on the globally engineered mutant, supporting the 
fact that local pathway engineering is of higher value when it is combined with global 
approaches, which take the whole metabolic network into account. 
Model incompleteness and lack of regulatory information are often pointed as potential factors 
for limiting the success of application of the genome-scale models. Although the usage of MoMA 
as biological objective function indirectly accounts for regulation imbedded in the wild type flux 
distribution, direct inclusion of regulatory genes on metabolic networks is still limited due to lack 
of knowledge of regulation at the genome-scale level. Additionally, regulatory genes modulate 
the expression of several genes, rendering the mathematical description of the relationship 
between the expression level of the genes and the corresponding flux changes an intricate task. 
Chapter 4 present experimental examples of overexpression of a transcription factor for 
metabolic engineering, using vanillin and succinate production in S. cerevisiae as case studies. In 
the case of production of vanillin, alleviation of the yeast glucose repression by overexpression 
of HAP4 lead to increased respiratory capacity, decreased ethanol formation and higher vanillin 
production, most likely due to higher ATP availability. In the case of succinate, the same strategy 
raised production by 15%, but it was also found to have a strong negative effect on biomass 
formation. Better characterization of the improved strains, particularly by obtaining the 
transcriptome and fluxome, could further explain the observed phenotypes. Concerning 
succinate production in particular, clarifying the reasons for the observed decreased fitness, as 
well as explaining the origin of the produced succinate, either cytosolic or mitochondrial, would 
reveal relevant information for future strain improvement. 
The results obtained in Chapter 4 confirm the potential of using regulatory genes as targets for 
metabolic engineering. In a recent study, Sauer and co-workers (2010) performed systematic 
flux analysis of 119 yeast transcription factor deletion mutants, under 43 different experimental 
conditions. Their results demonstrate that, despite the altered expression profile of numerous 
genes, the metabolic network operation mode is very robust towards transcription factor 
deletion. However, the results herein presented, also in agreement with previous work on 
overexpression of transcription factors, e.g. van Maris et al. (2001) and Sopko et al. (2006), 
suggest that transcription factor overexpression, instead of deletion, may in fact strongly affect 
growth rate, as well as the distribution of metabolic fluxes and modulate the activity of central 
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pathways in yeast. Efforts towards the systematic clarification of the relationship between 
changes in gene expression and metabolic fluxes upon overexpression of transcription factors, 
could largely contribute for understanding regulatory mechanisms. 
At last, Chapter 5 describes a new computational tool focusing on the formulation of objective 
functions for optimization-based algorithms using genome-scale models. MiMBl – Minimization 
of Metabolites Balance – presents an alternative methodology to formulate new and currently 
used biological principles in a stoichiometry representation independent manner. Several 
biological principles are currently formulated by using linear combination of fluxes, e.g. MoMA 
and minimization of intracellular flux, which was herein shown to be susceptible to alternative 
representations of stoichiometry. This is an undesirable feature, as alternative representation of 
the stoichiometric coefficients can be used to describe the same biochemical reaction, thus 
simulation algorithms should be insensitive towards such artifacts. MiMBl was used to perform a 
systematic study of the yeast genetic interaction network while assuming minimization of 
metabolic adjustment as biological principle and showed considerably higher prediction 
accuracy than lMoMA. Despite the apparently modest accuracy of prediction of genetic 
interactions using metabolic modeling, MiMBl accurately captured the largest fraction of genetic 
interactions comparing to other simulation algorithms, namely FBA. Nevertheless, the results 
herein obtained support the observations previously reported by Constanzo et al. (2010), where 
correlation between genetic interaction degree and different cellular features, such as single 
mutant fitness, physical interactions and gene multi-functionality was observed, suggesting that 
the wide map of genetic interactions is explained by diverse biological traits. Analogously, as FBA 
and MiMBl describe different biological principles, their combined use captures genetic 
interactions potentially explained by different biological traits. Indeed, by performing such 
analysis, we observed that FBA mostly captures negative generic interactions, as a direct 
consequence of its objective function, while MiMBl is more suitable for describing both positive 
and negative interactions, due to the prevalence of minimizing metabolic adjustment relatively 
to the reference over maximizing growth. Furthermore, MiMBl accurately captures interactions 
between genes which are more distant in the metabolic network than FBA. Ultimately, 
differently predicted genetic interactions between both approaches provide mechanistic insights 
about modes of operation of metabolic networks. 
The use of genome-scale metabolic models is currently increasing; the scope of their 
applications is expanding, as well as the number of organisms with their metabolic network 
reconstructed. The work herein developed evidenced the effectiveness of such models for 
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investigating genotype to phenotype relationship, particularly contributing to the analysis of 
perturbed metabolic networks. MiMBl versatility for implementation of objective functions can 
be explored in the future for formulation of many different biological principles potentially 
governing the metabolic phenotype. To this end, availability of large-scale datasets, such as 
internal flux distribution of the single and double gene deletion libraries, as well as of 
overexpression libraries, in combination with transcriptome, proteome and metabolome, would 
largely increase the potential of uncovering biological principles underlying metabolism. 
Furthermore, developing new computational tools which can describe complex relationships 
between these cellular components would enhance systematic investigation of how changes in 
genotype influence the phenotype. Consequent improvement of the predictive power of 
metabolic models would contribute for increasing their usefulness in supporting fundamental 
and applied research. 
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Chapter 2: Systems Biology, Genome Scale Metabolic Modeling and 
Metabolic Engineering of S. cerevisiae – Acts and Facts 
Table ST2.1: Database and other online resources useful for research in S. cerevisiae and other 
yeasts. Adapted from [33]. 
Database URL Comments 
SGD (Saccharomyces Genome Database) 
http://www.yeastgenome.or
g/  
The most widely used genome database. It 
contains a wide range of data and community 
resources. It employs Gene Ontology (GO) for 
functional annotation. 
CYGD (Comprehensive Yeast Genome 
Database) 
http://mips.helmholtz-
muenchen.de/genre/proj/yea
st  
Particularly useful for protein sequence and 
structure. It employs FunCat for functional 
annotation, often complementary to GO. 
EUROSCARF (European Saccharomyces 
cerevisiae Archive for Functional Analysis) 
http://web.uni-
frankfurt.de/fb15/mikro/euro
scarf/index.html 
Index to the S. cerevisiae strains and plasmids 
repository. It contains the complete deletion 
collections and several other important 
resources. 
PROPHECY (Profiling of phenotypic 
characteristics in yeast) 
http://prophecy.lundberg.gu.
se/ 
Quantitative phenotypic information for the 
complete library of S. cerevisiae deletion 
mutants. 
BioGRID (Biological General Repository 
for Interaction Datasets) 
http://thebiogrid.org/ 
A curated database of genetic and protein-
protein interactions for a number of organisms, 
including S. cerevisiae. 
YEASTRACT (Yeast Search for 
Transcriptional Regulators and Consensus 
Tracking) 
http://www.yeastract.com/ 
A curated repository for regulatory associations 
between transcription factors and target genes 
in S. cerevisiae. 
SGRP (Saccharomyces Genome 
Resequencing Project) 
http://www.sanger.ac.uk/res
earch/projects/genomeinfor
matics/sgrp.html 
Contains the genome sequence of S. cerevisiae 
and S. paradoxus, as well as of several wild and 
industrial strains. 
WoLF PSORT (Protein subcellular 
localization prediction) 
http://wolfpsort.org/ 
An online tool for prediction of sucellular 
localization of proteins in S. cerevisiae and other 
fungi. 
YGOB (Yeast Gene Order Browser) http://wolfe.gen.tcd.ie/ygob/  
An easy-to-use online viewer that enables 
synthetic comparisons between 16 yeast 
species, as well as the reconstruction of their 
ancestral genome 
NetPhosYeast 
http://www.cbs.dtu.dk/servic
es/NetPhosYeast/ 
A web based tool for prediction of serine and 
threonine phosphorylation sites in yeast 
proteins. 
YTPdb (Yeast Transport Proteins 
database) 
http://homes.esat.kuleuven.b
e/~sbrohee/ytpdb/  
A manually annotated set of S. cerevisiae 
proteins either demonstrated or predicted to be 
transporters. 
YEASTNET (A consensus reconstruction 
for yeast metabolism) 
http://www.comp-sys-
bio.org/yeastnet/ 
A consensus reconstruction of the S. cerevisiae 
metabolic network. 
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Chapter 3: Metabolic Engineering for Vanillin Production in S. 
cerevisiae. Part 1 – Metabolic Modeling for Strain Improvement 
Table ST3.3: List of primers used in this study. 
Primer name Primer sequence Purpose 
His3_Fw attgctatgacccgggCATAACACAGTCCTTTCCCGC Amplify HIS3 marker from pWJ1213 
His3_Rev attgctatgtcccgggTCACACCGCATAGATCCGTC Amplify HIS3 marker from pWJ1213 
MarkSeq_Fw CTGTGTCTATGAAAGTCGACGCG Sequencing marker in plasmid ARB021 
MarkSeq_Rev GGGGCTGGCTTAACTATGC Sequencing marker in plasmid ARB021 
dKL5’ gtcagcggccgcatccctgcTTCGGCTTCATGGCAATTCCCG Amplify N-terminal URA3 from plasmid pWJ1042 
Kl URA3 3’-int GAGCAATGAACCCAATAACGAAATC Amplify N-terminal URA3 from plasmid pWJ1042 
Kl URA3 5’-int CTTGACGTTCGTTCGACTGATGAGC Amplify C-terminal URA3 from plasmid pWJ1042 
cKL3’ cacggcgcgcctagcagcGGTAACGCCAGGGTTTTCCCAGTCAC Amplify C-terminal URA3 from plasmid pWJ1042 
GDH1(UP)_Fw GTCATCATTTCAAATATATG Amplify GDH1 upstream fragment from VG0 genomic DNA 
GDH1(UP)_Rev gcagggatgcggccgctgacATAGTCTAAAAGAAAGAAAA Amplify GDH1 upstream fragment from VG0 genomic DNA 
GDH1(DW)_Fw ccgctgctaggcgcgccgtgTTCTTTTTCTTTTTGGTCTC Amplify GDH1 downstream fragment from VG0 genomic DNA 
GDH1(DW)_Rev AAAGTATACGTAATCTAAGT Amplify GDH1 downstream fragment from VG0 genomic DNA 
GDH1_Ver_FW TTGCAAGTTAAAGCGGTC Analytical PCR for verifying GDH1 deletion from VG2 genomic DNA 
GDH1_Ver_REV GCCCATGCATTTTCAGT Analytical PCR for verifying GDH1 deletion from VG2 genomic DNA 
PDC1(UP)_Fw TCGTTTAAGAGAAATTCTCC Amplify PDC1 upstream fragment from VG0 genomic DNA 
PDC1(UP)_Rev gcagggatgcggccgctgacGCGATTTAATCTCTAATTAT Amplify PDC1 upstream fragment from VG0 genomic DNA 
PDC1(DW)_Fw ccgctgctaggcgcgccgtgTTTGATTGATTTGACTGTGT Amplify PDC1 downstream fragment from VG0 genomic DNA 
PDC1(DW)_Rev GTGATGGCACATTTTTGCAT Amplify PDC1 downstream fragment from VG0 genomic DNA 
PDC1_Ver_FW AGCAATGGCTTGCTTAATAG Analytical PCR for verifying PDC1 deletion from VG2 genomic DNA 
PDC1_Ver_REV ATTTGCAAAATGCATAACCT Analytical PCR for verifying PDC1 deletion from VG2 genomic DNA 
GDH2(UP)_Fw AGCAATGTCATACTGGCC Amplify GDH2 upstream fragment from VG3 genomic DNA 
GDH2(UP)_Rev gcagggatgcggccgctgacTTGAGATCGTGACAATCAC Amplify GDH2 upstream fragment from VG3 genomic DNA 
PGK1_GDH2(Dw)_Fw ccgctgctaggcgcgccgtgTCTAACTGATCTATCCAAAACTG Amplify PGK1_GDH2 (DW) fragment from  pPGK1_GDH2 
PGK1_GDH2 (DW)_Rev GAATCATCCATTTCAATCC Amplify PGK1_GDH2 (DW) fragment from pPGK1_GDH2 
PGK1verifb GTCACACAACAAGGTCCTA Analytical PCR for verifying GDH2 overexpression from VG4 genomic DNA 
Gdh2verifb GGTTTTCTACAATCTCCAAAAGAG Analytical PCR for verifying GDH2 overexpression from VG4 genomic DNA 
aSmall case letters indicate non homologous region of the primer, rather they code for restriction sites for cloning 
purposes or tails for fusion PCR. 
bPrimers by TL Nissen et al. (2000) 
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Chapter 4: Metabolic Engineering for Vanillin Production in S. 
cerevisiae. Part 2 – Pathway and Regulatory Engineering 
Table ST4.4: List of oligonucleotides used in this study. 
Name Sequence Purpose  
O1_f ATGGTGCAAGACACATCAAGC npgA (Aspergillus nidulans) amplification from pESC-
npgA-pcbAB O2_r attgctatgaGGTACCTTAGGATAGGCAATTACACACCC 
O3_f GGAGTTTAGTGAACTTGCAA 
npgA (Aspergillus nidulans) verification in pARB118 
O4_r GATGACTACGGAAAGCTTT 
O5_f attgctatgaGGCGCGCCGAGTTTGGCCGAGTGGTT MET15 (S. cerevisiae) amplification from CEN.PK 113 7D 
gDNA O6_r attgctatgaGGCGCGCCGAAACCTCCATCATCCTCTT 
O7_f CTGTGTCTATGAAAGTCGACGCG 
MET15 (S. cerevisiae) verification in pARB030 
O8_r GGGGCTGGCTTAACTATGC 
UO1_f AGTCGCCCCCUTTCGGCTTCATGGCAATTCCCG 
Recyclable URA3 marker amplification from pWJ1042 
UO2_r ACTCACTGCUGGTAACGCCAGGGTTTTCCCAGTCAC 
UO3_f GGGTTTAAU ATAAAGCAGCCGCTACCAAA YPRCΔ15 - UP fragment amplification from CEN.PK 113 
7D gDNA UO4_r AGGGGGCGACUAATGGAAGGTCGGGATGAG 
UO5_f AGCAGTGAGUGCTGAGGGTTTAATTAAGTCCTCAGCCCTTTCGTCATGGACACTTCT YPRCΔ15 - DW fragment amplification from  CEN.PK 
113 7D gDNA UO6_r GGACTTAAUTACCAACGGACTTACCTTCAG 
UO7_f GGGTTTAAUCACACACCATAGCTTCAAA 
PTEF1 amplification from CEN.PK 113 7D gDNA 
UO8_r AGGGGGCGACUTTTGTAATTAAAACTTAGATTAG 
UO9_f AGCAGTGAGUCATGTAATTAGTTATGTCACGC 
TCYC1 amplification from CEN.PK 113 7D gDNA 
UO10_r GGACTTAAUGCAAATTAAAGCCTTCGA 
UO11_f AGTCGCCCCCUATGACCGCAAAGACTTTTCT 
HAP4 amplification from CEN.PK 113 7D gDNA 
UO12_r ACTCACTGCUCAACATGCCTATTTCAAAATAC 
UO13_f AGTCGCCCCCUATGGGTGACACTAAGGAGC 
hsOMT amplification from pARB033 
UO14_r GGACTTAAUCGCGTCGACTTTCATAGA 
O9_f CTTGACGTTCGTTCGACTGATGAGC Internal URA3 primers for amplifing bipartite fragments 
for yeast transformation O10_r GAGCAATGAACCCAATAACGAAATC 
O11_f ATCTGCTGCGCTACCACTG Amplification of  YPRCΔ15 locus from CEN.PK 113 7D 
gDNA (verification) O12_r GGCTTGTGGTCACCTGTCAT 
Note 1: Lower case letters indicate “jungle” to ensure DNA restriction by the endonucleases.  
Note 2: UO_# distinguishes the USER oligonucleotides. 
Note 3: Gray highlighting designates restriction sites or USER tails, in case of USER cloning primers. 
Note 4: Underlined text designate PacI/Nt.BbvCI User cassette. 
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Chapter 5: Minimization of Metabolite Balance Explains Genetic 
Interactions within the Yeast Metabolic Network 
Supplementary methods 
All the simulation algorithms were formulated as Linear Programming (LP) optimization 
problems and implemented in C++ using the GLPK (http://www.gnu.org/s/glpk/). 
Supplementary Method 5.1: Flux Balance Analysis [2] was formulated as follows: 
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Supplementary Method 5.2: Minimization of overall intracellular flux [3] was formulated as 
follows: 
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Supplementary Method 5.3: Minimization of metabolic adjustment (lMoMA, [4]) was 
formulated as follows: 
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Supplementary figures 
 
Figure S5.1: Profiles obtained for the objective function value (minimization of overall 
intracellular flux) using alternative stoichiometry representations of S. cerevisiae genome-scale 
model [5]. This analysis is complementary to and based on the same simulation constraints as 
used for Fig. 5.1 in the main text. As the contribution of each flux to the objective function 
changes based on the corresponding stoichiometry representation, different situations could be 
described, leading either to the same (a, b) or distinct (c, d) optimal solutions. To illustrate these 
different situations, four reactions within the model were linearly scaled one at a time by 
multiplying by a scalar θ as described in Methods. a) Linear scaling of the reaction FBP1. As FBP1 
carries no flux under the simulated conditions, the scaling of this reaction does not affect the 
objective function value. b) Linear scaling of the reaction RPE1. For the range of θ tested, the 
objective function value perfectly correlated with the scaling factor of the reaction RPE1, which 
indicates that all obtained solutions are in fact the same optimal solution (or alternative optimal 
solutions, depending on the model complexity). This profile means that there is no pathway 
alternative to RPE1 that can become part of the optimal solution. c) Linear scaling of the 
reaction RPI1. For the range of tested θ, at least two slopes are observed when correlating the 
objective function value with 1/θ, indicating that at least two different optimal solutions were 
found for the same problem. d) Linear scaling of the reaction NDI1. Similarly to that of RPI1, 
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scaling of NDI1 leads to different optimal solutions. However, in this case, the objective function 
value stabilizes after a given θ, which means that this flux no longer influences the optimization. 
Such profile suggests that the optimal solution found after the given value of θ does no longer 
involve NID1, but an alternative pathway, which became preferred for minimizing the objective 
function. 
 
Figure S5.2: A toy-model illustrating how, and why, alternative stoichiometry representations 
influence simulation of minimization of metabolic adjustment by using normalized lMoMA – 
normlMoMA. a) Toy-model: R1 to R7 and A to D represent reactions and metabolites, 
respectively. In the wild-type, or reference, flux goes from A to D via R5. R6 and R2-R3-R4 are 
two alternative pathways for flux re-distribution after deletion of R5. b) Flux through reactions 
R2 (full symbols) and R6 (open symbols) obtained after simulation with normlMoMA by using 
alternative representations of reaction R6 (given by different θR6, Methods). c) Formulation of 
normlMoMA objective function (Methods). d) Optimal objective function value (distance) 
obtained for minimization of metabolic adjustment as function of θR6. 
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Figure S5.3: Stoichiometry representation impacts the design of metabolic engineering 
strategies for improving succinate production in S. cerevisiae depending on the nature of the 
objective function formulation. Shown is the comparison of predicted succinate yield for a) 
single, b) double and c) triple gene knockout mutants obtained with two alternative 
stoichiometric matrices (S0 and S1, Methods).  The number of mutants diverging in their lMoMA-
predicted succinate yield for the two alternative representations of stoichiometry is represented 
on the y-axis, while the percentage of deviation of product formation by the mutants relative to 
S0 is represented on the x-axis. d-f) Comparison of ranks of lMoMA-predicted metabolic 
engineering strategies for improving succinate production obtained by using S0 and S1 for d) 
single, e) double and f) triple gene knockout mutants. 
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Figure S5.4: Stoichiometry representation impacts the design of metabolic engineering 
strategies for improving vanillin-glucoside production in S. cerevisiae depending on the nature of 
the objective function formulation. Shown is the comparison of predicted vanillin-glucoside yield 
for a) single, b) double and c) triple gene knockout mutants obtained with two alternative 
stoichiometric matrices (S0 and S1, Methods).  The number of mutants diverging in their lMoMA-
predicted vanillin-glucoside yield for the two alternative representations of stoichiometry is 
represented on the y-axis, while the percentage of deviation of product formation by the 
mutants relative to S0 is represented on the x-axis. d-f) Comparison of ranks of lMoMA-predicted 
metabolic engineering strategies for improving vanillin-glucoside production obtained by using 
S0 and S1 for d) single, e) double and f) triple gene knockout mutants. 
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Figure S5.5: Stoichiometry representation impacts the design of metabolic engineering 
strategies for improving succinate and vanillin-glucoside yields in S. cerevisiae depending on the 
nature of the objective function formulation. a-f) Number of mutants diverging in their lMoMA-
predicted a-c) succinate and d-f) vanillin-glucoside yields for two alternative representations of 
stoichiometry, S0 and S2 (Methods). Results for a,d) single, b,e) double and c,f) triple gene 
knockout mutants are presented. g-l) Comparison of ranks of lMoMA-predicted metabolic 
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engineering strategies for improving g-i) succinate and j-l) vanillin-glucoside production obtained 
by using S0 and S2. Results for g,j) single, h,k) double and i,l) triple gene knockout mutants are 
presented. 
 
Figure S5.6: Comparing the performance of MiMBl, FBA and lMoMA for predicting yeast genetic interactions using 
iAZ900 metabolic model. 
Supplementary tables 
Table ST5.1: Number of lMoMA-predicted lethal gene/reaction knockouts in S. cerevisiae that 
differ between alternative representation of stoichiometry (S1 and S2), relative to S0 (Methods). 
The yeast genome scale model [5] was constrained as per Szappanos et al, 2011, and FBA was 
used to generate the reference flux distributions. Single, double and triple gene/reaction 
deletions were simulated. 
Number 
of 
Deletions 
S2 S1 
Total number of 
combinations 
Reactions Genes Reactions Genes Reactions Genes 
1 0 0 4 3 387 424 
2 0 13 1526 1166 74691 89676 
3 189 4565 289664 225548 9585345 12614424 
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Table ST5.2: lMoMA-predicted epistatic interactions within S. cerevisiae genome-scale metabolic 
model [5]. Simulations were performed using three alternative representations of stoichiometry, 
S0, S1 and S2 (Methods). The yeast genome-scale metabolic model was constrained as in 
Szappanos et al. 2011.  
S0 S2 S1 
Positive interactions 2219 2154 2087 
Negative interactions 840 781 742 
Synthetic lethals 197 217 97 
Total number of 
interactions 89676 
 
Table ST5.3: MiMBl-predicted epistatic interactions within S. cerevisiae genome-scale metabolic 
model [5]. Simulations were performed using two alternative representations of stoichiometry, 
S0 and S1 (Methods). The yeast genome-scale metabolic model was constrained as in Szappanos 
et al. 2011. 
S0 S1 
Positive interactions 2019 2019 
Negative interactions 811 811 
Synthetic lethals 198 198 
Total number of 
interactions 89676 
 
Supplementary notes 
Supplementary Note 5.1: Toy-model 
Reaction ID Reaction  [lower bound, upper bound] 
 
R1:  Axt -> A  [1,1] 
R2:  A -> B  [0,100] 
R3:  B -> C  [0,100] 
R4:  C -> D  [0,100] 
R5:  A -> D  [0,100] 
R6:  A -> D  [0,100] 
R7:  D -> Dxt [0,100] 
 
Where R1 to R7 represent reactions, A, B C and D represent internal metabolites, Axt and Dxt 
represent external metabolites. Constraints are represented as [lower bound, upper bound]. 
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Reference flux distribution 
R1 1 
R2 0 
R3 0 
R4 0 
R5 1 
R6 0 
R7 1 
 
Reference intracellular metabolite turnovers 
A 1 
B 0 
C 0 
D 1 
 
Supplementary Note 5.2: normlMoMA 
One possible approach to normalize the objective function variables with respect to the 
stoichiometric representation, can be achieved by dividing each variable by its value on the wild-
type flux distribution – normalized lMoMA (normlMoMA). Albeit being simple, this 
normalization method has several drawbacks, the first one being the fact that many reactions 
have null fluxes on the wild-type flux distribution. The simplest solution to this problem would 
be to disregard the contribution of null fluxes to the objective function, biologically meaning that 
the onset of new enzymes would be costless. This normalization solves the inconsistency of the 
initial problem, since the calculated distance is constant independently of the matrix 
representation. However, as R2-R3-R4 and R6 (toy-model, Fig. S5.2) have null fluxes on the wild-
type flux distribution, and therefore they do not take part of the objective function, they 
represent alternative optima to the problem. Moreover, exclusion of the wild-type null fluxes 
from the objective function alters the biological principle underlying MoMA and increases the 
number of alternative optimal solutions. 
Supplementary Note 5.3: Impact of scaling stoichiometry on finding the optimal solution for 
metabolic flux distributions using FBA-like objective functions – Analytical evidence 
Consider the problem 
Niv
bvSts
vc
i
aa
t
 
,0
..
min
 
Where a  is the index of variable av on the matrix S . Note that this is a particular case of having 
a sum of non-normalized variables on the objective function, where all the entries of the 
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objective function coefficients vector c  are zero, except for the ath entry )( ac . As described in 
Methods, after scaling matrix S with4 , the optimality condition becomes: 
  0' 1 t4  jjjBBj SBcc T  
where j  is the index of variable v  in matrix S , jc is the reduced cost of the variable jv , jc is 
the objective function coefficient of jv , Bc is the vector containing the objective coefficients of 
basic variables, jS is the jth column of matrix S , 4 is a nxn positive diagonal matrix (scaling 
matrix) and jjT is the scaling factor for the jth column of matrix S [6]. 
 
Three different cases should be considered and in all of them we will show that the optimality 
condition is satisfied. 
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The optimality condition is satisfied. 
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The optimality condition is satisfied. 
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As 0' 1 d jB SBc and all entries of the matrix 4 are positive, the optimality condition is 
always satisfied. 
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